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head of the Hospital in the period 1937–1941, is sitting in the centre of the first row (see 
the article by Verica Josimovska, pp. 997–1003). 
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The role of three-phase 99mTc-MDP bone scintigraphy in the diagnosis 
of periprosthetic joint infection of the hip and knee 
Uloga trofazne scintigrafije kostiju sa 99mTc-MDP u dijagnozi periprotetske 
infekcije kuka i kolena  
 
Dragan Pucar*, Zoran Janković*†, Zoran Baščarević‡, Srdjan Starčević†§,  
Milica Čizmić†║, Marija Radulović* 
Military Medical Academy, *Institute of Nuclear Medicine, §Clinic for Orthopedic 
Surgery and Traumatology, ║Clinic for Endocrinology, Belgrade, Serbia; University of 
Defence, †Faculty of Medicine of the Military Medical Academy, Belgrade, Serbia; 
University of Belgrade, Faculty of Medicine, ‡Institute for Orthopedic Surgery 
“Banjica”, Belgrade, Serbia
Abstract 
 
Background/Aim. In the last five decades primary hip and 
knee arthroplasty is the most common and effective surgical 
intervention worldwide. Infection, although unfrequented, 
is the most serious complication. Nuclear medicine imaging, 
not affected by metallic hardware, is the current imaging 
modality of choice for the evaluation of suspected joint re-
placement infection. The aim of this study was to estimate 
the diagnostic accuracy of three phase 99m technetium me-
thylene diphosphonate (99mTc-MDP) bone scintigraphy in 
periprosthetic hip and knee joint infection. Methods. Inclu-
sion criteria of patients in the study were suspected knee or 
hip periprosthetic joint infections. In this study, we exam-
ined 45 patients (14 men and 31 women) with 39 hip and 24 
knee prosthesis (total 63). In all patients, three-phase bone 
scintigraphy was performed after intravenous application of 
555 MBq of 99mTc-MDP. The final confirmation of infec-
tion was microbiological or pathohistology finding. Re-
sults. Infection was confirmed in 29 prosthetic joints, in 13 
(44.8%)  knee and 16 (55.2%) hip joints while there was no 
infection in 34 prosthetic joints. The connection of different 
modalities of negative and positive findings 99mTc-MDP 
three-phase bone scintigraphy with the final confirmation of 
infection showed a high statistical significance (p < 0.001). 
Three phase bone scintigraphy showed a high sensitivity of 
90% but a modest specificity of 69.7% in the detection of 
periprosthetic infection with the diagnostic accuracy of 
79%. The calculated positive predictive value was 73% but 
the negative predictive value was high 89%. Our results of 
three-phase bone scintigraphy with calculated sensitivity, 
specificity and diagnostic accuracy of 79% are in consent 
with the majority of published studies, or even slightly bet-
ter. Conclusion. Bone scintigraphy is sensitive in the diag-
nosis of periprosthetic infection but insufficiently specific. 
In the detection of periprosthetic infections three-phase 
bone scan can be used as a diagnostic method of the first li-
ne only aimed at its exclusion. The only reasonable use of 
bone scintigraphy is in combination with other radionuclide 
methods with high specificity. 
 
 
Key words:  
hip prosthesis; knee prosthesis; infection; diagnosis; 
sensitivity and specificity; technetium tc99m 
medronate. 
Apstrakt 
 
Uvod/Cilj. U poslednjih pet decenija primarna artroplasti-
ka kuka i kolena predstavlja jednu od najčešćih i najefikasni-
jih hirurških intervencija širom sveta. Infekcija, iako retka, 
jeste najozbiljnija komplikacija. Nuklearno medicinsko sni-
manje, koje nije ometeno metalnim hardverom proteskog 
zgloba, je trenutno modalitet izbora za procenu sumnje na 
periprotetsku infekciju zgloba. Cilj ovog istraživanja bio je 
da se proceni dijagnostička tačnost trofazne 99m technetium 
methylene diphosphonate (99mTc-MDP) scintigrafije kostiju kod 
periprotetske infekcije kuka i kolena. Metode. Kriterijumi 
za uključivanje bolesnika u studiju bili su postojanje sumnje 
na periprotetsku infekciju zgloba kuka i kolena. U ovoj stu-
diji smo ispitivali 45 bolesnika (14 muškaraca i 31 žene) sa 
39 implanta kuka i 24 proteze kolena (ukupno 63). Kod svih 
bolesnika bila je urađena trofazna scintigrafija skeleta nakon 
intravenske aplikacije 555 MBq 99mTc-MDP. Konačna pot-
vrda infekcije ustanovljena je bio mikrobiološkim ili patohis-
tološkim nalazom. Rezultati. Infekcija je bila potvrđena 
kod 29 protetskih zglobova, 13 (44,8%) kolena i 16 (55,2%) 
kuka, a isključena kod 34 protetska zgloba. Povezanost raz-
Correspondence to: Dragan Pucar, Military Medical Academy, Institute of Nuclear Medicine, Crnotravska 17, 11 000 Belgrade, Serbia.  
E-mail: draganpucar@yahoo.com  
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ličitih modaliteta negativnih i pozitivnih nalaza 99mTc-MDP 
trofazne scintigrafije kostiju sa konačnom potvrdom infek-
cije pokazuje visoku statističku značajnost (p < 0,001). Tro-
fazna scintigrafija skeleta pokazala je visoku osetljivost od 
90%, ali skromnu specifičnost od 69,7% u otkrivanju perip-
rotetske infekcije, dok je dijagnostička tačnost bila 79%. Iz-
računata pozitivna prediktivna vrednost za metodu iznosila 
je 73%, ali negativna prediktivna vrednost bila je visoka 
(89%). Naši rezultati trofazne scintigrafije skeleta sa vredno-
stima osetljivosti od 90%, specifičnosti od 69,7% i dijagnos-
tičke tačnosti od 79% u saglasnosti su sa većinom objavlje-
nih studija, pa i diskretno bolji. Zaključak. Scintigrafija ske-
leta je osetljiva metoda u dijagnostici periprotetske infekcije, 
ali je nedovoljno specifična. U otkrivanju periprotetske infe-
kcije, trofazna scintigrafija kostiju može se koristiti kao dija-
gnostička metoda prve linije samo u cilju njenog isključiva-
nja. Jedino razumno korišćenje scintigrafije kostiju je u 
kombinaciji sa drugim radionuklidnim metodama visoke 
specifičnosti. 
 
 
Ključne reči: 
kuk, proteza; koleno, proteza; infekcija; dijagnoza; 
senzitivnost i specifičnost; tehnecijum tc99m medronat. 
 
Introduction 
Over the last five decades primary hip and knee 
arthroplasty procedures have been among the most common 
and effective surgical intervention worldwide 1. The number of 
performed joint replacements has significantly increased in re-
sponse to demographic change. The number of total hip art-
hroplasties (THA) carried out in the USA increased 2.5 times 
from 200,216 in 1993 to 497,419 in 2005. In the same period, 
the amount of primary total knee arthroplasties (TKA) grew 
1.7-fold 2. The most implanted artificial joints are hip and knee 
prostheses (more than 95%). Patients who failed conservative 
and comprehensive care may be considered for joint replace-
ment surgery. Intractable pain, severe osteoarthritis (OA), and 
limitation of motion are the main reasons to consider joint re-
placement surgery. Inability to flex the knee more than 90 de-
grees considerably limits the functional capacity of rising from 
a chair. Life expectancy is also an important consideration re-
garding the longevity of joint replacements and the risk of fu-
ture loosening or implant failure. However, some patients have 
prosthesis more than 20 years. The most important contraindi-
cations are an acute infection and severe obesity, while relative 
contraindications include: poor health and high anesthetic 
risks, poor bone stock, significant deformities, severe 
neuropathy. Although hip or knee joint replacement is highly 
successful surgical intervention, long-term outcomes continue 
to suffer from aseptic loosening and periprosthetic joint infec-
tion (PJI). More than 25% of all prostheses will demonstrate 
evidence of loosening, often after a revision arthroplasty 3. 
Most authors agree that many cases understood as aseptic fai-
lure may be due to an unrecognized infection. 
Infection, although unfrequented, is the most serious 
complication. In patients with primary joint replacement, the 
infection rate in the first 2 years usually ranges from 0.5 to 
2%. Commonly isolated microorganisms are Gram-positive 
cocci: coagulase-negative staphylococci, Staphilococcus au-
reus, and enterococci (65%) 4. Infection rates after a surgical 
revision are usually higher (25% to 40%) than after a 
primary replacement 5. Important risk factors for arthroplasty 
are a postoperative surgical site infection, previous 
arthroplasty, older age, malnutrition, joint disease, obesity, 
diabetes mellitus, remote infection 6, 7. 
Increased erythrocyte sedimentation rate (ESR) and 
high C-reactive protein (CRP) levels are sensitive for non-
specific inflammation but not specific for PJI. Findings such 
as radiolucency, osteolysis, and migration obtained by plain 
radiography are not enough sensitive or specific and may be 
present in both infection and aseptic loosening 8. Cross-
sectional imaging techniques, such as computed tomography 
and magnetic resonance imaging, are of limited value in the 
presence of metallic prosthetic implants owing to beam har-
dening and dephasing artefacts 9. 
Nuclear medicine imaging, which is, in general, not af-
fected by metallic hardware, is the current imaging modality of 
choice for the evaluation of suspected joint replacement infec-
tion 10. One of the oldest radionuclide imaging modalities used 
for this purpose is bone scintigraphy (BS) 11. BS is widely ava-
ilable, relatively inexpensive, easily performed, and quickly 
completed. Uptake of bone-seeking tracer such as 99m techne-
tium methylene diphosphonate (99mTc-MDP), which accumu-
lates on the surface of the bone mineral matrix, depends on 
blood flow and especially on the rate of new bone formati-
on 12. The cause of accelerated new bone formation may be se-
en as increased periprosthetic activity on BS in infection, but 
also in the postoperative physiological bone remodeling, as 
well as pathological conditions such as fracture, heterotopic 
ossification and aseptic loosening. Persistent uptake more than 
12 months after arthroplasty is usually abnormal. In general, 
BS is highly sensitive but not very specific for PJI. The litera-
ture on the diagnostic efficiency of bone scintigraphy shows a 
considerable variability due to several factors, such as the use 
of different scan interpretation criteria (quantitative vs 
qualitative approach) and performing a three-phase study in-
stead of only a delayed bone scan. 
The aim of this study was to estimate the diagnostic 
accuracy of three phase 99mTc-MDP bone scintigraphy in pe-
riprosthetic hip and knee joint infection. 
Methods 
A total of 45 patients (14 men and 31 women) with 39 
implanted hip and 24 knee prosthesis (total 63) were inclu-
ded in this study. The mean age of patients was 68.6 (range 
43–82) years. The study was performed during a 5-months 
period from August 2015 to January 2016. Criteria for inclu-
ding patients in this study were suspected PJI based on: pain-
ful prosthetic joint (especially in locomotion but also in peace), 
restricted joint movements and increased value of 
erythrocyte sedimentation rate and/or high levels of C-
reactive protein. All patients underwent plain radiography. 
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Table 1 
Descriptive parameters of the patients 
Parameters Values 
Age (years), mean ± SD 68.64 ± 9.56 
Gender, n (%)  
male 14 (31.1) 
female 31 (68.9) 
Confirmation of infection  
(the gold standard), n (%)  
confirmed 16 (35.6) 
unconfirmed 29 (64.4) 
Total   45 (100.0) 
SD – standard deviation 
 
Table 2 
The relationship between the results of 99mTc-MDP and confirmed infection 
Infection Results of 99mTc-MDP scyntigraphy No Yes Total 
Negative finding 
n 
MDP finding (%) 
Infection (%) 
 
9 
100.0 
26.5 
 
0 
0.0 
0.0 
 
9 
100.0 
14.3 
Borderline negative finding 
n 
MDP finding (%) 
Infection (%) 
 
14 
82.4 
41.2 
 
3 
17.6 
10.3 
 
17 
100.0 
27.0 
Borderline positive finding 
n 
MDP finding (%) 
Infection (%) 
 
5 
45.5 
14.7 
 
6 
54.5 
20.7 
 
11 
100.0 
17.5 
Positive finding 
n 
MDP finding (%) 
Infection (%) 
 
6 
23.1 
17.6 
 
20 
76.9 
69.0 
 
26 
100.0 
41.3 
Total 
n 
MDP finding (%) 
Infection (%) 
 
34 
54.0 
100.0 
 
29 
46.0 
100.0 
 
63 
100.0 
100.0 
Significance χ2 = 23.498;  p < 0.001 
99mTc-MDP – technetium methylene diphosphonate. 
In all patients, after intravenous injection of 555 MBq 
99mTc-MDP, three-phase bone scintigraphy was performed 
on ADAC vertex gamma camera using a large field of view 
dual detectors filtered with low energy all-purpose collima-
tor. Imaging was performed at various times in supine positi-
on: 0–5 minute (15 frames in the first minute and 6 frames in 
further 4 minutes), 6–10 minute (one frame with 300 seconds 
duration) and late static imaging after 3 hours. Scintigrams 
were analyzed visually without any quantification. 
The bone scintigraphy findings were semiquantitative: va-
lue 1 – normal, 2 – borderline normal, 3 – borderline abnormal, 
and 4 – clearly abnormal. The final diagnosis of infection was 
confirmed by microbiological or histopathological results. 
For the purpose of an initial analysis and description, 
usual descriptive statistics were used (mean age, standard de-
viation, number and percentage of frequency characteristics 
within a given set). To test the statistical significance of diffe-
rences the results of bone scintigraphy were compared with the 
gold standard. The χ2 test was used and statistically significant 
differences were evaluated at a level of at least p < 0.05. 
A software package SPSS version 18.0 (USA) was 
used. Sensitivity, specificity and predictive values of bone 
scintigraphy were calculated using the standard formulas. 
Results 
Descriptive parameters of patients are shown in Table 1. 
The relationship between the results of three-phase 
99mTc-MDP bone scintigraphy and confirmed infection is 
shown in Table 2. 
Infection was confirmed in 29 prosthetic joints – 13 (44.8%) 
knee and 16 (55.2%) hip joints, while not found in 34 patients. 
The association between different modalities of negati-
ve and positive findings of 99mTc-MDP three phase bone 
scintigraphy crossed with the final confirmation of infection 
showed high statistical significance (p < 0.001). 
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Three phase bone scintigraphy had a high sensitivity of 
90% but a modest specificity of 69.7% in detecting peripro-
sthetic joint infection, with a diagnostic accuracy of 79%. 
Calculated positive predictive value (PPV) was 73%, but the 
negative predictive value was high – 89%. 
Clearly positive findings of 99mTc-MDP three-phase bo-
ne scintigraphy in detecting periprosthetic joint infection of 
the knee are shown in Figure 1. 
The high negative predictive value of 89% resulted in a 
frequent number of true negative findings (Figure 2). 
Modest specificity of 69.7% in detecting periprosthetic 
joint infection resulted in false positive findings (Figure 3). 
 
Fig. 1 – A 72-year-old female patient with bilateral knee joint replacement. 
In the region of right knee replacement extensive increased activity 
is observed in all three phase of bone scintigraphy indicating infection. 
 
 
Fig. 2 –The results of three-phase 99m technetium methylene diphosphonate (99mTc-MDP) bone scintigraphy are 
negative at all stages of the imaging. Definite result: inadequate joint biomechanics due to adductor muscle  
weakness – aseptic. 
Pucar D, et al. Vojnosanit Pregl 2017; 74(10): 915–920. 
Vol. 74, No 10 VOJNOSANITETSKI PREGLED Page 919 
 
Fig. 3 – Positive findings at all stages of the imaging (increased uptake 
in the region of the greater trochanter and discreetly increased along 
the femoral stem). Definitive result: aseptic loosening. 
Discussion 
Assessment of the presence of periprosthetic joint infec-
tion using bone scan is considered problematic by many aut-
hors. Persistently increased binding of radiopharmaceuticals 
in the first year after application of arthroplasty, suggesting 
accelerated bone remodeling, occurs in approximately 60% 
of cases around the femoral component of the prosthesis and 
in about 90% around the tibial component 13–15. 
Most authors agree that the accuracy of bone 
scintigraphy in the evaluation of possible causes of painful 
prosthesis varies between 50 and 70% and that it is too low 
value for its clinical use unless combined with some other 
radionuclide imaging method of higher specificity 16. 
However, according to the recent study of Zajonz et 
al. 2, which included 320 prosthetic hip and knee joints, the 
obtained accuracy of three-phase bone scintigraphy was as 
much as 90%. Probably the greatest advantage of using this 
method alone is its high negative predictive value of 95%, 
making it a screening method with a high probability of peri-
prosthetic joint infection of the hip and knee 17. In that case 
should not be forgotten that the negative predictive value is 
lower in the first year after arthroplasty and that two-thirds of 
infections occur precisely in that period 8. 
Early efforts made by some authors in differentiating 
aseptic loosening from periprosthetic joint infection by 
analyzing the increased uptake were very interesting. 
Williamson et al. 18 found in 1979 that the focal zone of inc-
reased radiopharmaceutical uptake indicated aseptic loose-
ning, while diffused increased radiopharmaceutical binding 
around the femoral or acetabular endoprosthesis indicated in-
fection. Two years later, Williams et al. 19 reported that 
diffusely increased radiopharmaceutical binding around the 
implant might be an indication of infection and aseptic loo-
sening. Aliabadi et al. 20 published in 1989 that bone scan 
could accurately detect loosening, but not separate aseptic 
loosening from the loosening caused by the presence of in-
fections. Palestro et al. 21 have long argued that bone 
scintigraphy is neither enough sensitive nor specific method 
in the diagnosis of a periprosthetic knee infection. This sta-
tement was supported by some recent studies, except when it 
comes to its sensitivity. The accuracy of this method is 
slightly increased if carried out as a three-phase scintigraphy. 
In 2008 Love et al. 16, considering 150 prosthetic lower limb 
joints (96 joints of the hip and 54 joints of the knee), obtai-
ned a sensitivity of 76% and specificity of 51% in the diag-
nosis of infection. Diagnostic accuracy of 50% was obtained 
if only delayed static scintigraphy was done and increased to 
62% when performed as a three-phase bone scintigraphy. 
Our results of three-phase bone scintigraphy (diagnostic 
sensitivity 90%, specificity 69.7% and accuracy 79%) are in 
consent with the majority of published studies and even 
slightly better. 
Conclusion 
Bone scintigraphy is sensitive in the diagnosis of perip-
rosthetic joint infection, but due to its unacceptable 
specificity, it is not a method that could work independently 
and can not be used alone for detecting a periprosthetic joint 
infection. For that purpose, the three-phase bone scan can be 
used as the first line diagnostic method just for the definitive 
exclusion of infection. The only realistic possibility to use 
bone scintigraphy to detect a periprosthetic joint infection is 
its combination with other radionuclide methods of high 
specificity. 
Pucar D, et al. Vojnosanit Pregl 2017; 74(10): 915–920. 
Page 920 VOJNOSANITETSKI PREGLED Vol. 74, No 10 
R E F E R E N C E S
1. Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckel-
berg JM, et al. Executive summary: Diagnosis and management 
of prosthetic joint infection: Clinical practice guidelines by the 
Infectious Diseases Society of America. Clin Infect Dis 2013; 
56(1): 1−10. 
2. Zajonz D, Wuthe L, Tiepolt S, Brandmeier P, Prietzel T, von Salis-
Soglio GF, et al. Diagnostic work-up strategy for periprosthetic 
joint infections after total hip and knee arthroplasty: a 12-year 
experience on 320 consecutive cases. Patient Saf Surg 2015; 9: 
20. 
3. Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of pri-
mary and revision hip and knee arthroplasty in the United 
States from 2005 to 2030. J Bone Joint Surg Am 2007; 89(4): 
780−5.  
4. Lentino JR. Prosthetic joint infections: Bane of orthopedists, 
challenge for infectious disease specialists. Clin Infect Dis 
2003; 36(9): 1157−61. 
5. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. 
N Engl J Med 2004; 351(16): 1645−54. 
6. Kessler B, Sendi P, Graber P, Knupp M, Zwicky L, Hintermann B, et 
al. Risk factors for periprosthetic ankle joint infection: A case-
control study. J Bone Joint Surg Am 2012; 94(20): 1871−6.  
7. Bongartz T, Halligan CS, Osmon DR, Reinalda MS, Bamlet WR, 
Crowson CS, et al. Incidence and risk factors of prosthetic joint 
infection after total hip or knee replacement in patients with 
rheumatoid arthritis. Arthritis Rheum 2008; 59(12): 1713−20.  
8. Tigges S, Stiles RG, Roberson JR. Complications of hip arthro-
plasty causing periprosthetic radiolucency on plain radio-
graphs. AJR Am J Roentgenol 1994; 162: 1387−91. 
9. Palestro CJ, Love C, Miller TT. Infection and musculoskeletal 
conditions: Imaging of musculoskeletal infections. Best Pract 
Res Clin Rheumatol 2006; 20: 1197−218. 
10. Love C, Marwin SE, Palestro CJ. Nuclear medicine and the in-
fected joint replacement. Semin Nucl Med 2009; 39(1): 66−78. 
11. Palestro CJ, Love C. Radionuclide imaging of musculoskeletal in-
fection: conventional agents. Semin Musculoskelet Radiol 
2007; 11(4): 335−52.  
12. Love C, Din AS, Tomas MB, Kalapparambath TP, Palestro CJ. Ra-
dionuclide bone imaging: an illustrative review. Radiographics 
2003; 23(2): 341−58. 
13. Ashbrooke AB, Calvert PT. Bone scan appearances after unce-
mented hip replacement. J R Soc Med 1990; 83(12): 768−9. 
14. Rosenthall L, Lepanto L, Raymond F. Radiophosphate uptake in 
asymptomatic knee arthroplasty. J Nucl Med 1987; 28(10): 
1546−9. 
15. Hofmann AA, Wyatt RW, Daniels AU, Armstrong L, Alazraki N, 
Taylor A. Bone scans after total knee arthroplasty in asympto-
matic patients: cemented versus cemen-tless. Clin Orthop Re-
lat Res 1990; 251: 183−8. 
16. Love C, Tronco G, Yu A, Marwin S, Nichols K, Palestro C. Diag-
nosing lower extremity (LE) prosthetic joint infection: Bone, 
gallium & labeled leukocyte imaging. J Nucl Med 2008;  
49(Suppl 1): 133P.  
17. Smith SL, Wastie ML, Forster I. Radionuclide bone scintigraphy 
in the detection of significant complications after total knee 
joint replacement. Clin Radiol 2001; 56(3): 221−4. 
18. Williamson BR, McLaughlin RE, Wang GW, Miller CW, Teates 
CD, Bray ST. Radionuclide bone imaging as a means of differ-
entiating loosening and infection in patients with a painful to-
tal hip prosthesis. Radiology 1979; 133(3 Pt 1): 723−5. 
19. Williams F, McCall IW, Park WM, O'Connor BT, Morris V. Gal-
lium-67 scanning in the painful total hip replacement. Clin Ra-
diol 1981; 32(4): 431−9. 
20. Aliabadi P, Tumeh SS, Weissman BN, McNeil BJ. Cemented total 
hip prosthesis: radiographic and scintigraphic evaluation. Ra-
diology 1989; 173(1): 203−6. 
21. Palestro CJ, Swyer AJ, Kim CK, Goldsmith SJ. Infected knee pros-
theses: Diagnosis with In-111 leukocyte, Tc-99m sulfur col-
loid, and Tc-99m MDP imaging. Radiology 1991; 179(3): 
645−8. 
Received on March 03, 2016. 
Accepted on March 18, 2016. 
Online First June, 2016. 
   
 
Pucar D, et al. Vojnosanit Pregl 2017; 74(10): 915–920. 
Vojnosanit Pregl 2017; 74(10): 921–926. VOJNOSANITETSKI PREGLED Page 921 
O R I G I N A L  A R T I C L E    UDC: 616.858 https://doi.org/10.2298/VSP150723264D 
Risk factors for levodopa-induced dyskinesia in Parkinson’s disease 
patients 
Faktori rizika od diskinezija uzrokovanih levodopom kod obolelih od 
Parkinsonove bolesti  
 
Gordana Djurić*, Vladana Marković†, Tatjana Pekmezović‡, Aleksandra Tomić†, 
Nikola Kresojević†, Vladimir Kostić†, Marina Svetel† 
*Railway Health Care Institute, Belgrade, Serbia; Clinical Center of Serbia, †Neurology Clinic, 
Belgrade, Serbia; University of Belgrade, Faculty of Medicine, ‡Institute of Epidemiology, 
Belgrade, Serbia
Abstract 
 
Background/Aim. Levodopa, the precursor of dopamine, is a 
substitute therapy for Parkinson's disease. Long-term applica-
tion of levodopa causes fluctuation in motor response and the 
occurrence of involuntary movements or dyskinesia. The aim 
of this study was to assess the risk factors for dyskinesia in 
Parkinson’s disease (PD) patients undergoing treatment with 
levodopa. Methods. We included 177 consecutive outpatients 
with PD, who had been undergoing treatment for at least six 
months. A semi-structured interview was used to collect demo-
graphic and clinical data as well as a number of clinical scales. 
Results. Patients with dyskinesia (n = 90) were younger at dis-
ease onset and had longer disease duration. They had higher 
Unified Parkinson's Disease Rating Scale (UPDRS) scores and 
more frequently had other motor complications, such as 
wearing-off and freezing of gait, as well as non-motor ones, 
such as psychosis. They took higher levodopa doses and 
levodopa equivalent doses and were on levodopa therapy for 
a longer period of time. Multivariate analysis yielded that in-
dependent risk factors for dyskinesia were: disease duration 
of longer than 10 years [relative risk (RR = 2.90), 95% confi-
dence interval (CI) 1.19–7.10; p = 0.019), dopaminergic 
treatment duration of longer than 94 months (RR = 3.21, 
95% confidence interval (CI) 1.05–9.87; p = 0.041) and 
levodopa dosage of higher than 537 mg (RR = 3.62, 95%IP 
1.57–8.35; p = 0.002). Conclusion. We highlight the impor-
tance of known risk factors for dyskinesia and their occur-
rence in the context of advanced, complicated disease.  
 
 
Key words:  
parkinson disease; disease progression; levodopa; 
dyskinesia, drug-induced; risk factors; surveys and 
questionnaires.
Apstrakt 
 
Uvod/Cilj. Levodopa, prekursor dopamine pretstavlja supsti-
tucionu terapiju Parkinsonove bolesti. Dugotrajna upotreba 
levodopa uzrokuje fluktacije motornog odgovora i pojavu nežel-
jenih pokreta ili diskineziju. Cilj rada bio je procena značaja faktora 
rizika od razvoja diskinezija uzrokovanih levodopom kod obolelih 
od Parkinskonove bolesti (PB). Metode. Istraživanje je obuhvatilo 
177 bolesnika sa PB, regrutovanih na Neurološkoj klinici 
Kliničkog centra Srbije (Beograd), čije lečenje je trajalo duže od 
šest meseci. Za ispitivanje obolelih korišćene su standardizovane 
skale za kvantifikovanje PB, ali i detaljni posebno konstruisani 
upitnik za ovu studiju sa demografskim i kliničkim podatcima. 
Rezultati. Bolesnici sa diskinezijama (n = 50) bili su mlađi na po-
četku bolesti i imali su duže trajanje bolesti. Takođe, oboleli sa 
diskinezijama imali su veće skorove na Unified Parkinson's Disease 
Rating Scale (UPDRS), učestalije motorne komplikacije – fluktua-
cije terapijskog odgovora (bilo u formi skraćenja trajanja pojedi-
načnih doza (“wearing off”) ili motornih blokova hoda (“freez-
ing”) i češće su ispoljavali medikamentoznu psihozu. Oni su bili i 
na statistički višim dozama levodope, ali i višoj ekvivalentnoj dozi 
levodope, pri čemu je njihovo lečenje trajalo značajno duže. Multi-
varijantna analiza pokazala je da su nezavisni prediktori pojave 
diskinezija u grupi bolesnika sa PB bili: dužina bolesti preko 10 
godina [relativni rizik (RR = 2.90, 95% interval poverenja (IP) 
1.19–7.10; p = 0.019), dužina terapije više od 94 meseci 
(RR = 3.21, 95%IP 1.05–9.87; p = 0.041), dnevna doza levodope u 
trenutku ispitivanja veća od 537 mg (RR = 3.62, 95%IP 1.57–8.35; 
p = 0.002). Zaključak. Potvrđen je značaj poznatih faktora rizika 
od razvoja diskinezija u odmakloj fazi Parkinsonove bolesti. 
 
Ključne reči: 
parkinsonova bolest; bolest, progresija; levodopa; 
diskinezija izazvana lekovima; faktori rizika; ankete i 
upitnici. 
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Introduction 
Parkinson's disease (PD) is a progressive neurodegene-
rative disorder whose key motor manifestations (e.g., 
bradykinesia, rigidity, tremor at rest) mainly result from the 
degeneration and death of dopaminergic neurons in substan-
tia nigra pars compacta, with effects of a hypo-
dopaminergic state and disturbed dopaminergic neurotran-
smission in the striatum 1.  Levodopa, the precursor of do-
pamine, is a substitute therapy, which, following more than 
half of a century since its introduction, continues to be the 
basis of PD treatment 2 because it enables control of the basic 
motor symptoms which have occurred due to lack of dopa-
mine.  In idiopathic PD a good response to levodopa is the 
rule, which has also become a part of diagnostic criteria for 
this disease 3. However, the long-term application of levodo-
pa has been followed with, amongst others, the occurrence of 
motor complications which generally involve the fluctuation 
of motor response and the occurrence of involuntary move-
ments or dyskinesia 4, 5. 
The first description of dyskinesia was given by Cotzias 
et al. 6 in affected patients who were initially successfully 
treated with levodopa. It has been shown that the dyskinesia 
additionally disables the affected individuals, sometimes 
even more so than the basic disease, and moreover, it limits 
the ability for treatment with dopaminomimetic drugs 7. Even 
though it is considered that dyskinesias are unavoidable at 
some point of disease progression, not all affected individu-
als will develop them at the same time, nor will their 
intensity be uniform 8. As a risk factor for the development 
of dyskinesias, notables are: an earlier onset of PD, a longer 
duration of disease, longer exposure to levodopa, higher total 
dose of levodopa, female sex, and likely, different genetic 
factors 9, 10. Their recognition is especially important for the 
planning of individual therapies 11. 
The aim of our study was to identify demographic and 
clinical factors of risk which most significantly impact the 
appearance of dyskinesia during the chronic use of levodopa 
in our population of affected individuals with PD. 
Methods 
Our research included 177 patients with PD, who were 
recruited at the Neurology Clinic of the Clinical Center of 
Serbia from 2009 to 2011. The PD diagnosis was made ac-
cording to the afore-published criteria of Ward and Gibb 3. 
Demographic and clinical data were obtained through the use 
of a detailed, specially designed (for this study) 
questionnaire which, among other facts, included the age of 
the patient at onset of PD, the initial dose of levodopa, the 
latency period between the first PD symptoms and the be-
ginning of levodopa therapy, the time of the occurrence of 
dyskinesia, and the therapy that the patient underwent at that 
time, use of other antiparkinsonian drugs and levodopa-
equivalent doses (calculated per the method described by 
Tomlinson et al. 12). 
The PD severity was assessed with reference to the Uni-
fied PD Rating Scale (UPDRS) 13, and in order to determine 
the stage of disease, the Hoehn and Yahr 14 (HY) system was 
applied. The functionality and performance of daily activities 
were assessed using the modified Activities of Daily Living 
Scale 15. Dyskinesia was quantified per the modified Abnor-
mal Involuntary Movement Scale (AIMS) 16 and Goetz’s 
scale for the Quantification of Dyskinesia 17. For the asses-
sment of depression and anxiety, the Hamilton Depression 
Rating Scale (HDRS) 18 and the Hamilton Anxiety Rating 
Scale (HARS) 19 were used, respectively, and for patient co-
gnitive function, the Mini Mental State Examination 
(MMSE) 20 was applied. Testing was performed during the 
“on” phase (the phase in which the optimal drug therapy and 
motor improvement were achieved in the patient). 
Statistical analysis of the acquired data involved the 
following methods: descriptive statistics, parametric and 
non-parametric tests, univariate and multivariate logistic re-
gression analysis.  For the comparison of continuous variab-
les, we used the analysis of variance, and for the categorized 
variables, the χ2 test. The criteria for the multivariate model 
were defined by the statistical significance of 0.05, obtained 
from the  univariate analysis. As a measure of the effects, re-
lative risk (RR) was used with a 95% confidence interval 
(95% CI). 
Results 
In our study 177 PD patients were involved, 118 
(65.5%) men and 61 (34.5%) women, of an average age of 
58.9 ± 10.9 years (mean value ± standard deviation), with di-
sease onset at the age of 49.0 ± 11.2 years, and a duration of 
9.7 ± 6.2 years. 
Of the 177 patients in the study group, 90 developed, 
whereas 87 did not develop dyskinesia (Table 1). Patients in 
these two groups did not have any differences based on sex, 
dominant hand, age, education, heredity, and form of PD, or 
presence of depression symptoms. The statistically signifi-
cant difference was noted for age at onset of PD, duration of 
disease and MMSE score (Table 1). 
Patients with dyskinesia were at a statistically signifi-
cant more advanced PD stage, as well as higher scores on the 
UPDRS, and more problems in daily functioning as measu-
red per the Schwab and England scale (Table 2). This group 
of affected patients had statistically significant more frequent 
fluctuations in therapeutic response (either in the form of a 
shorter duration of individual doses (referred to as wearing 
off), or the on-off phenomenon. They developed motor 
blocks while walking (referred to as freezing of gait) more 
frequently and with a shorter latency from the both disease 
onset and the moment in which treatment began, in compari-
son to the patients without dyskinesia (Table 2). Finally, pa-
tients with dyskinesia in a statistically significant manner, 
more often demonstrated medication psychosis. 
PD patients with dyskinesia, as compared to those 
without dyskinesia, in a statistically significant manner, dif-
fered with respect to the duration of treatment, application of 
therapy (more often were on levodopa, amantadine and clo-
zapine, and less often on monoamine oxidase (MAO) B inhi-
bitors) (Table 3). In addition, these patients were on larger 
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Table 1  
Demographic and clinical characteristics of Parkinson's disease (PD) patients (n = 177), with and without  
dyskinesia 
Parameters PD-Dys+ PD-Dys- p 
Patients, n (%) 90 (50.8) 87 (49.2) 0.214 
Male, n (%) 57 (63) 59 (68) 0.530 
Right-hand dominant, n (%) 88 (98) 84 (97) 0.623 
Age (years), ґ ± SD (range) 60.3 ± 8.9 (38–79) 57.3 ± 12.7 (28–82) 0.067 
Education (years), ґ ± SD (range) 11.4 ± 3.7 (3–17) 12.4 ± 3.3 (4–17) 0.136 
Positive family history, n (%) 20 (22) 13 (15) 0.214 
Age at PD onset (years), ґ ± SD (range) 47.3 ± 9.6 (20–66) 50.7 ± 12.4 (27–72) 0.045 
Duration of disease (years), ґ ± SD (range) 12.5 ± 6.7 (3–37) 6.7 ± 5.1 (0–25) 0.001 
Form of disease, n (%)   0.241 
tremor dominant 44 (49) 43 (49)  
akinetic-rigid 24 (27) 20 (23)  
postural instability 12 (13) 11 (13)  
MMSE score, n (%) 27.6 ± 3.1 (14–30) 28.5 ± 2.2 (16–30) 0.033 
HDRS score, n (%) 11.7 ± 8.6 (0–39) 10.3 ± 7.2 (0–26) 0.220 
HARS score, n (%) 7.7 ± 6.1 (0–21) 6.9 ± 5.8 (0–22) 0.506 
PD-Dys+ – PD patients with dyskinesia; PD-Dys- – PD patients without dyskinesia; MMSE – Mini Mental State 
Examination; HARS – HDRS – Hamilton’s Depression Rating Scale; Hamilton’s Anxiety Rating Scale;  
ґ – mean; SD – standard deviation. 
 
Table2  
Severity of motor and non-motor symptoms in Parkinson's disease (PD) patients with and without dyskinesia 
Parameters PD-Dys+ PD-Dys- p 
H-Y state, ґ ± SD (range)  2.5 ± 0.7 (1.5–4) 2.1 ± 0.5 (1–3) 0.001 
UPDRS total score, ґ ± SD (range) 68.9 ± 22.3 (15–125) 48.8 ± 22.2 (7–101) 0.001 
SE score, ґ ± SD (range) 72.6 ± 16.1 (3–100) 80.6 ± 13.2 (50–100) 0.001 
Fluctuations, n (%) 72 (80) 26 (30) 0.001 
latency from PD onset (months), ґ ± SD (range) 77.2 ± 47.3 (0–252) 61.8 ± 50.9 (0–180) 0.179 
latency from introduction of therapy (months), ґ ± SD (range) 73.7 ± 46.7 (12–294) 55.2 ± 30.5 (5–144) 0.073 
Wearing off, n (%) 60 (67) 21 (24) 0.001 
On-off, n (%) 25 (28) 7 (8) 0.001 
Motor blockade (freezing), n (%)  50 (56) 22 (25) 0.001 
Latency from PD onset (months), ґ ± SD (range)  97.2 ± 59.6 (6–240) 62.8 ± 67.3 (0–288) 0.037 
Latency from introduction of therapy (months), ґ ± SD (range) 102.5 ± 53.6 (20–294) 62.7 ± 39.6 (0–168) 0.004 
Medication psychosis, n (%) 31 (34) 10 (12) 0.001 
PD-Dys+ – PD patients with dyskinesias; PD-Dys- – PD patients without dyskinesia; H-Y – Hoehn-Yahr;  
UPDRS – Unified Parkinson’s Disease Rating Scale; SE – Schwab and England. 
ґ – mean; SD – standard deviation. 
 
Table 3  
Therapy applied in Parkinson's disease (PD) patients with and without dyskinesia 
Parameters PD-Dys+ PD-Dys- p 
Latency (symptoms onset until therapy introduction) (months),  ґ ± SD  22.5 ± 25.6  19.2 ± 17.9  0.320 
Duration of therapy (months), ґ ± SD 129.5 ± 62.7  58.1 ± 52.8  0.001 
Levodopa, n (%) 90 (100) 70 (81) 0.001 
Pramipexole, n (%) 36 (40) 28 (32) 0.279 
Ropinirole, n (%) 23 (26) 16 (18) 0.250 
Bromocriptine, n (%) 15 (17) 5 (6) 0.022 
Amantadine, n (%) 64 (71) 25 (29) 0.001 
MAO B inhibitors, n (%) 2 (2) 9 (11) 0.024 
COMT inhibitors, n (%) 4 (4) 5 (6) 0.693 
Clozapine, n (%) 27 (31) 10 (12) 0.003 
Anticholinergics, n (%) 13 (14) 6 (7) 0.117 
PD-Dys+ – PD patients with dyskinesia; PD-Dys- – PD patients without dyskinesia; MAO-B – monoamine oxidaze B; 
COMT – catechol-O-methyltransferase. 
ґ – mean; SD – standard deviation. 
 
doses of levodopa (605 ± 212 mg vs 450.7 ± 200.8 mg), and 
also on higher levodopa equivalent doses (808.3 ± 256.9 mg 
vs 497.3 ± 286.5; p = 0.000). 
Multivariate analysis demonstrated that independent pre-
dictors of the onset of dyskinesia in the group of patients with 
PD were: duration of disease of more than 10 years (RR = 2.90, 
95% CI 1.19–7.10; p = 0.019), duration of levodopa therapy of 
more than 94 months (RR = 3.21, 95% CI 1.05–9.87; 
p = 0.041), daily dose of levodopa at the date of testing of more 
than 537 mg (RR = 3.62, 95% CI 1.57–8.35; p = 0.002), and 
amantadine therapy (RR = 2.99, 95% CI 1.29–6.89; p = 0.010). 
The results of univariate analysis are not shown. 
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In regard to certain types of involuntary movements 
(dyskinesias) that were noted, the most frequent among 
them were choreatic ones (82.2%), followed by dystonic 
movements (77.8%), whereas ballistic dyskinesias (8.9%) 
were least frequent. Dyskinesias were most often presented 
at the moment when the highest concentration of levodopa 
was attained after each individual dose (“peak of dose” 
dyskinesia, 77.8%), in approximately one-half of patients 
they appeared at the end of the effectiveness of the indivi-
dual dose of levodopa (“end of dose” dyskinesia, 45.6%), 
whereas diphasic dyskinesia (at the beginning and at the 
end of the effectiveness of the individual dose of levodopa) 
were identified in only 4.4% of the test subjects. 
Dyskinesias in 73% of the patients worsened their functio-
nal abilities, and such disability was heavy in 15.4%, mo-
derate in 46.2% and light in 38.5% of the PD patients.  
Dyskinesia appeared with a latency of 74.6 ± 48.8 months 
from the initiation of dopaminergic therapy. 
Discussion 
The main findings of our research indicate that PD pati-
ents who developed dyskinesia, differed from those who did 
not, according to the following:  age at the onset of disease, 
length of disease, results on the MMSE scale, and had a mo-
re difficult form of Parkinson’s disease, higher scores on the 
UPDRS, greater difficulty in daily functioning, more 
frequent motor fluctuations and medication-induced 
psychosis, in the duration of treatment and in larger daily do-
ses of levodopa, or of dopaminometics. As the strongest pre-
dictors of dyskinesia induced by levodopa, the following 
were identified:  the length of disease of more than 10 years, 
length of treatment of more than 94 months and an actual 
daily dose of levodopa of more than 537 mg. 
Dyskinesias developed in approximately 50% of pati-
ents involved in our study, which is in accordance with the 
average findings of other researches (30%–80%). This range 
is explained by the variety of methodological approaches 
used in identifying dyskinesia, by the different age groups 
that were analyzed, and by the difference in the length of 
monitoring of affected patients. In individuals who have had 
PD for 4 to 7 years, the presence of dyskinesia has been 
20%–40% 21–23. Schrag and Quinn 24 found dyskinesia in 
32% of patients treated with levodopa for 6 to 9 years, and in 
89% of patients treated for more than 10 years. In the DA-
TATOP study 23 after 20.5 months of being treated with Le-
vodopa, dyskinesias presented in a third of the PD patients.  
In short, it is assumed that after a sufficiently long treatment 
period with levodopa, all patients will, in the end, develop 
dyskinesia 25. 
Similarly to the other authors 26, we identified chorea 
and dystonia as the most frequent types of dyskinesia that 
arise from levodopa use. They presented most frequently as 
the peak of dose dyskinesias, but in almost half of the pati-
ents, they manifested at the end of the levodopa dose effecti-
veness (“end of dose” dyskinesia). Dyskinesia heavily disab-
led only 15% of our patients. This result is similar to the fin-
ding that dyskinesia whose intensity requires therapeutic in-
tervention, or otherwise the adjustment of levodopa therapy 
after a treatment period of 10 years, is found in 12% of pati-
ents 8. This finding is identical to the Sidney study 25 that re-
vealed that only 12% of patients developed a difficult (or 
heavy) form of dyskinesia. 
The development of dyskinesia is associated with diffe-
rent risk factors such as an earlier onset of disease, a longer 
duration and difficulty of PD, a longer duration of treatment 
with levodopa, a larger cumulative dose of levodopa, a hig-
her daily dose of levodopa at the time of testing, and also its 
initial daily dose, female sex and possible genetic fac-
tors 9, 10, 27. Our study confirmed the significance of these fac-
tors in the development of dyskinesia arising from levodopa. 
Of particular significance in the planning of individual 
therapy is the finding that in individuals who had an earlier 
onset of PD, fluctuations and dyskinesia more frequently 
presented, and thus such affected patients had a more diffi-
cult disease progression. After five years of treatment with 
levodopa, more than 50% of patients in which PD was pre-
sented during the ages of 40 through 59, had dyskinesia, 
while such frequency decreased in the group with PD was 
arising during the ages of from 60 to 69, to 26% or even 16% 
in so far as the PD was presented after the age of 70 9, 28. Ko-
stic et al. 28 indicate that after five years of levodopa treat-
ment, they identified dyskinesia in 90% of patients in which 
PD had been presented before the age of 40. Hence, the same 
authors suggest initial therapy with dopamine agonists inste-
ad of levodopa for patients with PD for whom disease onset 
is presented at earlier age 11. Dyskinesia was more prevalent 
in patients treated with higher daily doses of levodopa. This 
is in agreement with the findings of the ELLDOPA study 29 
which demonstrated that the prevalence of dyskinesia increa-
sed with the increase in a daily dose of levodopa. 
In our research, the length of the duration and difficulty 
of PD were significant factors.  Van Gerpen et al. 8 showed 
that in a group of 126 PD patients, the likelihood that 
dyskinesia will develop during the first five years of illness 
was 30%, whereas it was 59% during the first ten years of il-
lness. Advanced forms of PD with greater pathological fin-
dings upon the introduction of levodopa were followed by 
the faster onset of heavier forms of dyskinesia in comparison 
to the lighter forms of the illness 30, which also was confir-
med in the animal model of PD 31. 
As a key factor in the development of dyskinesia, intermit-
tent (“pulse”), non-physiologic stimulation of dopamine recep-
tors in the basal ganglia utilizing standard oral forms of dopami-
ne mimetics was noted, as in all of our patients 32, 33. Hence a 
large segment of pharmacotherapeutic interventions is focused 
on establishing forms of treatment by which continuous dopa-
minergic stimulation is achieved 34. The finding that dyskinesia 
is more rarely presents in patients being treated with dopamine 
agonists in relation to levodopa 35 is explained by their longer 
half-life in blood plasma. The finding of our study that PD pati-
ents with dyskinesias, in comparison to those without them, 
were significantly more frequently treated with amantadine, can 
be explained by the fact that at this moment, it is the only drug 
that specifically lessens their intensity 36. This can in part be an 
explanation for the more frequent use of clozapine in this 
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group of patients because it possesses anti-dyskinetic ef-
fects too 36, however, it is much more likely that a more 
frequent presentation of medication psychosis occurred in 
this group. It is interesting to note that affected patients 
who did not develop dyskinesia, in a statistically relevant 
manner more frequently received selegiline therapy (MAO 
B inhibitor), however the scope and methodology of our 
study are inadequate so as to be able to present the assump-
tion that this drug has a protective effect involved in the 
onset of dyskinesia.  The application of MAO B inhibitors 
in the early phase of PD was connected with the 
statistically relevant, less frequent fluctuations in motor re-
sponse, whereas such a difference was not noted with res-
pect to dyskinesias 37.  
Conclusion 
In our research, on average, slightly more than half of 
our PD patients developed dyskinesia. In comparison to the 
patients without dyskinesia, they were significantly younger 
at the onset of disease, the PD had a longer duration, and PD 
patients were on levodopa therapy for a longer period, and 
on the statistically significant higher daily dose. 
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Abstract 
 
Background/Aim. Recent studies have shown a significant 
relation of the post-traumatic stress disorder and impairment 
of quality of life. The research on the relations of other stress-
related disorders and quality of life is scarce. The aim of this re-
search was to determine which symptoms within the stress-
related disorders (depressive, anxious and somatization) have 
the strongest effect on the quality of life decrease. Methods. 
The study group comprised 80 subjects who have developed a 
certain stress-related disorder. The diagnosis was made based 
on the International Classification of Diseases (ICD-10) crite-
ria. Manchester Short Assessment Quality of Life Scale 
(MANSA) and Symptom Check List-90 Revised (SCL-90-R) 
were administered. Results. The presence of all three types of 
symptoms (depressive, anxious or somatization) was in nega-
tive correlation with the quality of life, contributing to the vari-
ation of quality of life with 40%. Depressive symptoms had the 
greatest impact on the quality of life impairment. Conclusion. 
When it comes to stress-related disorders, the quality of life is 
mostly impaired by depressive symptoms. Target therapeutic 
interventions aimed at depressive symptoms might have a sig-
nificant effect on the quality of life improvement in the person 
who developed stress-related disorders. 
 
Key words:  
stress, psychological; quality of life; surveys and 
questionnaires; stress disorders, post-traumatic; 
depression; neurotic disorders; somatoform disorders.
Apstrakt 
 
Uvod/Cilj. Skorašnje studije pokazale su značajnu povezanost 
posttraumatskog stresnog poremećaja i smanjenja kvaliteta života. 
Istraživanja o korelaciji drugih poremećaja povezanih sa stresom i 
kvaliteta života izuzetno su retka. Cilj ovog istraživanja bio je da se 
utvrdi koji simptomi u okviru poremećaja povezanih sa stresom 
(depresivni, anksiozni i somatizacioni) najviše utiču na smanjenje 
kvaliteta života. Metode. Studijska grupa sastojala se od 80 
ispitanika koji su razvili neki od poremećaja povezanih sa stresom. 
Dijagnoza je postavljena na osnovu kriterijuma Međunarodne 
klasifikacije bolesti (MKB-10). Primenjeni su sledeći instrumenti: 
Mančesterska kratka skala za procenu kvaliteta života (Manchester 
Short Assessment Quality of Life Scale – MANSA) i revidirana lista 
simptoma (Symptom Check List-90 Revised – SCL-90-R) Rezultati. 
Prisustvo sve tri grupe simptoma (depresivni, anksiozni i 
somatizacioni) bilo je u negativnoj korelaciji sa kvalitetom života, 
doprinoseći varijaciji kvaliteta života sa 40%. Depresivni simptomi 
imali su najveći uticaj na smanjenje kvaliteta života. Zaključak. 
Depresivni simptomi kao deo poremećaja povezanih sa stresom 
najviše utiču na smanjenje kvaliteta života. Ciljane terapijske 
intervencije usmerene na depresivne simptome mogle bi imati 
značajan uticaj na poboljšanje kvaliteta života kod osoba koje su 
razvile neki od poremećaja povezanih sa stresom. 
 
Ključne reči: 
stres, psihički; kvalitet života; ankete i upitnici; stresni 
poremećaji, posttraumatski; depresija; neurotski 
poremećaji; psihofiziološki poremećaji. 
 
Introduction 
Stress-related disorders always appear as a direct 
consequence of an acute severe stress or of continuous trau-
ma, i.e. they represent a maladaptive response to a severe or 
continuous stress. It is necessary to emphasize that the stress 
or continuous trauma are primary etiological factors, i.e. that 
the disorder would not develop in their absence 1. According 
Correspondence to: Vanja Mandić Maravić, Institute of Mental Health, Palmotićeva 37, 11 000 Belgrade, Serbia. Fax: +381 11 3231 333. 
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to the Tenth Revision of the International Classification of Dise-
ases and Related Health Problems (ICD-10) 1, stress-related di-
sorders are the disorders that are identified not only by their 
symptoms and course but also based on one of two causing ef-
fects – extremely stressful life events or significant life changes. 
The above-mentioned criteria are met by the diagnostic 
category F 43 (Reaction to severe stress and adjustment disor-
ders) which includes: F 43.0 (Acute stress reaction), F 43.1 
(Post-traumatic stress disorder – PTSD), and F 43.2 (Adjus-
tment disorders). Apart from these diagnoses, one more diagnos-
tic category meets the above-mentioned criteria – F 62.1 (Endu-
ring personality changes after catastrophic experience) 1. 
During the past two decades, the prevalence of the stress-
related disorders significantly increased in our country due to 
numerous stressful factors 2–5. Some recent studies have shown 
a significant relationship between PTSD and the decrease in 
quality of life (QOL) 6, which we have also shown in our pre-
vious research 7. Studies on the relationship between other 
stress-related disorders and QOL are rather scarce. Studies on 
adjustment disorders are mostly done in populations of soma-
tic patients, and their results show that the QOL is significantly 
lower in those who develop these disorders rather than those 
who suffer from the somatic disease alone 8. 
The QOL as a concept became significant with the emer-
gence of an idea that the impact of the disease was not limited 
only to symptoms and signs, but also to the global subjective 
impression of one’s health. Therefore, the QOL may be conside-
red as an operational measure of the overall health and welfare 9. 
According to the definition of the World Health Organization, 
the QOL is defined as “individuals' perception of their position 
in life in relation to their goals and in the context of value 
systems, incorporated in their decision making” 10. This definiti-
on primarily emphasizes the significance of the individual’s rea-
diness and capacity to communicate and participate in the per-
sonal QOL assessment. 
Mental disorders have a significant impact on the life 
of an individual. Apart from the symptoms of a disorder, 
the following are present: changes in functionality and in 
access to the resources and possibilities, the subjective sen-
se of welfare, burden on the family, and sometimes endan-
gered safety of the society. Due to a wide range of the rele-
vant consequences, and the prevailing opinion that the as-
sessment should include patient’s perspective as well, the 
increased attention has been directed to the development of 
the measures and procedures for the assessment of their 
QOL 11, 12. 
Clinical experience suggests that specific forms of di-
sorders from the stress-related group can have various im-
pacts on patients’ QOL 13, 14, affecting physical as well as 
mental health 15. Patients may have difficulties in work or in 
relationships with others, as well as problems in leisure acti-
vities due to cognitive symptoms of fear, worry, and obsessi-
ons, they may be upset due to symptoms of increased 
irritability that are present in PTSD, or can be limited by 
avoidance symptoms that are inherent to this group of disor-
ders. The researchers have only recently started to examine 
this topic in a more comprehensive and sophisticated way, 
using various approaches on different samples 16. 
The studies which were not focused on stress-related 
disorders have shown the influence of anxious and depressi-
ve symptoms on the reduction of QOL 17–19 , with the notion 
that depressive symptoms lead to a decrease in quality of life 
significantly more compared to the anxious symptoms 20. 
Furthermore, it has been shown that in PTSD patients who 
had depressive comorbidity, the QOL decreased to the most 
significant extent 21. Studies focusing on QOL in somatic ill-
nesses showed that it decreases significantly if patients deve-
lop depression 22, 23. 
In our previous study 7, we showed that persons in 
whom some stress related disorders were diagnosed had a 
significantly lower QOL compared to persons who 
experienced stress but did not develop a disorder. 
The aim of our study was to determine which type of 
symptoms within the group of stress-related disorders (dep-
ressive, anxious, and somatization symptoms) has the stron-
gest impact on the decrease of the QOL. By defining the type 
of symptoms that are the most important for the decrease of 
the QOL, a more directed treatment and prevention of disor-
ders from this group could be achieved, thus improving the 
QOL of patients. 
Methods 
Sample 
The sample comprised 80 subjects who were recruited 
during the period from 2002 to 2005. It included patients 
from a University Psychiatric Clinic who developed some 
of the stress-related disorders after a stressful life event.  
This group comprised 31 men (38.75%) and 49 women 
(61.25%), with average age 42.16 years [standard deviation 
(SD) = 11.56], ranging from 18 to 68 years. This sample of 
80 subjects was the study group described in our aforemen-
tioned research 7, for which we have shown significantly 
greater impairment of quality of life for these 80 subjects, 
in comparison to the control group (80 subjects who 
experienced a stressful life event but did not develop a 
stress-related disorder). The total score of the QoL (measu-
red by Manchester Short Assessment Quality of Life Scale 
– MANSA) 24 in the study group was 42.99 ± 9.5, while the 
same score in the control group was 53.01 ± 8.23 
(p < 0.01) 7. 
The diagnosis was based on clinical psychiatric 
interview and was made according to ICD-10 criteria 1. The 
sample did not include patients with the accompanying 
psychiatric comorbidity. All subjects experienced a traumatic 
or stressful life event that led to the development of the di-
sorder (acute stress reaction, PTSD, adjustment disorder and 
enduring personality change after a catastrophic experience); 
none of them had received any psychiatric treatment. All su-
bjects were given the explanation about the aims of the study 
and have signed the Informed Consent Form. The 
confidentiality of obtained results was preserved. The study 
was approved by the Ethical Committee and was carried out 
according to the good research practice of the Faculty of 
Medicine in Belgrade. 
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Table 1 
The significance of contribution of somatization, depressive and anxious symptoms (SCL-90-R)  
 to prediction of quality of life (MANSA) 
Symptoms 
type β t p Correlation 
Partial 
correlation 
Semipartial 
correlation 
Somatization -0.267 -2.77 0.01 -0.50 -0.22 -0.17 
Depressive -0.610 -6.16 0.00 -0.61 -0.44 -0.38 
Anxious 0.240 2.18 0.03 -0.43 0.17 0.13 
Instruments 
The following questionnaires were administered to all 
the subjects: MANSA 24  and Symptom Check List-90 Revi-
sed (SCL- 90-R) 25. 
MANSA 24 is a short scale which assesses the general 
level of the QOL often used for evaluation of mental health, 
and it consists of three parts. The first part includes general 
data (date of birth, gender, ethnic background, and the diag-
nosis of disorder). The second part includes nine questions 
related to education, employment, finances, state support, 
dwelling conditions, the number of children and number of 
individuals within the family community person lives in. The 
third part (the satisfaction scale) measures a subjective satis-
faction with the quality of different aspects of life, as well as 
the QOL as a whole. It consists of sixteen items, four of 
which are considered as ”objective” while the remaining 
twelve are considered as ”subjective“ assessment of satisfac-
tion with specific life aspects and with life as a whole. This 
instrument has a seven-degree scale, where 1 represents un-
favorable, while 7 represents favorable pole of the scale. 
SCL-90-R 25 consists of ninety items related to the 
symptoms of different disorders. They range from 0 to 4, for the 
population aged 13 to 70. The factor analysis of the symptom 
list distinguishes nine factors measured by this instrument: 1. 
somatization; 2. obsessions; 3. interpersonal sensitivity and 
vulnerability; 4. depression; 5. anxiety and phobias; 6. hostility; 
7. paranoia; 8. psychoticism; and 9. various symptoms.  The di-
scrimination value refers to only three factors: somatization, de-
pression, and anxiety with phobias. By scoring them, three more 
general indexes of the disorder are obtained: the severity of the 
disorder, the variability of symptoms, and the level of the sub-
jective feeling about the disease. 
Statistical analysis 
The following statistical measures were used: arithme-
tic mean (AM) and standard deviation (SD) for quantitative 
parameters (subject age). 
Pearson’s correlation coefficient was used to determine 
the relationship between the QOL and the presence of soma-
tization, depressive and anxious symptoms in our subjects, 
while multiple regression analysis has been used to determi-
ne to which extent the QOL was determined by the presence 
of somatization, depressive and anxious symptoms. Student 
t-test has been used to analyze the differences within the 
sample itself (in different diagnostic categories) – by presen-
ce of somatization, depressive and anxious symptoms. 
Results 
The presence of specific diagnostic categories from the 
group of stress-related disorders was the following: acute re-
action to stress (F 43.0) was diagnosed in one (1.25%) sub-
ject, PTSD (F 43.1) in twenty (25%) subjects and adjustment 
disorder (F 43.2) in fifty seven (71.25%) subjects, while the 
diagnosis of the enduring personality change after a catas-
trophic experience (F 62.0) was made in two (2.5%) subjects. 
The evaluation of the impact of depressive, anxious, 
and somatization symptoms on QOL suggested that the pre-
sence of all the three groups of symptoms was in negative 
correlation with the QOL. The multiple regression analysis 
showed that the presence of three mentioned types of 
symptoms explains as much as 40% of the variation in QOL 
(R² = 0.4;  F3,156  = 34.9; p < 0.01). 
After further examining which of the three above men-
tioned groups of symptoms had the greatest effect on the 
decrease of quality of life, the findings pointed at depressive 
symptoms, suggesting that the β ponder of this group was the 
highest, as shown in Table 1. 
By using partial correlation, we tried to exclude mutual 
interlacing effects of somatization, depressive and anxious 
symptoms. Our findings demonstrated that somatization and 
depressive symptoms were in negative correlation with the 
QOL, explaining 2.89% (squared semipartial correlation) and 
14.44% of variance, respectively, while anxious simptoms 
were in positive correlation with QOL, explaining 1.69% of 
variance, as shown in Table 1. 
The comparison of the presence of the somatization, dep-
ressive and anxious symptoms among subjects with a different 
diagnosis of stress-related disorders, is shown in Table 2. 
Our findings showed that there was a significant diffe-
rence in the scores for somatization and anxious symptoms 
between subjects with adjustment disorders and subjects with 
PTSD – the subjects with PTSD had higher scores for both 
somatization and anxious symptoms. For depressive 
symptoms, there was no significant difference between the 
two groups of subjects (p = 0.24). 
Discussion 
Our findings have shown that all the three groups of 
symptoms (somatization, depressive and anxious) were in 
negative correlation with the QOL (somatization – 0.50; dep-
ressive – 0.61; and anxious – 0.43) and that they account for 
as much as 40% of the variation in QOL.  We have found 
that depressive symptoms (compared to anxious and somati-
SCL-90-R – Symptom Check List-90 Revised; MANSA – Manchester Short Assessment Quality of Life Scale. 
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Table 2 
Average scores for somatization, depressive and anxious symptoms (SCL-90-R) in subjects  
diagnosed with various stress-related disorders 
Symptoms Diagnosis      n Mean  SD t df p 
Somatization F 43.1 
F 43.2 
20 
57 
2.40  1.03 
1.69  0.93 2.88 75 0.01 
Depressive 
 
F 43.1 
F 43.2 
20 
57 
2.33  0.70 
2.08  0.84 1.19 75 0.24 
Anxious 
 
F 43.1 
F 43.2 
20 
57 
2.50  0.92 
1.84  0.98 2.61 75 0.01 
SCL-90-R – Symptom Check List-90 Revised; F43.1 – Posttraumatic stress disorder; F43.2 – Adjustment 
disorder; SD – standard deviation. 
zation) within stress-related disorders had the greatest impact 
on the decrease of QOL. 
In order to apprehend how anxious, depressive and soma-
tization symptoms independently influence the QOL, we attem-
pted to exclude the mutual overlapping effect of these three gro-
ups of symptoms (using partial correlation). By doing so, some 
interesting findings have been obtained. The negative correlati-
on with QOL has been observed in 4.8% of somatization 
symptoms, and in 19% of depressive symptoms, while 2.9% 
anxious symptoms were in positive correlation with QOL. 
A question arises – which parts of anxiety have a positive 
effect on QOL? It is possible that it is the “normal” anxiety, ha-
ving useful, adaptive function, representing a warning signal 
suggesting that something should be done, i.e. facilitating an 
adequate perception of danger which gives a possibility of an 
appropriate protective reaction proportional to the level of thre-
at26. On the other hand, this may also be certain kind of a ’’posi-
tive” tension stimulating an individual, i.e. provoking an action 
that is a part of the course towards attaining life goals. Future 
studies on the impact of anxiety on the QOL may confirm or di-
sapprove these hypotheses. 
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Comparing the group with adjustment disorders and the 
group with PTSD by presence of the three groups of symptoms, 
our findings have shown significant differences in scores for 
somatization and anxious symptoms (the subjects with PTSD 
diagnosis had higher scores for these two types of symptoms), 
while there was no significant difference between the two gro-
ups in presence of depressive symptoms. 
Our findings are in accordance with the results of some 
other studies demonstrating the effect of anxious and depres-
sive symptoms on the decrease of QOL 6, 16, where it is emp-
hasized that depressive symptoms have a more compromi-
sing effect on QOL compared to anxious symptoms 17. 
Furthermore, recent studies have shown that the QOL 
has been reduced the most in individuals with PTSD and 
with depressive comorbidity 27, 21, 28. It was shown in a sam-
ple of primary care patients with various anxiety disorders 21, 
in a clinical sample of patients with PTSD 27, as well as in a 
sample of survivors of the war who developed PTSD 28. 
To our knowledge, there are no other studies that 
explored the individual effect of specific types of symptoms 
in the whole stress-related disorders group. Although, accor-
ding to ICD-10, the diagnosis of enduring personality change af-
ter catastrophic experience (F62.0) is not in the group F43 (Reac-
tion to severe stress, and adjustment disorders) 1, we included it 
in our sample of stress-related disorders because, by definition, it 
can develop exclusively and only after a catastrophic stress 
experience and it is not necessary to explore personal 
vulnerability in order to explain its occurrence. This disorder do-
es not exist in the Diagnosis and Statistical Normal of Mental Di-
sorders (DSM) V 29, but there was a great debate whether the 
classification should include “a disorder related to extreme stress, 
not otherwise specified” 30, to which some authors relate to as 
“complex PTSD” 31. It takes into consideration the functioning of 
an individual with the history of severe or prolonged trauma. 
On the other hand, when it comes to specific stress-
related disorders, such as PTSD, to our knowledge there are 
no other studies that explored the individual effect of somati-
zation symptoms. 
Apart from all methods of control that have been im-
plemented, both methodological and statistical, our study 
may have certain limitations. Firstly, the study was retros-
pective and the data on the stressful event were collected 
retroactively. Another limitation of this study may also be 
the unequal proportion of certain diagnostic categories 
among subjects. 
Conclusion 
Our study showed that depressive symptoms (compared 
to anxious and somatization ones) of stress-related disorders 
have the greatest impact on the decrease of the QOL. For de-
pressive symptoms, no significant difference was shown 
between individuals with adjustment disorders and those 
with a diagnosis of PTSD, while the subjects with PTSD had 
higher scores for somatization and anxious symptoms. 
A clear identification and specific treatment of each of 
the mentioned groups of symptoms is necessary throughout 
all phases of treatment of stress-related disorders. 
Targeted psychotherapeutic and psychopharmacological 
interventions aimed at depressive symptoms that are part of 
stress-related disorders could have a major effect on impro-
vement of QOL of these patients and might be the way for an 
efficient prevention of the relapse of these disorders. 
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Abstract 
 
Background/Aim. Preterm birth and retinopathy of prema-
turity (ROP) could affect optical and biometric features of eyes 
and cause refractive errors. The aim of this study was to com-
pare the ocular axial length, anterior chamber depth and lens 
thickness changes during the first year in preterm born babies 
with and without ROP. Methods. This prospective longitudi-
nal study included 87 preterm born babies. The examinations 
were performed at 3 and 12 months after birth and included 
fundus examination and measurements of the ocular axial 
length, anterior chamber depth and lens thickness. Based on 
the results of fundus examination at 3 months, the subjects 
were divided into two groups and the measurements of those 
with and without ROP were compared. Results. At 3 months 
60.92% of infants had ROP. The mean values in the ROP 
group were: axial length 16.56 mm and 16.53 mm, chamber 
depth 2.34 mm and 2.38 mm and lens thickness 4.04 mm and 
3.96 mm, in the right and the left eye, respectively. In the no 
ROP group these values were: axial length 17.06 mm and 17.08 
mm, chamber depth 2.31mm and 2.39 mm and lens thickness 
4.16 mm and 4.14 mm in the right and the left eye, respectively. 
At 12 months 28.74% of the children had a change in the ocu-
lar fundus as a result of the ROP therapy. In the ROP group 
the axial length was 19.94 mm in both eyes, chamber depth 
3.01 mm and 2.99 mm and lens thickness 4.28 mm and 4.29 
mm, in the right and the left eye, respectively. In the no ROP 
group the axial length was 20.64 mm and 20.29 mm, lens 
thickness 4.37 mm and 4.36 mm, in the right and the left eye, 
respectively and chamber depth 3.10 mm in both eyes. Con-
clusion. In the group of children with ROP axial length of the 
eye at 3 and 12 months was statistically significantly smaller in 
comparison to the group without ROP. Statistically significant 
difference was not found between these groups in the anterior 
chamber depth and lens thickness. 
 
Key words:  
infant, premature; retinopathy of prematurity; biometry; 
refraction, ocular; eye.
Apstrakt 
 
Uvod/Cilj. Prevremeno rođenje i prematurna retinopatija 
(ROP) mogu dovesti do nastanka refraktivnih mana, uticajem 
na optičke i biometrijske karakteristike oka. Cilj ovog rada bio 
je da se uporede promene u aksijalnoj dužini oka, dubini pred-
nje očne komore i debljini sočiva prematurusa sa i bez ROP 
tokom prve godine života. Metode. Ispitivanje je sprovedeno 
kao prospektivna longitudinalna studija, koja je obuhvatila 87 
prevremeno rođenih beba. U uzrastu od 3 i 12 meseci urađen je 
pregled očnog dna i merenje aksijalne dužine oka, dubine pred-
nje očne komore i debljine očnog sočiva. Prema nalazu na oč-
nom dnu 3 meseca posle rođenja bebe su podeljene u dve gru-
pe, sa i bez ROP i i izmerene vrednosti praćenih parametara su 
upoređene. Rezultati. Prilikom pregleda beba sa 3 meseca kod 
60,92% njih je ustanovljen ROP. Prosečne vrednosti merenih 
parametara na desnom i levom oku u grupi sa ROP bile su: ak-
sijalna dužina 16,56 mm i 16,53 mm, dubina prednje očne ko-
more 2,34 mm i 2,38 mm i debljina sočiva 4,04 mm i 3,96 mm 
na desnom, odnosno levom oku. U grupi bez ROP ove vred-
nosti na desnom i levom oku bile su: aksijalna dužina 17,06 
mm i 17,08 mm, dubina prednje komore 2,31 mm i 2,39 mm i 
debljina sočiva 4,16 mm i 4,14 mm. Sa 12 meseci 28,74% dece 
je imalo promene na retini kao posledice tretmana ROP. U 
grupi sa ROP pri prvom pregledu, aksijalne dužine bile su 
19,94 mm na oba oka, dubine prednje komore 3,01 mm i 2,99 
mm, a debljine sočiva 4,28 mm i 4,29 mm na desnom, odnosno 
levom oku. U grupi bez ROP aksijalne dužine desnog, odnosno 
levog oka bile su 20,64 mm i 20,29 mm, dubine komore 3,10 
mm na oba oka, a debljine sočiva 4,37 mm i 4,36 mm, desno i 
levo. Zaključak. U grupi dece sa ROP aksijalna dužina oka sa 
3 i 12 meseci bila je statistički značajno manja u odnosu na 
grupu bez promena na retini. Statistički značajna razlika nije 
nađena između grupe sa i bez ROP poređenjem parametara 
očne komore i sočiva. 
 
Ključne reči: 
nedonošče; retinopatija kod prematurusa; biometrija; oko, 
refrakcija; oko. 
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Introduction 
The number of infants born prematurely (that is before 
37 weeks of gestation), which survive the neonatal and peri-
natal period is currently increasing. The focus of medical ca-
re is therefore shifted to long-term functional results of all 
organ systems 1. Vision is a complex and highly functional 
set of processes at the levels of the retina and nervous 
system 2. The impressions that an infant receives through the 
sense of sight are highly important for its normal 
psychological and cognitive development 3. Potential 
consequences of premature delivery for visual, motor and 
cognitive functions are numerous 3. There are many causes 
for visual impairment, but they mainly occur as a 
consequence of the immaturity of the central nervous system 
and not of localized damage to the eye or cerebral cortex 1. 
Retinopathy of prematurity (ROP) is a vasoproliferative di-
sorder of the retina in prematurely born infants 4, which is 
the most common cause of preventable blindness in children. 
Preterm birth is also characterized by a higher incidence of 
strabismus, refractive disorders, nystagmus, glaucoma, optic 
nerve hypoplasia, eye movement disorders and reading di-
sorders 1. 
ROP develops in two distinct phases 2, 5, 6 and according 
to the International Classification, the severity of the disease 
is described in five stages, the localization of the process 
with three zones and the circumferential extent of the disease 
is based on the clock hours (from 1 to 12), where the extent 
of five hours is regarded as the critical value 7. Generally, 
stage 1 is defined by the presence of the so-called demarcati-
on line, stage 2 by the presence of the so-called ridge, stage 3 
by extraretinal fibrovascular proliferation. Stages 4 and 5 are 
severe conditions, the former of which is characterized by 
sub-total retinal detachment and the latter by total retinal de-
tachment 7. The zones are defined according to the posterior 
position of the process, so that the severity of the disease 
decreases from zone I to zone III 5, 7. 
Screening of prematurely born infants is performed in 
order to identify cases with a high risk of permanent visual 
loss due to ROP, which in turn could be decreased by 
adequate and timely intervention 8, 9. The criteria for scree-
ning infants in our country, following the recommendation of 
the American Academy of Pediatrics, are the birth weight 
2,000 grams or less and gestational age 36 weeks or less, 
with the postnatal application of oxygen. The presence of 
additional risk factors during the development of the child 
points to the need of screening regardless of the criteria men-
tioned 5, 7. The first examination should be performed 4 to 6 
weeks after birth 5, 8 or between gestational weeks 31 and 
33 8, 10. After that, the second examination is performed after 
a week or two, depending on the local findings 8. The scree-
ning takes place until blood vessels reach zone III in infants 
without ROP in the zones I and II 8, 11, 12, or to the completed 
vascularization of the ora serrata after intravitreal application 
of anti-vascular endothelial growth factor or until week 50 
postmenstrually for children with prior milder ROP forms or 
until ROP recedes 12. A repeated ophthalmological 
examination of prematurely born babies at 12 months is of 
crucial importance, regardless of the presence of ROP, in or-
der to identify amblyogenic factors such as strabismus or ref-
ractive disorders 11, 13. 
Premature birth, i.e. gestational age, birth weight, 
retinopathy and the development of refractive disorders are 
closely related 14. These characteristics indirectly affect refrac-
tion, by influencing the optical characteristics of the eye 15. Re-
fractive disorders occur when the ocular axial length does not 
correspond to the focal plane, created by the cornea, lens and 
anterior chamber 16. The process of balancing out the strength 
of the refractive power of the optical system and the ocular 
axial length is called emmetropization 17 and it generally oc-
curs between month 3 and 12 after birth. This process is diffe-
rent in full-term and preterm infants and the differences are 
noticeable depending on the presence of the retina disorder 15. 
The changes in the refractive power of the cornea and lens 
show a negative correlation with the axial growth of the eye 18. 
At the age of one, 6.66% of prematurely born children with 
ROP at the earliest age and 3.75% of those without ROP have 
a refractive error 19. The main causes of the high incidence of 
myopia, in general, are the greater axial length 20, 21, shallower 
anterior chamber and the greater thickness of the ocular lens 21. 
However, prematurity, lower gestational age and birth weight 
are characterized by a more convex cornea, shallower anterior 
chamber, thicker lens, but also, a smaller axial length, compa-
red to the values which might be expected from the dioptric 
value of the eye 14, 19, 22, 23. The early effect of growth restricti-
on within retinopathy is later followed by irregularities in the 
growth of the eye posterior segment 23, so that in preterm in-
fants there is no direct correlation between the ocular axial 
length and its refractive status. Proportions of the eye are not 
later fully compensated for by the growth of the eye and visual 
experience 14, 22. 
In this study is shown how the ocular axial length, anterior 
chamber depth and lens thickness were changing during the first 
year of life in preterm born babies with and without ROP. 
Methods 
The research was conducted as a prospective, longitu-
dinal study at the Clinic for Eye Diseases of the Clinical 
Center of Vojvodina during the period of 5 years, from 2005 
till 2010. The study was approved by the Clinical Centre of 
Vojvodina Ethics Committee. The parents of the participa-
ting babies provided their informed consent, after being pro-
vided written and verbal information about the study. The 
study enrolled 87 preterm infants (174 eyes), divided into the 
two groups according to the presence of ROP. Two 
examinations were performed, at 3 and 12 months of age. 
The study included preterm born babies whose birth 
weight was 2000 grams or lower and gestational age 36 
weeks or lower, who received oxygen, as well as infants 
satisfying these criteria, but with other risk factors that might 
affect the development of the retinal vasculature, such as: di-
seases of the respiratory tract, brain hemorrhage, sepsis, ana-
emia, enterocolitis, blood transfusion, non-physiological va-
lues of partial pressure of oxygen and carbon dioxide, acido-
sis, phototherapy and multiple pregnancies. The preterm in-
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fants with risks were selected by neonatologists. Infants that 
developed severe forms of retinopathy (stages IV and V) 
were excluded from the study, since the biometrical data and 
the refractive status that would have been acquired in those 
cases would bear no relevance for this research. 
For the collection of necessary data, an original 
questionnaire was used. The research was conducted according 
to the preset methodological plan with precisely defined criteria. 
It included: the scrutiny of medical documentation, i.e. the dis-
charge note from the Institute for Child and Youth Health Care 
of Vojvodina, biometric measurements, including the measure-
ments of the ocular axial length, anterior chamber depth and lens 
thickness of both eyes, as well as the bilateral fundus 
examination in mydriasis and with indentation at the two respec-
tive ages. The values were taken for each eye separately in order 
to record differences in values for each eye, taking into account 
the higher incidence of anisometropia in preterm population. 
Medical records provided the basic personal data, the 
data on the values of birth weight, gestation age and the pre-
sence of risk factors. 
Biometric measurements were performed after the applica-
tion of the local anesthetic Tetracaine hydrochloride® 0.5% eye 
drops, three times at 5 minutes intervals. The ocular axial length, 
anterior chamber depth and the thickness of the lens were mea-
sured by the ultrasonographic A-method using the Sonomed Inc, 
USA, A-2500 ultrasound machine, with the transducer 
frequency of 10 MHz. The values were taken three times for all 
the parameters and the mean value was calculated. The measu-
rements were expressed in millimeters. 
The examination of the ocular fundus was performed 
through dilated pupils. The maximal mydriasis was provided 
by the application of Phenylephrine hydrochloride® 2.5% eye 
drops or Cyclopentolate® 0.5% eye drops, twice at 10- minu-
te intervals one hour before the examination. The 
examination was performed by indirect binocular ophthal-
moscope, Indirekte Ophthalmoskop Omega 180, Heine Op-
totechnik, Hersching, Germany and a 20 D lens. For a more 
detailed view of the peripheral segments of the retina scleral 
indentation was used. Eyelid separation was obtained by 
using blepharostat. The results were expressed in accordance 
with the International Classification of Retinopathy of 
Prematurity. 
Statistical analysis of the data was performed using the 
Statistical Package for Social Sciences software - SPSS 21. 
The numerical values were expressed as mean values and 
variability measurements (range, standard deviation) and the 
attributive features by frequencies and percentages. The 
comparison of the numerical values between the groups was 
done using t-test and the differences between the frequencies 
of attributive features by χ2 test. The correlation between two 
features was determined by Pearson’s correlation coefficient. 
Statistical significance was set at level p < 0.05.  
The results are presented as tables and figures. 
Results 
The research included 87 preterm born babies (174 
eyes): 43 (49.43%) boys and 44 (50.57%) girls. The mean 
gestational age at birth was 31.45 weeks, ranging from 24 to 
36 weeks. Birth weight ranged from 1,190 grams to 3,620 
grams, with the mean value 1,643.51 grams. 
The results at 3 months 
The incidence of ROP at 3 months was present in 
60.92% of the infants and was identical in both eyes. In the 
right eye 41.5% infants with ROP had ROP 1, 9.4% ROP 2, 
43.4% ROP 3, 1.9% ROP 4 and 3.8% ROP 5. In the left eye, 
the occurrence of specific ROP stages was: 41.5% with ROP 
1, 9.4% with ROP 2, 45.3% with ROP 3, ROP 4 was found 
in none of the infants and ROP 5 was found in 3.8% babies 
(Table 1). 
Table 1 
The incidence of specific retinopathy of prematurity (ROP)  
stages in eyes of premature born infant at the age of 3 months 
ROP stages Right eye, n (%) Left eye, n (%) 
 1 22 (41,5) 22 (41.5) 
 2 5 (9,4) 5 (9.4) 
 3 23 (43,4) 24 (45.3) 
 4 1 (1,9)  
 5 2 (3,8) 2 (3.8) 
Total 53 (100) 53 (100) 
Mean 2,17  
Median 2,00  
Mode 3  
 
The mean values of the axial length in patients with 
ROP were 16.56 mm (15.02 to 17.78 mm; standard deviation 
(SD) = 0.72 mm) in the right and 16.53 mm (15.10 to 17.78 
mm; (SD) = 0.68 mm) in the left eye. Axial length values in 
the group of infants without ROP were 17.06 mm (15.97 to 
18.27 mm; (SD) = 0.55 mm) in the right and 17.08 mm 
(15.66 mm to 18.27 mm; (SD) = 0.54) in the left eye. The 
standard deviation was higher in the group of patients with 
ROP in both eyes, which points to the higher heterogeneity 
of this group. The results of the differences in the axial valu-
es between the two groups were statistically highly signifi-
cant both in the right (t = 3,451, p = 0,001) and in the left eye 
(t = 3.996, p = 0.000) (Figure 1). 
The analysis of the values of the anterior chamber depth 
of the right (t = 0.420, p = 0.676) and the left eye (t = 0.149, 
p = 0.882) revealed no statistical difference between the gro-
ups with and without ROP, while the values of standard de-
viation, similarly to the values of axial length, were higher in 
the group of infants with ROP. The mean of the anterior 
chamber depth was 2.31mm (1.92 to 2.90 mm; SD = 0.24 
mm) in the right and 2.39 mm (2.11 to 3.36 mm; SD = 0.27 
mm) in the left eye in the group without ROP, while in the 
group with ROP it was 2.34 mm (1.92 to 4.34 mm; SD = 
0.38 mm) in the right and 2.38mm (1.85 to 4.27 mm; SD = 
0.36 mm) in the left eye (Figure 2).  
The mean values of the lens thickness in infants without 
ROP were 4.16 mm (3.40 to 4.90 mm; SD = 0.30 mm) and 
4.14 mm (2.75 to 4.79 mm; SD = 0.37 mm) and in babies 
with ROP they were 4.04 mm (2.10 to 4.70 mm; SD = 0.49 
mm) and 3.96 mm (2.26 to 4.75 mm; SD = 0.47 mm) in the 
right and the left eye respectively. The differences obtained 
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Fig. 1 – Axial length of eyes in premature born infants with and without retinopathy of prematurity (ROP) at the  
age of 3 months: a) right eye; b) left eye. 
 
 
Fig. 2 – Anterior chamber depth of eyes at the age of 3 months in premature born infants with and without 
 retinopathy of prematurity (ROP) at the age of 3 months: a) right eye; b) left eye. 
 
were not statistically significant in either the right (t = 1.360, 
p = 0.177) or the left eye (t = 1.852, p = 0.067) and the valu-
es of higher standard deviation point to the greater 
heterogeneity of the group with ROP (Figure 3). 
The results at 12 months 
At 12 months of age 62 (71.26%) babies had a normally 
developed blood network of the retina. The remaining 25 
(28.74%) had a change in the ocular fundus as a result of 
cryopexy or retinal laser therapy due to ROP. The results 
were almost identical in both eyes. The axial length of the 
right (t = 2.329, p = 0.022) and the left eye (t = 2.087, p = 
0.040) in the no ROP group was statistically significantly 
greater than in the group with ROP. The values of standard 
deviation of this parameter in both eyes were approximately 
the same in the group with ROP, while the standard deviati-
on in the right eye in the other group was significantly hig-
her, since the values of one child deviated considerably from 
the others, whose results were homogeneous. In the group 
without ROP the mean value of the axial length of the right 
eye was 20.64 mm (19.0 to 30.4 mm; SD =1.89 mm) and of 
the left one 20.29 mm (19.0 to 22.0 mm; SD = 0.65 mm). In 
the group with ROP, these values of the right eye ranged 
from 17.4 to 22.1 mm (SD = 0.87 mm) and of the left eye 
from 16.7 to 21.8mm (SD = 0.84 mm). The mean value of 
both eyes was 19.94 mm (Figure 4). 
The difference in the mean values of the anterior 
chamber depth was not statistically significant neither in 
the right (t = 1.048, p = 0.268), nor in the left eye (t = 
1.408, p = 0.163) in both groups, with or without ROP. In 
the group without ROP the mean value of both eyes was 
3.10 mm (right eye: 2.14 to 3.58 mm; SD = 0,34 mm; left 
eye: 2.26 to 3.81 mm; SD = 0.37 mm) and in the group 
with ROP the mean values were 3.01mm (2.15 to 3.77 mm; 
SD = 0.41 mm) and 2.99 mm (2.40 to 3.57 mm; SD = 0.34 
mm) in the right and left eye, respectively. The differences 
in standard deviations were not statistically significant 
which pointed to close homogeneity of both groups regar-
ding this parameter (Figure 5). 
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Fig. 3 – Lens thickness of eyes in preterm born infants with and without retinopathy of 
 prematurity (ROP) at the age of 3 months: a) right eye; b) left eye. 
 
 
Fig. 4 – Axial length of the eyes in preterm born infants with and without retinopathy of 
 prematurity (ROP) at the age of 12 months: a) right eye; b) left eye. 
 
 
Fig. 5 – Anterior chamber depth of eyes in preterm born infants with and without retinopathy of 
 prematurity (ROP) at the age of 12 months: a) right eye; b) left eye. 
No statistical significance was found in the mean values 
of the lens thickness of both eyes in patients with and 
without ROP (right: t = 1.357, p = 0.178; left: t = 1.092, p = 
0.278). Standard deviations of the values obtained in the two 
groups point to their relative homogeneity, although the ROP 
group was even somewhat more homogeneous. In the group 
without ROP the values were 4.37 mm (3.77 to 4.92 mm; SD 
= 0.30 mm) in the right and 4.36 mm (3.02 to 4.90 mm; SD 
= 0.36 mm) in the left eye, whereas in the group with ROP 
they were 4.28 mm (3.69 to 5.13 mm; SD = 0.28 mm) in the 
right and 4.29 mm (3.81 to 4.96 mm; SD = 0.26 mm) in the 
left eye (Figure 6). 
Discussion 
The objective of this study was to examine the effect of 
retinopathy of prematurity on the growth and development of 
the eye. 
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Fig. 6 – Lens thickness of the eyes in preterm born infants with and without retinopathy of 
 prematurity (ROP) at the age of 12 months: a) right eye; b) left eye. 
The study enrolled a similar number of boys and girls 
and therefore, the difference between the genders in the gro-
ups was of no statistical significance. The findings reported 
in the literature regarding the influence of gender on the bi-
ometric characteristics of the eye have been inconsistent thus 
far. Siegwart and Norton 16 claim that gender does affect the 
development of the eye. According to O'Brien and Clark 24, 
and Laws et al. 25 the mean axial length of the eye and the ra-
te of its growth are greater in male infants notwithstanding 
the correction of the birth weight, gestational age and head 
dimensions. On the other hand, Mutti et al. 18 reported that 
gender is not a factor affecting the development and change 
in refraction and eye growth. Similar results were obtained 
by Chen et al. 22, who also consider the characteristics of the 
anterior segment of the eye in preterm infants to be indepen-
dent of the gender. 
Gestational age and birth weight are highly important 
parameters of the development and progression of ROP 23, 26. 
Various screening criteria are found in the literature, but they 
are primarily related to these two characteristics. The diffe-
rences between the criteria are also conditioned by the diffe-
rences in the economic prosperity and investments into me-
dical care, including neonatal, one as well as differences in 
the incidence of more severe forms of ROP 4, 8, 9, 11, 27–29. The 
mean gestational age of our subjects was 31.45 weeks, while 
the mean birth weight was 1,643.51 grams. 
The overall incidence of ROP in this sample was 
60.92%, which is higher than the data reported in the literature. 
The incidence of ROP among preterm infants reported in the 
studies by Chen et al. 22 was 44%. The need for more frequent 
and long-term follow-up examinations due to the disorders of 
the retina may explain the obtained differences in incidence. 
Namely, the infants with normal findings in the first or second 
examination were not taken to the follow-up examination at 1 
year of age, so they were not included in this study. The grea-
test majority of infants had ROP 1 (41.5% in both the right and 
the left eye) and ROP 3 (43.4% in the right and 45.3% in the 
left eye), while the incidence of ROP 2 was lower than ten 
percent in both eyes (9.4%). ROP 4 was only found in the 
right eye, in 1.9% cases and the incidence of ROP 5 was the 
same in both eyes (3.8%). Chen et al. 22 also report the inci-
dence of specific stages of ROP in preterm infants, ROP 1 and 
3 being of the highest incidence, then ROP 2 and the lowest 
incidence is found with ROP 4 and 5. 
The mean axial length of the right and the left eye in in-
fants without retinopathy (17.06 mm and 17.08 mm) was 
statistically significantly higher in comparison to these valu-
es in infants with retinopathy (16.56 mm and 16.53 mm). 
The values of the axial length of the eye in preterm children 
at birth 30, as well as at 3 months, are lower compared to full-
term babies and this difference is particularly marked in the 
presence of ROP 23. Fledelius and Fledelius 30 report about 
the values of this parameter in full-term infants at birth and 
preterm newborns at the full-term gestational age, pointing 
that they are similar in the two groups. They also state that 
visual and biometric parameters in preterm infants with mil-
der forms of ROP and spontaneous regression are similar to 
those of preterm infants without ROP 30. Full-term newborns 
have the mean axial length ranging from 16.6 mm to 17.6 
mm, while the mean value in the preterm infants at 40 gesta-
tional weeks ranges from 16.6 mm to 17.16 mm 30. Accor-
ding to the data reported by Pennie et al. 31, at 3 months of 
age, the axial length in full-term infants is 17.99+/-0.67 mm, 
whereas Mutti et al. 18 report the mean value of 19.03+/-0.58 
mm. Cook et al. 23 report the data on the values of the eye 
axial length of preterm infants at 3 months, giving a compa-
rison to the findings of the fundus. Thus at 3 months infants 
without ROP have the approximate mean axial diameter of 
18.6 mm and with ROP 18.5 mm. After this period the axial 
length of the eye increases, so that in full-term children at 9 
months it is approximately 20.23+/-0.64 mm 18 but at 12 
months approximately 19.71+/-0.87 mm 31. However, very 
few studies report on the axial length values of prematurely 
born children at 1 year of age. Our study found a statistically 
significant difference in axial length values of both eyes in 
the groups of infants with and without ROP, such that in the 
case of normal development of retinal blood vessels the axial 
length of the eye was greater compared to the group of in-
fants who had ROP at 3 months of age. In addition to this, 
the group without ROP was significantly more homogeneo-
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us. The mean value of the axial length of the right eye in the 
group of infants with ROP at 12 months was 19.94 mm and 
without ROP it was 20.64 mm. The corresponding values of 
the left eye for the two respective groups were 19.94 mm and 
20.29 mm. 
Since at both ages investigated the axial length in both 
eyes was statistically significantly smaller in infants with 
ROP, but also in preterm infants compared to full-term in-
fants, it can be concluded that prematurity, as well as retina 
disorders related to premature birth, both affect the growth of 
the eye in total from birth to one year of age. Future research 
and analyses of older children are also necessary in order to 
determine the alteration of these values at later ages. 
In our population studied, there was no statistically sig-
nificant difference at 3 months of age between the anterior 
chamber depth in infants with and without ROP in the right 
(2.34 mm vs. 2.31 mm) or left eye (2.38 mm vs. 2.39 mm). 
However, the standard deviation of this parameter points to 
differences in the homogeneity between the two groups, 
which disappear at a later age. The depth of the anterior 
chamber in full-term children is approximately 2.38 mm to 
2.90 mm, while in preterm infants at the time of full-term ge-
station this value ranges from approximately 2.25 mm to 
2.44 mm, as reported by Fledelius and Fledelius 30. The 
depth of the anterior chamber in full-term infants at 3 months 
is 2.76+/-0.27 mm 18. Other authors also report lower values 
(2.24+/-0.31D) (31). As reported in the studies by Anna Co-
ok et al. 23 at 3 months of age the depth of the anterior cham-
ber in preterm infants is smaller than in full-term infants, 
especially in the case of ROP. Its mean value in preterm in-
fants without ROP is 2.8 mm and with ROP 2.7 mm at that 
age. 
The mean value of the depth of the anterior chamber of 
both eyes was somewhat lower in children with ROP at 12 
months but without any statistical significance in comparison 
to children without ROP. The depth of the anterior chamber 
was 3.01 mm in the right and 2.99 mm in the left eye in the 
group with ROP and 3.10 mm in both eyes in the group of 
children without ROP. The depth of the anterior chamber in-
creases gradually in the first months after birth and its value 
in full-term children reaches 3.03+/-0.35 mm at 9 months 18, 
but at 12 months of age the anterior chamber depth of full-
term children is around 2.8+/-0.26 mm 31. 
The mean lens thickness at the first examination of in-
fants with ROP in our study was 4.04 mm and 3.96 mm and 
in infants without ROP it was 4.16 mm and 4.14 mm. This 
difference had no statistical significance and in addition, the-
re was no statistical difference between the values of the 
right and the left eye. The homogeneity of the two groups 
studied increased between 3 and 12 months, especially in the 
group with ROP. The thickness of the lens of full-term in-
fants at birth ranges from 3.40 mm to 3.96 mm, while in pre-
term infants this value ranges from 3.89 mm to 4.04 mm 30. 
However, in contrast to the axial length and depth of the an-
terior chamber, the thickness of the lens in full-term children 
decreases 18. At 3 months of age the reported thickness of the 
lens in full-term children is 3.92+/-0.17 mm 18 or 3.65+/-0.25 
mm 31, at 9 months it is 3.86+/-0.18 mm (19) and at 12 
months approximately 3.65+/-0.14 mm 31. As for preterm in-
fants, Cook et al. 23 report that the mean value of lens thick-
ness of premature infants without ROP is 4.0 mm and with 
ROP 3.96 mm at 3 months, which corresponds to the results 
of our study. 
The mean values of the lens thickness of the right and 
the left eye in the group of children without ROP at 12 
months were 4.37 mm and 4.36 mm and with ROP 4.28 mm 
and 4.29 mm. The values obtained bear no statistically signi-
ficant difference between the patients with and without ROP. 
It is important to notice that, in contrast to full-term children, 
in preterm infants the thickness of the ocular lens increases 
during emmetropization, which also corresponds to the data 
reported in the literature 15, 22, 30, 32. 
Conclusion 
At 3 and 12 months of age, the axial length of both eyes 
is significantly smaller in preterm infants who develop 
retinopathy of prematurity at the earliest age, than in those 
infants who do not. However, the depth of the anterior 
chamber and the lens thickness of both eyes are not 
statistically significantly different in the two groups of pre-
term born infants. We can conclude that during the first year 
of life retinopathy of prematurity significantly affects the 
growth of the eye on the whole, but not the growth of the 
components of its anterior segment compared to the other 
premature population. 
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Abstract 
 
Background/Aim. The essence of rheumatoid arthritis (RA) 
pathogenesis is inflammation, modification of immune sys-
tem and cell damage. 5'-nucleotidase (5'-NT) and adenosine 
deaminase (ADA) have a significant role in the process of in-
flammation-caused tissue damage. The aim of the study is to 
define 5'-nucleotidase and adenosine deaminase activity in se-
rum of patients with RA treated with methotrexate (MTX) 
and patients with RA who were not treated with meth-
otrexate, as well as to determine the correlation between the 
enzymes’ activities and the disease activity. Methods. The 
study included 160 patients suffering from RA, 60 of them 
were not treated with methotrexate (average age 56.8 years; 
68.3% female) and 100 patients were treated with meth-
otrexate (average age 59.8 years; 88% female), as well as 60 
healthy controls (average age 58.8; 66.6% female). Patients 
suffering from chronic inflammatory diseases, chronic respi-
ratory, cardiac and kidney insufficiency, severe acute diseases 
and other diseases which might modify inflammatory re-
sponse were not included in the study. Results. There was no 
statistically significant difference in 5'-NT values among 
groups. ADA values were significantly different in all tested 
groups. Post-hoc analysis (Dunnett’s T3 test) showed that 
ADA activity in RA groups was significantly higher as com-
pared to that in the control group (p < 0.001), and that ADA 
activity in the RA group with MTX was significantly smaller 
as compared to RA group without MTX (p < 0.001). There 
was not significant correlation between the disease activity 
and activities of tested enzymes. Conclusion. We concluded 
that adenosine deaminase activity was increased in patients 
with rheumatoid arthritis, as well as that the application of 
methotrexate led to the decrease of this enzyme activity in the 
serum of patients with rheumatoid arthritis. The activity of 5'-
nucleotidase is not increased in patients with rheumatoid ar-
thritis and did not depend on methotrexate treatment. Serum 
adenosine deaminase and 5'-nucleotidase activities are not 
good indicators of rheumatoid arthritis activity. 
 
Key words: 
arthritis, rheumatoid; adenosine deaminase;  
5'-nucleotidase.
Apstrakt 
 
Uvod/Cilj. U patogenetskoj osnovi reumatoidnog artritisa 
(RA) su inflamacija, promena imunog sistema i oštećenje 
ćelija. Značajnu ulogu u procesu oštećenja tkiva posredo-
vanog inflamacijom imaju 5'-nukleotidaza (5'-NT) i adeno-
zin dezaminaza (ADA). Cilj rada bio je određivanje aktiv-
nosti adenozin dezaminaze i 5'-nukleotidaze u serumima 
obolelih od RA lečenih uz pomoć ili bez terapije metotre-
ksatom (MTX), kao i utvrđivanje povezanosti ovih enzima 
sa aktivnošću bolesti. Metode. Ispitivanjem je bilo obu-
hvaćeno 160 bolesnika obolelih od RA, od kojih 60 nije bi-
lo lečeno MTX (prosečne starosti 56,8 godina; 68,3% že-
na) i 100 bolesnika na terapiji MTX (prosečne starosti 59,8 
godina, 88% žena), kao i 60 ispitanika kontrolne grupe 
(prosečne starosti 58,8 godina; 66,6% žena). Bolesnici sa 
hroničnim inflamatornim oboljenjima, hroničnom respira-
tornom, srčanom i bubrežnom insuficijencijom, težim aku-
tnim oboljenjima, i drugim bolestima od značaja koje bi 
mogle da modifikuju inflamatorni odgovor bili su isključe-
ni iz istraživanja. Rezultati. Nije zabeležena razlika u akti-
vnosti 5'-NT između ispitivanih grupa. Vrednosti ADA su 
se značajno razlikovale između ispitivanih grupa. Post- hoc 
analizom (Dunnett-ov T3 test) pokazano je da je aktivnost 
ADA u grupama značajno viša u odnosu na kontrolnu 
grupu bolesnika (p < 0,001), kao i da je aktivnost ADA u 
grupi bolesnika sa RA lečenih MTX bila značajno niža u 
odnosu na aktivnost u grupi bolesnika sa RA koji nisu 
primili MTX (p < 0,001). Nije bilo statistički značajne ko-
relacije između DAS28 skora i aktivnosti ispitivanih enzi-
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ma. Zaključak. Aktivnost adenozin dezaminaze povećana 
je kod bolesnika sa reumatoidnim artritisom. Primena me-
totreksata dovodi do smanjenja aktivnosti ovog enzima u 
serumu bolesnika sa reumatoidnim artritisom. Aktivnost 
5'-nukleotidaze nije povećana kod bolesnika sa reumatoid-
nim artritisom i ne zavisi od terapije metotreksatom. Akti-
vnosti adenozin dezaminaze i 5'-nukleotidaze u serumu ni-
su dobri pokazatelji aktivnosti reumatoidnog artritisa. 
 
Ključne reči: 
artritis, reumatoidni; adenozin dezaminaza;  
5'-nukleotidaza. 
 
Introduction 
Rheumatoid arthritis (RA) is a frequent chronic 
inflammatory arthropathy which is present in 1% of the 
world population. Even though the etiology of the disease is 
not well known the present information indicates that RA is a 
result of the simultaneous influence of genetic risk factors, 
hormone factors, immunology and external factors 1. The di-
sease is characterized by the proliferation of autoreactive 
clones of T and B lymphocytes with the proliferation of 
synovial cells, the formation of pannus, activation of 
chondrocytes and metalloproteinases, which leads to the des-
truction of joint cartilage, bones and the surrounding structu-
res 2. The main characteristics of early immune reaction in 
RA are T lymphocytes, especially CD4 cells which initiate 
the entire sequence of further events.  
Rheumatoid arthritis is followed by the increased 
activity of enzymes which take part in nucleic acid metabo-
lism 3. Adenosine deaminase (ADA) plays a significant role 
in the process of inflammation-caused tissue damage. ADA 
is an enzyme which regulates cellular and extracellular con-
centration of adenosine and deoxyadenosine along with 5'- 
nucleotidase (5'-NT) and adenosine kinase. The increase of 
ADA in serum of RA patients is related to its release from 
damaged cells 4. This enzyme has the metabolic significance 
due to its role in the catabolism of purine derivatives of ade-
nosine and deoxyadenosine, as well as in proliferative 
activity of immunocompetent cells 5. ADA is a ligand of 
CD26 protein (ADA binding protein-ADAbp) which, in inte-
raction with CD26, has a stimulating effect on T cell receptor 
(TCR), i.e. acts as a mediator in T cell activation 6. Activati-
on of T-cell response initiates a sequence of reactions which 
result in increased inflammation, thickening of synovial 
membrane and deterioration of cartilage and bones.  
The central role of 5'- nucleotidase is the production of 
extracellular nucleotides, adenosine being the most important 
one. Ecto-5’-NT is believed to be the marker of human B-
lymphocyte maturation, having in mind that it is increased 
during normal development, and reduced in 
immunodeficiency conditions 7. Even though circulating 
monocytes show the low activity of ecto-5'-NT, differentiati-
on of monocytes results in increased activity of this enzyme. 
Additionally, increased values of this enzyme in synovial 
fluid are significant in terms of diagnostics 8. 
Clinical presentation of RA is characterized by nume-
rous symptoms and signs which refer to joints, periarticular 
structures and internal organs. The basic features of RA are a 
symmetrical pain, swelling, morning stiffness and specific 
radiological changes. Clearly defined parameters of clinical 
presentation and complex composite indices, obtained by the 
combination of subjective and objective parameters, are used 
for the presentation of the disease activity.  
In the era of biological targeted therapies, MTX is still 
the gold standard in the treatment of RA 9. After absorption, 
10% of this drug is converted in 7-hydroxy MTX in the liver, 
and afterwards, both are excreted through kidneys 10–12. Se-
veral pharmacological mechanisms of MTX effects are 
explained, including anti-inflammatory effect mediated by 
stimulating adenosine receptors 13, 14. MTX causes reduction 
of ADA level in three ways: firstly, MTX can directly inhibit 
ADA; secondly, MTX inhibits ADA indirectly through ami-
noimidazole carboxamide ribose-5-phosphate (AICAR) and 
its metabolites; and thirdly, ADA can be inhibited indirectly 
to compensate the adenosine reduction. The reduction of 
ADA causes an increase in adenosine level and consequently 
anti-inflammatory effect 14.  
Biomarkers which refer to synthesis and degradation of 
cartilage and bones, inflammation and autoimmune proces-
ses which might have clinical significance in the assessment 
of the diseases' presentation have been the subject of interest 
in the past ten years. Purine metabolism enzyme testing has 
become more frequent, having in mind that understanding 
pathophysiological role these enzymes have in the progressi-
on of RA may be useful, not only in diagnostics but also in 
the process of monitoring the clinical course of the disease 
and therapy effects.  
The aim of the study was to define 5'-nucleotidase and 
adenosine deaminase activity in the serum of patients with 
rheumatoid arthritis treated with methotrexate and patients 
with rheumatoid arthritis who were not treated with 
methotrexate, as well as to determine the correlation between 
the enzymes’ activities and the disease activity.  
Methods  
The study included 160 patients suffering from RA; 60 
of them were not treated with methotrexate (average age 
56.8; 68.3% female patients) and 100 patients were treated 
with methotrexate (average age 59.8 years; 88% female pati-
ents), as well as 60 healthy controls (average age 58.8; 
66.6% female patients). All included patients were treated at 
the Clinic for Rheumatology of the Institute for Treatment 
and Rehabilitation” Niška Banja”, and the study was appro-
ved by the local Ethics Committee. 
Diagnosis and classification of RA were performed ba-
sed on revised American College of Rheumatology (ACR) 
classification criteria from 1987 15. Patients suffering from 
chronic inflammatory diseases (connective tissue diseases, 
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Table 1 
Demographic and clinical characteristics of patients with rheumatoid arthritis (RA) and controls 
Characteristics of patients RA without MTX treatment (n = 60) 
RA with MTX treatment  
(n = 100) 
Control 
(n = 60) 
Age (years), ґ ± SD 56.86 ± 12.96 59.81 ± 11.82 58.86 ± 18.05
Gender (female), n (%) 41 (68.3) 88 (88) 40 (66.6) 
Disease duration (months), ґ ± SD 12.5 ± 7.2** 124.4 ± 81.0 - 
No. of painful joints, ґ ± SD 12.2 ± 7.5 12.3 ± 7.6 - 
No. of swollen joints, ґ ± SD 4.1 ± 3.0 3.2 ± 2.0 - 
ESR (mm/h), ґ ± SD 35.8 ± 27.8 29.9 ± 20.1 8.6 ± 4.3** 
VAS general health score  
(0–100 mm scale), ґ ± SD 
32.86 ± 19.9 40.02 ± 22.7 17 ± 16,5** 
DAS28 score, ґ ± SD 5.13 ± 1.3 4.66 ± 1.4 1.02 ± 1.23**
other systemic diseases), chronic respiratory, cardiac and 
kidney insufficiency, severe acute diseases and other disea-
ses which might modify inflammatory response were not in-
cluded in the study. General methodological approach impli-
ed a prospective analysis of medical history, as well as clini-
cal and laboratory indicators.  
Clinical assessment  
Clinical assessment of patients implied physical 
examination with special emphasis on locomotor system. 
The number of painful and swelling joints was recorded. Su-
bjective assessment of general health was defined by means 
of visual analogue scale (VAS) – 100 mm.  
Disease activity score-sedimentation rate (DAS28 SE), 
a combined index which included palpation sensitivity and 
swelling of 28 joints: shoulders, elbows, metacarpophalange-
al (MCP) joints, proximointerphalangeal (PIP) joints and 
knees, sedimentation rate and patients’ assessment of general 
health, was used for determining disease activity. DAS28 SE 
score was a number on a scale from 0 to 10 which showed 
current disease activity. Disease activity level was conside-
red low in case DAS 28 ≤ 3.2, medium in case 3.2 < DAS 28 
≤ 5.1 or high if DAS 28 > 5.1. In case of DAS 28 < 2.6 the 
disease was considered to be in remission 16. 
Laboratory assessment  
Patients were taken a blood sample from cubital vein 
early in the morning before they had breakfast (no food inta-
ke for 12 hours). Blood samples for laboratory analysis were 
kept in heparinized blood collection tubes. Peripheral blood 
was taken by means of venipuncture and the serum was sepa-
rated by centrifugation at room temperature at 3500 
cycle/min for 15 minutes. The samples were used for deter-
mining: erythrocytes (Er), hemoglobin (Hb), thrombocytes 
(Tr), leukocytes (Le), erythrocyte sedimentation rate (ESR), 
5'-NT and ADA.  
The activity of 5'-NT was defined by means of 
spectrophotometry, using Wood and Williams’ method 17. 
The method was based on defining released inorganic pho-
sphorus from adenosine monophosphate (AMP). Aliquot of 
0,5 ml of serum was incubated for 30 minutes at 37°C in the 
presence of barbiturate buffer pH = 7.8 with manganese as 
an activator and 10 μmol Mn-AMP as a substrate. After ad-
ding hydrazine sulfate-tin chloride solution and ammonium 
molybdate, released inorganic phosphorus was defined by 
means of spectrophotometry at 618 nm.  
Adenosine deaminase assay kit produced by Diazyme 
was used for determining ADA activity in the serum. ADA 
determination was based on the enzymatic conversion of 
adenosine to inosine which was converted to hypoxanthine 
with the aid of purine nucleoside phosphorylase (PNP). 
Hypoxanthine was then converted to uric acid and hydrogen 
peroxide (H2O2) with the assistance of xanthine oxidase 
(XOD). One ADA unit was defined as the quantity of 
enzyme necessary for releasing 1 μmol/min of inosine from 
adenosine at 37°C. Adenosine deaminase activity was 
expressed as unit per liter.  
Statistical assessment was carried out in Excel 7.0 and 
SPSS 11.0 in Windows 98 environment. The results were 
shown in tables. Comparison of mean values of continuous 
variables of the tested groups was carried out by means of 
ANOVA test with additional Post-hoc analysis (Dunnett’s 
T3 test). Bivariate correlation analysis [(Spearman’s correla-
tion coefficient (r) for nominal and ordinal data and Pear-
son’s correlation coefficient (C) for continuous numerical 
data] was used for the analysis of interrelation between the 
disease activity and activities of 5'-NT and ADA. Significan-
ce level p < 0.05 was accepted as significant. 
Results 
The study included 160 patients with RA; 60 of them 
were not treated with MTX (41 female, 19 male) and 100 pati-
ents were treated with MTX (80 female, 20 male), as well as 
60 healthy controls (40 female, 20 male). The average age of 
the patients was similar for all groups. The average duration of 
the disease in patients who were not treated with MTX was 12 
months, and 120 months in patients treated with MTX. 
Basic characteristics of the tested groups of RA patients 
and the controls were shown in Table 1.  
ґ – mean; SD – standard deviation; ESR – erythrocyte sedimentation rate; VAS – visual analogue scale;  
DAS – disease activity score; MTX – methotrexate; **p < 0.01 as compared to other groups. 
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Table 2 
Values of 5-nucleotidase (5'-NT) and adenosine deaminase (ADA) serum activities in tested  
groups of patients 
 Enzyme RA without MTX treatment RA with MTX treatment Control 
ADA (IJ/L), ґ ± SD  19.32  5.43** 12.05  6.57** 5.09  1.51** 
5'NT (IJ/L), ґ ± SD 37.63 ± 23.71 39.25 ± 15.01 39.15 ± 21.25 
ґ – mean; SD – standard deviation; **p < 0.01 as compared to other groups;  
ANOVA and Post-hoc Dunnett’s T3 test; RA – rheumatoid arthritis; MTX – methotrexate. 
  
Table 3 
Correlation coefficients between disease activity score (DAS28) and enzyme activity in patients  
with rheumatoid arthritis (RA) and controls 
Groups of patients 5'-NT ADA 
RA without MTX treatment 0.108 -0.115 
RA with MTX treatment 0.128 0.170 
Control -0.033 0.105 
5'-NT – 5-nucleotidase; ADA – adenosine deaminase; MTX – methotrexate. 
 
There was no statistically significant difference in the 
level of the disease activity assessed by DAS28 score in the 
above mentioned groups of patients. However, numerical re-
sults showed that the value of DAS28 score in patients not 
treated with MTX was 5.11 which pointed to the high 
activity of the disease. The average DAS28 score in patients 
treated with MTX was 4.66 which pointed to moderate 
activity of the disease. χ2-test showed that the controls had a 
significantly lower DAS28 score (p < 0.01). 
Values of the 5'-NT and ADA are shown in Table 2. 
ADA values were significantly different in all tested 
groups. Post-hoc analysis (Dunnett’s T3 test) showed that 
ADA values in the control group were significantly smaller 
as compared to those in the RA groups (p < 0.001), and that 
ADA value in the MTX group was significantly smaller as 
compared to that in the no MTX group (p < 0.001). There 
was no statistically significant difference in 5'-NT values 
among groups (Table 2).  
The correlation between DAS28 score and the serum 
activities of 5'-NT and ADA by groups is shown in Table 3. 
The connection between the activities of the tested 
enzymes and MTX treatment was analyzed by means of 
binary logistic regression. The analysis showed that the ente-
red model could explain 47% of the variance of the depen-
dent variable, which pointed to the strong predictive value of 
the model. The increase of ADA activities was found in the 
RA group without MTX treatment (OR = 0.98, 95% CI 
0.97–0.99).  
Even though the groups were of similar age structure, 
we tested the effect of the age on the activities of the tested 
enzymes. The results obtained by ANOVA analysis showed 
no statistically significant difference in ADA and 5'-NT 
enzymes serum activities in terms of age.  
The result obtained by t-test of independent samples did 
not show statistically significant difference in serum activiti-
es of ADA and 5'-NT in terms of genders.  
Having in mind that we recorded significant difference 
in the diseases duration for the MTX and no MTX groups, 
we tested the correlation between the disease duration and 
the serum activity of ADA and 5'-NT and recorded mean ne-
gative correlation between ADA activity and the disease du-
ration, i.e. the longer the disease, the less ADA activity. 
However, if we disregarded the effects of MTX treatment, 
we could see the stronger negative correlation between the 
two variables (significance level of 0.001). 
Discussion 
Previous research indicates that activities of some puri-
ne enzymes in rheumatoid arthritis differ from those in 
healthy controls. However, the question which referred to the 
way these enzymes affected the RA activity remained 
unanswered.  
We did not record the significant difference in 5'-NT 
activity in RA patients and the controls. One study showed 
that the activities of serum 5'-nucleotidase were increased in 
patients with RA, i.e. increase of serum 5'-NT appeared at 
30% to 66% of patients with RA 18. Some researchers poin-
ted that this enzyme was present in synovial fluid at 58% of 
RA patients and that its concentration was much larger than 
in the serum. Therefore, testing 5'-NT in synovial fluid could 
have significant diagnostic value for this type of patients 19. 
Literature data on role and origin of 5'-NT in RA was quite 
contradictory. Additionally, they believed that 5'-NT activiti-
es in synovial fluid represented a useful indicator of 
inflammatory activity in synovial membrane, but that 5'-NT 
in serum did not have the same significance. The majority of 
other researchers believed that the importance of this enzyme 
in RA inflammatory response was negligible, because the in-
crease of 5'-NT in synovial fluid was not statistically signifi-
cant even though it was verified. The goal of our study was 
to test the activity of this enzyme in the serum. However, our 
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further research would most definitely test synovial fluid in 
patients with RA. 
The analysis showed statistically significant higher va-
lues of ADA in patients with RA than in healthy controls. 
Mean value of ADA in the serum of RA patients with MTX 
therapy was 12.05 ± 6.57 U/L, the value of analyzed enzyme 
in patients with RA without MTX was 19.32 ± 5.43, while the 
recorded value for healthy controls was 5.09 ± 1.51 U/L. The 
results of most previous studies showed higher values of ADA 
- for instance, one group of authors 20 stated that patients with 
RA had ADA of 26.67 U/L ± 8.74 U/L and healthy controls 
19.79 ± 5.63. Surekha et al. 21 presented high serum activity of 
ADA in patients with RA (59.79 U/L ± 21.09 U/L), while the 
value in healthy controls’ was 20.71 ± 5.63. Aside from the di-
sagreement between the activities of the enzyme, this analysis 
confirmed the results of the above mentioned analyses 20, 21 
which stated that patient with RA showed higher activity of 
ADA in the serum. Unlike the results that we obtained, other 
studies 22, 23 showed similar results of ADA activity in patients 
with RA and Mn control group. 
The results of previous research, which referred to the 
interrelation between purine cycle enzymes and clinical pre-
sentation of RA, were contradictory, especially those which 
referred to the interrelation between RA activity and purine 
enzyme activity. The majority of studies showed a positive 
correlation between ADA activity in serum and the disease 
activity. A group of authors 24 tested the total serum of 
activity ADA in RA patients in different disease stages and 
showed that ADA activity was in significant correlation with 
DAS28. Some authors stated that ADA activity in the serum 
could predict RA activities 25. Results of several studies 24, 26 
showed that ADA and its isoenzymes could be used as alter-
native parameters for showing the disease activity. Namely, 
they recorded clear correlation between DAS28 score in RA 
and catalytic activity of total ADA and ADA2 isoenzymes. 
Additionally, they stated that isoenzyme form of ADA 2 was 
increased along with the disease progression.  
Unlike the above-stated results, one study 27 showed no 
positive correlation between ADA activity and parameters of 
RA activities, especially in patients who had been treated with 
the nonsteroidal anti-inflammatory drug (NSAIL) and anti-
TNF inhibitors. The latest research 28 which included 110 RA 
patients and 55 controls did not record any positive correlation 
between ADA values and the disease activity. However, the 
research confirmed increased activity of ADA in the serum of 
RA patients as compared to that in the control group.  
Attempting to continue previous research, we analyzed 
the correlation between serum ADA and the disease activiti-
es and showed that the disease activity measured by DAS28 
score was not in correlation with serum ADA activity. Even 
though our results showed increased serum ADA activity in 
the RA group without MTX (Table 2), we did not obtain a 
positive correlation between the disease activity and ADA 
activity in the serum.  
Literature data on role and origin of 5'-NT in RA were 
also contradictory. Most authors agreed that increased levels 
of this enzyme were present in the active disease, while 
lower levels were expected in remission stage. Erer et al. 27 
showed that the level of 5'-NT was increased with the disea-
se activity increase and stated that synovial 5'-NT was 
probably isoenzyme of the serum 5'-NT. Our results showed 
that there was no significant correlation between DAS28 sco-
re and 5'-NT activity in the MTX and no MTX groups. 
Additionally, we did not record the change of 5'-NT activity 
in terms of age. Contrary to our results, one extensive rese-
arch showed that the level of 5'-NT dropped with age, as 
well as that the values of 5'-NT were by 27% lower at male 
than at female patients 29.  
It would be very hard to compare the results of our 
study with previous ones because the enzymes were tested 
on different enzyme kits. Additionally, tests were carried out 
on different groups of patients (in terms of gender and age 
distribution) with different disease duration and therapeutic 
approach. Stolk et al. 29 pointed out that majority of RA pati-
ents who participated in the research at medical and research 
centers had already been treated with NSAIL, while large 
number of them was treated with some of the  disease-
modifying antirheumatic drugs (DMARD) and therefore the 
effects that such treatment had on ADA and 5’-NT activity 
cannot be excluded.  
It should be emphasized that almost all of our patients 
used NSAIL, while three patients were treated with parace-
tamol. Patients with RA and controls did not use corticoste-
roids during the month they were included in the study. The 
average dose of MTX applied in patients with RA was 14,5 
mg a week. 
It is well-known that reduction of the local concentrati-
on of adenosine, by ADA contributes to joint inflammation 
in RA. MTX increases the concentration of extracellular 
adenosine at inflammation area 30, 31. Analysis of results con-
firmed that activity of ADA was significantly lower in RA 
patients treated with MTX therapy than in patients who were 
not treated with MTX. These results are in accordance with 
the mechanism of MTX action on adenosine metabolism, i.e. 
ADA inhibition. Previously, researchers 22, 32, 33 also presen-
ted a significant difference between the ADA activity in pa-
tients with RA treated with MTX and in patients who did not 
receive MTX in their therapy. On the other hand, we did not 
find any positive correlations between the activity of 5'-NT 
and MTX treatment. 
The disease duration in patients with no MTX treatment 
was 12 months, which was significantly less as compared to a 
group treated with MTX (disease duration approximately 120 
months). Our results indicated that the longer the disease, the 
less serum ADA activity. However, if we disregarded the effects 
of MTX treatment, we could see the stronger negative correlati-
on between the two variables. The activity of 5'-NT in the tested 
groups did not depend on the disease duration. A study 13, which 
monitored the changes of purine cycle enzyme activities during 
MTX treatment of RA patients, showed similar results. There 
were no differences in enzyme activities after 6 weeks of MTX 
treatment. However, the study recorded a significant drop in the 
ADA activity and no changes in 5’-NT activity after 48 weeks.  
Recent research 13 did not show mutual dependence 
between 5’-NT and ADA activities, and gender. We did not 
find the changes in 5’-NT and ADA activities in terms of 
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gender. However, Stolk et al. 29 showed that the activity of 
5'-NT was by 27% lower in male than in female patients.  
Our research did not record the significant effect of age 
on ADA and 5’-NT activities. It should be emphasized that 
some researches showed the decrease of 5’NT with age inc-
rease 29, 34. 
Conclusion 
We demonstrated that serum adenosine deaminase 
activity was increased in patients with rheumatoid arthritis, 
as well as that the application of methotrexate led to its dec-
rease. Serum activity of 5'-nucleotidase was not increased in 
patients with rheumatoid arthritis and did not depend on 
methotrexate treatment. Serum adenosine deaminase and 5'-
nucleotidase activities were not good indicators of rheumato-
id arthritis activity.  
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Two-dimensional echocardiographic evaluation in liver cirrhosis 
patients in prediction of cirrhotic cardiomyopathy 
Dvodimenzionalna ehokardiografska evaluacija obolelih od ciroze jetre u 
predviđanju cirotične kardiomiopatije  
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Abstract 
Background/Aim. Cirrhotic cardiomyopathy (CCM) is a 
clinical syndrome in liver cirrhosis (LC) patients, which is 
characterized by the abnormal cardiovascular (CV) response 
to physiologic, pathologic, or pharmacologic stress provoca-
tion, but normal to increased cardiac output and contractil-
ity at rest. The aim of the study was to identify the structural 
and functional myocardial changes in the prediction of 
CCM in patients with LC of various origins in advanced 
stages. Methods. The research was performed as a prospec-
tive, nest case-control study, on carefully selected 40 patients 
in the advanced stage of LC and negative personal medical 
history on previous CV disease and 40 healthy subjects as 
the control, from January 2012–December 2014. Echocar-
diographic parameters significant for prediction of the de-
velopment and/or presence of CCM were determined by 
trans-thoracic two-dimensional Doppler echocardiography 
imaging. Results. Most of the LC patients were alcoholic 
(80%), dominantly in Child-Pough C stage of the disease 
(70%). The average value of QT interval in the LC patients 
was significantly higher (0.44 ± 0.03 ms vs 0.42 ± 0.01 ms; 
p < 0.001), as well as brain natriuretic peptide (BNP) serum 
level (284.61 ± 181.44 ng/L vs 69.41 ± 31.08 ng/L; 
p < 0.001) compared to those in the healthy subjects. A sig-
nificant association with serum BNP level in LC patients 
was shown with left atrial diameter (p = 0.031), left ven-
tricular ejection fraction (p = 0.014), pulmonary artery 
systolic pressure (PASP) (p = 0.000) and the presence of tri-
cuspid valve regurgitation of 2+ (p = 0.000), affecting its 
change of 41.6%. Conclusion. The obtained results suggest 
that LC patients have significant echocardiographic signs of 
myocardial dysfunction, as well as the increased BNP serum 
level. Left atrial diameter, left ventricular ejection fraction, 
PASP and tricuspid valve regurgitation are valuable echo-
cardiographic predictors of CCM. 
Key words: 
liver cirrhosis; cardiomyopathies; echocardiography, 
doppler; natriuretic peptide, brain.
Apstrakt 
Uvod/Cilj. Cirotična kardiomiopatija predstavlja klinički sin-
drom obolelih od ciroze jetre, koji karakteriše nenormalno 
usporen odgovor na fiziološke, patološke, ili farmakološke 
draži, uz normalno povećan minutni volumen srca i kontrak-
tilnost u mirovanju. Cilj istraživanja je bio identifikacija struk-
turnih i funkcionalnih promena miokarda, kao prediktora ci-
rotične kardiomiopatije, kod bolesnika sa cirozom jetre različ-
ite etiologije u odmaklim fazama bolesti. Metode. Is-
traživanje je sprovedeno po tipu prospektivne studije slučaja, 
na odabranih 40 bolesnika u odmakloj fazi ciroze jetre sa 
negativnom ličnom medicinskom istorijom na kardiovasku-
larne bolesti i 40 zdravih ispitanika kao kontrolom, u periodu 
od januara 2012. do decembra 2014. godine. Pomoću trans-
torakalne dvodimenzionalne dopler ehokardiografije određi-
vani su parametri od značaja za razvoj i/ili prisustvo cirotične 
kardiomiopatije. Rezultati. Većina obolelih bila je sa alko-
holnom cirozom jetre (80%), dominantno u Child-Pough C 
stadijumu bolesti (70%). Prosečne vrednosti QT intervala kod 
obolelih od ciroze bile su značajno više (0,44 ± 0,03 ms vs 
0,42 ± 0,01 ms; p < 0,001), kao i serumske vrednosti  možda-
nog natriuretskog peptida (BNP) (284,61 ± 181,44 ng/L vs 
69,41 ± 31,08 ng/L; p < 0,001), u poređenju sa onima kod 
zdravih ispitanika. Oboleli od ciroze jetre imali su značajnu 
povezanost između serumskih vrednosti BNP i dijametra leve 
pretkomore (p = 0,031), ejekcione frakcije leve komore 
(p = 0,014), sistolnog pritiska u pulmonalnoj arteriji 
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(p = 0,000) i prisustva regurgitacije trikuspidne valvule od 2+ 
(p = 0,000), koji su uticali na promenu vrednosti BNP za 
41,6%. Zaključak. Rezultati ovog istraživanja sugerišu da 
oboleli od ciroze jetre imaju značajne ehokardiografske znake 
miokardne disfunkcije, uz povećan serumski nivo BNP. Di-
jametar leve pretkomore, ejekciona frakcija leve komore, pri-
tisak u pulmonalnoj arteriji i prisustvo regurgitacije trikuspi-
dalne valvule, predstavljaju važne ehokardiografske prediktore 
cirotične kardiomiopatije.  
Ključne reči: 
jetra, ciroza; kardiomiopatije; ehokardiografija, dopler; 
natriuretski peptid, moždani. 
Introduction 
The heart and liver may interact in several different 
ways. Acute or chronic heart failure (HF), especially in case 
of the right HF, may lead to a spectrum of many liver disor-
ders, including the cardiac cirrhosis, or congestive 
hepatopathy 1. On the other hand, chronic liver disease such 
as cirrhosis may affect the heart and the whole cardiovascu-
lar system, leading to a clinical syndrome of cirrhotic 
cardiomyopathy (CCM) 2. 
Cirrhotic cardiomyopathy was first defined in 2005 on 
the annual expert consensus meeting of the World 
Gastroenterology Organisation in Montreal as: “a cardiac 
dysfunction in patients with liver cirrhosis characterised by 
impaired contractile responsiveness to stress and/or altered 
diastolic relaxation with electrophysiological abnormalities 
in the absence of other known cardiac disease” 3, 4. Although 
this term had a significant lack of strict criteria, the prevalen-
ce of CCM is reported to be between 40% to 50% in cirrho-
sis patients, while its development seems to be independent 
of the etiology of liver disease 5, 6. 
The different myocardial adaptations seen in liver cirrhosis 
(LC) can be classified in structural, electrophysiological and 
functional changes. Structural changes include enlarged cardiac 
chambers and increased myocardial mass 7. A prolonged QT in-
terval and an abnormal chronotropic response to stress, are the 
main electrophysiological changes. Functional changes mainly 
consist of an impaired cardiac response to exercise or diastolic 
dysfunction 1, 7, 8. The most common cardiac abnormalities on 
autopsy were left or right ventricular dilatation and left ventricu-
lar hypertrophy, which are encountered in more than 30% of the 
patients 9. Some echocardiographic studies show conflicting da-
ta, but left atrial (LA) dilatation and mild left ventricular (LV) 
hypertrophy are the most common reported abnormalities 10, 11. 
These changes probably reflect a combination of mechanical 
overload due to hyperdynamic circulation and neurohormonal 
activation 2, 12, 13. 
Diastolic dysfunction is the most prominent functional alte-
ration seen in CCM 3, 4. It is due to a combination of myocardial 
hypertrophy, fibrosis due to increased aldosterone levels and su-
bendothelial oedema. The reported prevalence is between 45% 
and 56% 8. There are no strict diagnostic criteria but impaired 
cardiac response to stress, LV diastolic dysfunction, and prolon-
ged QT are the most prominent features 14. 
Cirrhotic cardiomyopathy is diagnosed if there is any 
evidence of systolic or diastolic myocardial dysfunction, 
along with associated criteria such as electrophysiological 
abnormalities and/or changes in serum markers levels 4, 14. 
Many studies have made the link between the decrease in LV 
function and increased concentrations of natriuretic peptides 
in plasma, which opened the possibility of biochemical con-
firmation of heart failure 15, 16.  The most reliable results are 
obtained with the N-terminal atrial natriuretic peptide (NT 
ANP), brain natriuretic peptide (BNP) and its precursor N-
terminal pro BNP (NT pro BNP) 13. Analysis of these pepti-
des is clinically significant as a test to exclude the diagnosis 
of heart failure due to their high negative predictive value 12. 
Data on the clinical significance of CCM are scarce but 
several publications indicate a poor prognosis for these patients. 
In patients prior to performing a transjugular portosystemic 
shunt (TIPS), diastolic dysfunction expressed as an E/A ratio 
≤ 1, was a predictor of ascites persistence and death 17. The pre-
sence of the cardiomyopathy should be suspected in patients 
with worsening hemodynamics. Such patients may benefit from 
more aggressive monitoring and treatment of the underlying 
pathology leading to decompensation, and from close monito-
ring during procedures that could cause decompensation i.e., 
TIPS, paracentesis, liver transplantation (LT) 18, 19. 
The aim of the study was to identify the structural and 
functional myocardial changes in patients with liver cirrhosis 
of various origin in advanced stages of the disease, by two-
dimensional echocardiographic evaluation, assessing its sig-
nificance and correlation with serum levels of BNP in the 
prediction of CCM. 
Methods 
Patients 
The research was performed as a prospective, nest case-
control study, in the Clinic for Gastroenterology and Hepatology 
and Clinic for Cardiovascular Disease, Clinical Center of Niš, 
on carefully selected 40 patients with verified liver cirrhosis in 
the advanced stage of the disease (Child-Pough B and C stage) 
and the negative personal medical history on previous cardiova-
scular disease, as an experimental group, and 40 healthy subjects 
as the control one, in the period between January 2012 and De-
cember 2014. All the patients gave informed and written consent 
for the participation in the study, while the ethical approvement 
for the research was obtained from the Academic Council of 
Faculty of Medicine, University of Niš (No 04-828/12). 
Diagnosis and staging of liver cirrhosis 
The diagnosis of cirrhosis was based on clinical, echocar-
diographic (Toshiba Ecossee 96, 3.75 MHz convex probe, 1996, 
Japan) and laboratory parameters of liver damage, and in some 
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cases histologically by parenchymal biopsy. The severity degree 
of cirrhosis was evaluated by "scoring" system of functional li-
ver damage by using the Child-Pough classification 20. 
Cardiovascular examination 
In all of the observed patients was done: a) standard 
electrocardiogram in 12 leads, b) arterial blood pressure me-
asurement (mmHg), c) heart rate measurement, d) serum va-
lues of brain natriuretic peptide (ng/L) (Olympus, AU 400, 
2003,  Japan) and e) echocardiography examination determi-
ning the values of left ventricular end-diastolic and end-
systolic diameter, LV ejection fraction and LA diameter, E/A 
ratio, deceleration time (DT) and isovolumic relaxation time 
(IVRT), right ventricular diameter, presence of tricuspid val-
ve regurgitation and pulmonary artery systolic pressure 
(PASP). Echocardiographic study was made in M-mode 
technique, by two-dimensional Doppler echocardiographic 
examination (ACUSON X 300, KT-LM 150 HD, Siemens, 
Germany) 21. 
Follow-up of the patients 
At the moment of hospitalization, patients underwent a 
standard clinical, echosonographic and laboratory processing 
in order to verify the cause and severity of liver cirrhosis, 
and then performed cardiovascular analysis in accordance 
with inclusion and exclusion criteria for the entry into the 
study, whereupon were placed in the experimental subjects 
group. All subjects of the experimental group were treated by 
hepatoprotective and substitution therapy in accordance with 
the stage of liver cirrhosis. The control group subjects made 
only the cardiovascular analysis. 
Statistical analysis 
Statistical analysis was performed on the personal compu-
ter. Excel program from Microsoft Office 2007 software packa-
ge was used for entering, ranking, clustering, tabular and graphi-
cal display of data. All calculations were performed using SPSS 
program ver.18.0. In all analysis, the limit of statistical signifi-
cance as the default error estimates of 0.05. 
The mean (ґ), standard deviation (SD), structure (%) 
and 95% confidence interval (95% CI) were shown in the de-
scription analysis. Comparison of mean values of numerical 
characteristics between two examined groups of patients was 
done by Student's-t test or Mann-Whitney U test in cases 
where the distribution of values did not meet the 
requirements of the normal distribution. Comparison of the 
frequency of attribute characteristics between groups was 
performed by Mantel-Haenszel χ2 test or Fisher exact test’s 
probability of the null  hypothesis, in cases where some of 
the features expected frequency was less than five 22. 
Analysis of the relationship of investigated factors and 
indicators of cardiac function were done by the linear regres-
sion analysis. There were calculated values of the regression 
coefficients (β) and the boundaries of their 95% confidence 
intervals (95% CI). All the examined factors were involved 
in a univariate model of analysis. Those factors which shown 
significant association with the dependent variables in univa-
riate models, were included in the multivariate models, and 
then, applying the backward method of multivariate model, 
were excluded under the control of the influence of other fac-
tors involved, which did not show a significant impact on the 
dependent variable, as long as the model did not contain only 
major factors and constant of regression 23. 
Results 
The observed groups of patients were homogenous in re-
lation to the average distribution of general demographic cha-
racteristics (age, gender, social status, living and working pla-
ce). In relation to ethiology of liver cirrhosis, most of the pati-
ents in experimental group were with alcoholic liver cirrhosis 
(32/80%). According to Child-Pough classification, there was 
registered a significantly higher number of patients in stage C 
of disease (28/70%), in relation to those in stage B of disease 
(12/30%). From typical clinical symptoms and signs of cirrho-
sis deterioration, which were decisive parameters in the further 
assessment for the effects on cardiovascular function in obser-
ved patients of the experimental group, there were registered: 
ascites in 29 (72.5%), encephalopathy in 19 (47.5%), jaundice 
in 21 (52.5%) and the presence of esophageal varices in 30 
(75%) of the patients. 
Results of examined cardiovascular system parameters 
in liver cirrhosis patients (experimental group) 
The average values of arterial blood pressure in cirrhosis 
patients were within normal limits and amounted to 113.38 ± 
14.82 mmHg for systolic blood pressure, and 70.13 ± 10.03 
mmHg for diastolic one. For these subjects, electrocardiogram 
registered an average moderately elevated heart rate frequency 
from 86.9 ± 14.45 beats per minute, while in 22 (55%) of res-
pondents, the extended value of the QT interval (> 0.44 s) was 
registered, an average of 0.44 ± 0.03 s. In 34 (85%) patients 
with cirrhosis, an average increased serum level of BNP of 
284.61 ± 181.44 ng/L was registered. The presence of 
pathologically altered values of echocardiographic parameters 
in patients with liver cirrhosis is shown in Figure 1. 
Only in 5% of cirrhosis patients, a reduced LV ejection 
fraction (<55%), with average values at the group level of 
64.43 ± 4.12% was registered. Increased LA diameter (> 40 
mm) was registered in 40% of respondents, the average at 
the group level of 38.28 ± 6.17 mm. Reduced E/A ratio (< 1 
ms), was registered in 29 (72.5%) cirrhosis patients, with 
mean values at the group level of 0.93 ± 0.28 ms. Extending 
values of DT (> 200 ms), were registered in 38 (95%) pati-
ents, with average values, at the group level of 
275.65 ± 71.25 ms, as well as IVRT (> 80 ms) in 30 (75%) 
with an average value at the group level of 90.52 ± 22.82 ms. 
Increased right ventricular diameter (RVD) (> 25 mm), was 
registered in 31 (77.5%) of cirrhosis patients, with average 
values of 26.63 ± 2.93 mm and tricuspid valve regurgitation 
was present in 24 (60%), mostly of the first degree (55%). 
The average value of the inferior vena cava diameter in in-
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Fig. 1 – The presence of pathologically  altered values of echocardiographic parameters in patients with liver cirrhosis 
PASP – pulmonary artery systolic pressure; RVD – right ventricular diameter; IVRT – isovolumic relaxation time;  
LV – left ventricle. 
spirium amounted to 2.27 ± 3.69 cm. In 30 (70%) an increa-
sed PASP (>25 mm) was registered, in an average of 31.75 ± 
7.89 mm, as shown in Figure 1. 
Comparison of the cardiovascular system parameters in 
the assessment of myocardial functions between two obser-
ved groups of patients 
The average value of the arterial systolic blood pressure 
in the cirrhosis patients was 113.38 ± 14.82 mmHg, which 
was significantly lower compared to the healthy subjects 
(125.38 ± 8.65 mmHg) (p < 0.001). Mean arterial diastolic 
blood pressure was not significantly different between the 
observed groups and was within normal range (70.13 ± 10.03 
vs 72.0 ± 8.83 mmHg; p = 0.378). From the examined elec-
trocardiographic parameters, the average value of heart rate 
was statistically significantly higher in the cirrhosis patients 
compared to that in healthy subjects (86.9 ± 14.45 vs 
70.97 ± 6.07 n/min; p < 0.001), as well as the average value 
of QT interval (0.44 ± 0.03 vs 0.42 ± 0.01; p < 0.001). In pa-
tients with liver cirrhosis, the average value of BNP was 
284.61 ± 181.44 ng/L, being significantly higher compared 
to the value of healthy subjects (p < 0.001). 
Echocardiographic examination of morphological and fun-
ctional characteristics of the heart cavities, as well as all tested 
parameters of myocardial dysfunction in patients with liver cirr-
hosis, verified significant differences in the average values, 
compared to values in healthy subjects, as shown in Table 1. 
Analysis of relationship between the values of echocar-
diographic characteristics and serum brain natriuretic pep-
tide in cirrhosis patients for predicting cirrhotic 
cardiomyopathy 
Univariate linear regression analysis as significant pre-
dictors of serum levels of BNP, among the examined echo-
cardiographic characteristics of heart cavities and the para-
meters of diastolic dysfunction in liver cirrhosis patients, 
confirmed: LA diameter, LV ejection fraction, DT, RVD, 
PASP and the presence of tricuspid valve regurgitation, as 
shown in Table 2. 
Multivariate regression analysis as the most important 
predictors of serum levels of BNP, among the investigated 
echocardiographic characteristics of the cirrhosis patients, al-
located values of : LA diameter, LV ejection fraction, PASP 
and the presence of tricuspid valve regurgitation of 2+, as 
shown in Table 3. 
These echocardiographic parameters in common 
analysis model of association with serum levels of BNP, af-
fecting its change of 41.6%. 
Discussion 
Liver cirrhosis of various etiology manifests as a state 
of low systemic vascular resistance, high peripheral volume 
with low central blood volume, precipitating a state of neu-
rohormonal activation and high cardiac output, which may 
adversely affect cardiac reserve and lead in clinical 
syndrome of CCM 14. In its most benign form, CCM mani-
fests as subtle electrocardiographic (ECG) and echocardio-
graphic abnormalities, most commonly as prolonged QT in-
terval and diastolic dysfunction, but typically with preserved 
systolic function by two-dimensional ultrasound imaging in 
the resting and pre-transplant vasodilated state 24–25. At the 
extreme, CCM progresses to the heart failure under the 
hemodynamic stress, unmasked by the demands of variceal 
bleeding, high doses of vasopressors, reversal of low to high 
afterload, withdrawal of cardioprotective medications used in 
the treatment of end stage LC (beta-blockers and mineralo-
corticoid antagonists), worsened by concomitant sepsis or 
systemic inflammatory response syndrome 24. Recently, there 
is increasing data on the role of cardiac biomarkers, such as 
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Table 1 
Comparison of the average echocardiographic parameters values between liver cirrhosis patients (experimental 
group) and healthy subjects (control group) 
Echocardiographic parameters  Cirrhosis patients (n = 40) 
Health subjects 
(n = 40) 
Significance 
(p-value) 
Left heart cavities    
left atrial diameter (mm), ґ ± SD 38.28 ± 6.17 34.73 ± 1.91 0.001* 
end-systolic left ventricular (LV) diameter (mm) , ґ ± SD 29.48 ± 5.35 27.33 ± 1.69 0.018* 
end-diastolic LV diameter (mm), ґ ± SD 47.78 ± 5.48 46.68 ± 3.32 0.281 
LV ejection fraction (%), ґ ± SD  64.43 ± 4.12 69.68 ± 3.29 0.001* 
Diastolic dysfunction    
E/A ratio (ms), ґ ± SD 0.93 ± 0.28 1.16 ± 0.07 0.001* 
deceleration time (ms), ґ ± SD 275.65 ± 71.25 185.15 ± 8.34 0.001* 
isovolumic relaxation time (ms), ґ ± SD 90.52 ± 22.82 76.95 ± 2.29 0.001* 
Right heart cavities    
right ventricular diameter (mm), ґ ± SD 26.63 ± 2.93 23.38 ± 3.03 0.001* 
pulmonary artery systolic pressure (mm Hg), ґ ± SD 31.75 ± 7.89 23.35 ± 2.66 0.001* 
inferior vena cava diameter in inspirium (cm), ґ ± SD 2.27 ± 3.69 1.59 ± 0.14 0.253 
Tricuspid valve regurgitation, n (%)     
1+  22 (55) 6 (15) 0.001* 
2+  2 (5) 0 (0) 0.494 
ґ – arithmetic mean; SD – standard deviation; *statistically significant difference. 
Table 2 
Correlation between echocardiographic parameters of the liver cirrhosis patients with the values of serum brain 
natriuretic peptide (results of univariate linear regression analysis) 
Boundaries of 95% CI for ß Echocardiographic parameters ß lower limit upper limit 
Significance 
(p-value) 
Left heart cavities 
left atrial diameter (mm) 12.927 5.698 20.156 0.001* 
end-systolic left ventricular diameter (mm) -3.021 -14.41 8.371 0.598 
end-diastolic left ventricular diameter (mm) 6.058 -3.997 16.112 0.233 
left ventricular ejection fraction (%)  -13.528 -21.30 -5.748 0.001* 
Diastolic dysfunction 
E/A ratio (ms) 53.522 -120.0 227.046 0.540 
deceleration time (ms) 0.733 0.199 1.268 0.008* 
osovolumic relaxation time (ms) 0.996 -1.436 3.428 0.417 
Right heart cavities 
right ventricular diameter (mm) 12.998 2.146 23.850 0.020* 
pulmonary artery systolic pressure (mm Hg) 11.977 4.631 19.323 0.002* 
inferior vena cava diameter (inspirium) (cm) 2.058 -16.03 20.146 0.821 
Tricuspid valve regurgitation     
1+ 152.444 81.066 223.822 0.000* 
2+ 404.293 722.3 86.380 0.013 
ß – regression coefficient; CI – confidence interval; * statistically significant difference. 
 
Table 3 
Correlation between echocardiographic parameters of the liver cirrhosis patients with the values of serum brain 
natriuretic peptide (results of multivariate regression analysis) 
Boundaries of 95% CI for ß Echocardiographic parameters ß 
lower limit upper limit 
Significance 
(p-value) 
Left atrial diameter (mm) 7.368 0.711 14.025 0.031* 
0.014* Left ventriculary ejection fraction (%) -8.752 -15.675 -1.829 
0.000* Pulmonary artery systolic pressure (mm Hg) 12.940 7.405 18.474 
0.000* Tricuspid valve regurgitation 2+ 477.794 714.254 241.334 
Constant of regression 150.344 -424.484 725.172 0.604 
ß – regression coefficient; CI – confidence interval; * statistically significant difference. 
BNP, and advanced echo imaging techniques using tissue 
Doppler imaging (TDI) and strain imaging, to advance the 
better understanding of this clinical entity. 
Prolongation of the QT interval is the most common 
ECG finding in LC, seen in up to 50% of patients and is as-
sociated with sudden cardiac death 26. Chronic 
hyperactivation of the sympathetic nervous system and 
delayed repolarization of cardiomyocytes secondary to de-
fects in K+ channel function, have been observed in cirrhotic 
patients with the associated QT interval prolongation, which 
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may reverse after LT, although may persist in up to 50% of 
patients 27. On the other hand, the use of beta-blockers for the 
varices treatment is associated with QT prolongation reduc-
tion 28, 29. There is also a strong evidence of electromechani-
cal uncoupling, with dysregulation in the normal sequence of 
cardiomyocyte depolarization and contraction 30, 31. In our 
study, 55% of LC patients had prolonged QT interval values, 
significantly higher compared to the healthy subjects on ave-
rage (p < 0.001). 
In addition to ECG testing, echocardiography provides 
more valuable information regarding the development of 
clinically important systolic and diastolic dysfunction. Two-
dimensional transthoracic echocardiography with TDI is an 
important imaging technique for better understanding of the 
dynamic myocardial changes that may occur as cirrhosis 
worsens, while volume overload becomes more severe, deve-
loping a hepatorenal syndrome. The American Association for 
the Study of Liver Diseases recommends this method as part 
of the evaluation of liver transplantation cirrhosis candidates to 
assess for systolic and diastolic dysfunction, outflow gradients, 
hypertrophy, chamber sizes, and non-invasive assessment of 
pulmonary pressures 32. Many echo studies in this patient po-
pulation have been done, demonstrating variable findings, 
most notably the presence of diastolic dysfunction, using both 
two-dimensional imaging and TDI assessments, demonstrating 
the association of diastolic dysfunction with worsening of cirr-
hosis 4, 8, 18. In a recent autopsy study of 133 patients with LC, 
cardiomegaly and left ventricular hypertrophy were found in 
up to 43% of patients 9. 
Diastolic dysfunction is common in LC patients and has 
been widely reported in many clinical studies, most 
commonly evaluating abnormalities in E/A ratio 17, 24. Using 
basic two-dimensional echocardiography indices of diastolic 
dysfunction, pulsed-wave Doppler at the mitral valve leaflet 
tips provide information about early and late diastolic filling 
in normal sinus rhythm, with rapid passive filling followed 
by atrial contraction. Measurements of DT, along with mea-
surement of isovolumic relaxation time by pulsed-wave 
Doppler at the septal insertion of the mitral valve, provide 
estimates of diastolic parameters and can guide in categori-
zing patients on the spectrum of diastolic abnormalities using 
a validated grading system 33. However, E/A ratio is load-
dependent, making its use in cirrhosis problematic, as the 
fluid shift is a prominent physiologic derangement in this 
condition. Diastolic dysfunction parameters may change ba-
sed on weight, whether or not measurements were obtained 
before or after paracentesis, or whether obtained before or 
soon after other major interventions such as TIPS, which 
precipitates a marked increase in preload and can precipitate 
fulminant heart failure from latent or subclinical CCM. TDI 
is an increasingly attractive modality to assess diastolic 
dysfunction in the setting of suspected CCM given both an-
gle-independence and load-independence 34. In our investiga-
tion, reduced E/A ratio (< 1 ms) has been registered in 72.5% 
cirrhosis patients, significantly lower compared to healthy 
subjects (p < 0.001). Extending values of DT (> 200 ms), 
were registered in 95% of patients, as well as prolonged 
IVRT (> 80 ms) in 75%  LC patients, significantly higher 
compared to values in healthy subjects (p < 0.001). On the 
other hand, we registered a reduced LV ejection fraction 
(< 55%) in only 5 LC patients, generally significantly lower 
average values compared to those in the healthy subjects and 
increased LA diameter (> 40 mm) at 40% of patients. Increa-
sed RVD (> 25 mm) was registered in 77.5% of LC patients, 
while the tricuspid valve regurgitation was present in 60.0%, 
mostly of the first degree. In 70.0% of investigated LC pati-
ents an increased PASP was registered, significantly higher 
in average compared to values found in the healthy subjects, 
which is corresponding to the previously mentioned literatu-
re data. 
Nowadays, a serial use of biomarkers is an increasingly 
important strategy for the diagnosis and management of pati-
ents with CCM. Both BNP and NT-proBNP have been repor-
ted to be significantly increased in patients with advanced ci-
rrhosis compared to controls. This increase is probably 
secondary to increased cardiac production of natriuretic pep-
tides since hepatic degradation does not seem to be affected. 
Increased BNP and NT-proBNP were associated with the 
severity of both cirrhosis and cardiac dysfunction 13. Our in-
vestigation showed a significantly higher the average BNP 
value in LC patients in Child-Pough stage B and C of the di-
sease, compared to values in the healthy subjects (p < 0.001). 
BNP has been studied in cirrhotic patients as a surrogate for 
cirrhotic cardiomyopathy, with recent predictive data regar-
ding the incidence of renal failure and mortality after liver 
transplantation, and its association with a model for the end 
stage liver disease (MELD) and Child-Pough scores, the 
severity of LC, and diastolic or systolic dysfunction 13, 35, 36. 
In our study, the most important predictors of serum levels of 
BNP, among the investigated echocardiographic characteris-
tics of the LC patients, were values of: LA diameter, LV 
ejection fraction, PASP and the presence of tricuspid valve 
regurgitation of 2+. Therefore, an increasing BNP levels in 
the setting of dyspnea, exertional intolerance, and progressi-
ve renal dysfunction in LC patients may alert clinicians to re-
assess myocardial systolic and diastolic function. 
Conclusion 
Data obtained in this study indicate that in patients with 
liver cirrhosis, morphological and functional myocardial da-
mages in the form of cirrhotic cardiomyopathy, are created 
and developed in the field of the advanced stage of the disea-
se, mostly as a consequence of altered systemic 
hemodynamics. Patients with liver cirrhosis had significant 
echocardiographic signs of myocardial dysfunction, as a pro-
longed deceleration time and isovolumic relaxation time, to-
gether with reduced E/A ratio, as well as the increased BNP 
serum level. Left atrial diameter, LV ejection fraction, 
pulmonary artery systolic pressure and tricuspid valve regur-
gitation, were strongly associated with BNP serum levels, 
which suggests their importance as predictors in the asses-
sment of the origin and development of cirrhotic 
cardiomyopathy.  
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Abstract 
 
Background/Aim. Ventilator-associated pneumonia (VAP) 
incidence, causative pathogens, and resistance patterns are 
different among countries and intensive care units (ICUs). In 
Europe, resistant organisms have progressively increased in the 
last decade. However, there is a lack of data from Serbian ICUs. 
The aims of this study were to evaluate etiology and 
antimicrobial resistance for pathogens causing VAP in ICU 
patients, to examine whether there were differences among 
pathogens in early-onset and late-onset VAP and to identify 
mortality in patients with VAP after 30 and 60 days of 
hospitalization. Methods. A retrospective cohort study was 
conducted in the respiratory ICU and all adult patients diagnosed 
with VAP from 2009 to 2014 were included. Results. Gram 
negative organisms were the major pathogens (80.3%). The most 
commonly isolated was Acinetobacter spp (59.8%). There was a 
statistically significant increase in the incidence of infection with 
Klebsiella pneumoniae (8.9% vs 25.6%; p = 0.019). Extensively drug-
resistant strains (XDR) were the most common (78.7%). Late-
onset VAP was developed in 81.1% of patients without 
differences among pathogens in comparison with early-onset 
VAP. Acinetobacter spp was susceptible to tigecycline and colistin 
with a significant increase in resistance to ampicillin/sulbactam 
(30.2% vs 58.6%; p = 0.01). Resistance rate of Pseudomonas 
aeruginosa and Klebsiella pneumoniae to carbapenems was 38% and 
11%, respectively. In methicillin-resistant Staphylococcus aureus no 
resistance was observed against vancomycin and linezolid. There 
was no difference in mortality rate between patients with early-
onset and late-onset VAP after 30 and 60 days of hospitalization. 
Conclusion. Gram negative organisms were the primary cause 
of bacterial VAP of which the most common was the XDR 
strain of Acinetobacter spp. Patients with early- and late-onset VAP 
had the same pathogens. There was no difference in mortality 
between this two group of patients during 60 days of 
hospitalization. 
 
Key words:  
pneumonia; cross infection; anti-bacterial agents; drug 
resistance, bacterial; respiration, artificial; mortality.
Apstrakt 
 
Uvod/Cilj. Incidencija pneumonije udružene sa ventilatornom 
potporom bolesnika (VAP), njeni uzročnici i njihova rezistencija 
razlikuju se između zemalja i jedinica intenzivne nege (JIN). U 
Evropi je u poslednjih deset godina došlo do progresivnog porasta 
rezistentnih bakterija. Međutim, ne postoji dovoljno podataka za 
JIN u Srbiji. Ciljevi rada bili su da se ispita etiologija i rezistencija 
uzročnika VAP na antibiotike u JIN, da se ispita da li postoji 
razlika između uzročnika ranog i kasnog VAP i da se utvrdi letalitet 
kod bolesnika sa VAP nakon 30 i 60 dana hospitalizacije. Metode. 
Retrospektivno kohortno ispitivanje je bilo sprovedeno u 
pulmološkoj JIN. Bili su uključeni svi odrasli bolesnici sa 
dijagnostikovanim VAP od 2009. do 2014. godine. Rezultati. 
Glavni uzročnici VAP bili su gram negativne bakterije (80,3%). 
Najčešće je bio izolovan Acinetobacter spp (59,8%). Zabeležen je 
statistički značajan porast incidencije oboljevanja usled Klebsiella 
pneumoniae (8,9% vs 25,6%; p = 0,019). Najzastupljeniji su bili 
ekstremno rezistentni (XDR) sojevi bakterija (78,7%). Kasni VAP 
je dijagnostikovan kod 81,1% bolesnika bez razlike u patogenima u 
poređenju sa ranim VAP. Acinetobacter spp je bio osetljiv na 
tigeciklin i kolistin uz statistički značajan porast rezistencije na am-
picilin/sulbaktam (30,2% vs 58,6%; p = 0,01). Rezistencija 
Pseudomonas aeruginosa i Klebsiella pneumoniae na karbapeneme iznosila 
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je 38%, odnosno 11%. Kod meticilin-rezistentnog Staphylococcus 
aureus nije postojala rezistencija na vankomicin i linezolid. Nisu 
utvrđene razlike u letalitetu između bolesnika sa ranim i kasnim 
VAP posle 30 i 60 dana hospitalizacije. Zaključak. Gram 
negativne bakterije bile su glavni uzročnici VAP, od kojih je 
najzastupljeniji bio XDR soj Acinetobacter spp. Bolesnici sa ranim i 
kasnim VAP imali su iste uzročnike. Nije bilo razlike u letalitetu 
između te dve grupe bolesnika tokom 60 dana hospitalizacije. 
 
Ključne reči: 
pneumonija; infekcija, intrahospitalna; antibiotici; lekovi, 
rezistencija bakterija; disanje, mehaničko; mortalitet. 
 
Introduction 
Ventilator-associated pneumonia (VAP) is the most 
common nosocomial infection in patients receiving mechanical 
ventilation. VAP remains a major cause of morbidity and 
mortality among critically ill patients and accounts for more 
than one-half of all antibiotic use in an Intensive Care Unit 
(ICU) 1. The estimated incidence of VAP is 9% to 27%, with a 
mortality rate of 25% to 50% 2. The appropriateness of empirical 
antimicrobial therapy for VAP is a key determinant of patient 
outcome 2. Changes in pathogen distribution and patterns of 
antibiotic resistance complicate antibiotic treatment and care of 
the patients. Duration of mechanical ventilation was found to be 
one of the most important factors determining the composition 
of offending VAP pathogens 3. Whereas early-onset VAP is 
more likely to be caused by antibiotic-sensitive bacteria, late-
onset VAP is more likely to be caused by multi-drug resistant 
(MDR) pathogens. However, studies with opposite results were 
published recently 4–7, which showed that bacteriology of VAP 
may not follow a pattern of early versus late infection, 
particularly in patients that are at risk for MDR infections 8. 
The incidence of infection with specific pathogens with 
different susceptibility patterns causing VAP may not only 
vary from hospital to hospital but also within the same 
hospital or ICU over time 8. This is the reason why empiric 
initial antibiotic treatment for VAP should be based on 
general guidelines, but also on up-to-date information on 
local epidemiology 8. There is a lack of National registry 
consisting data from Serbian ICUs in regard to the local 
microbiological profile of pathogens causing VAP as well as 
to their antibiotic susceptibility and resistance patterns. 
Given the scarcity of data, the primary aim of the 
present study was to evaluate etiology and antimicrobial 
resistance trends for nosocomial pathogens causing VAP in 
respiratory ICU patients and to examine whether there were 
differences among pathogens in early-onset and late-onset 
VAP. The aim of the study was also to identify mortality in 
patients with VAP after 30 and 60 days of hospitalization. 
Methods 
Study design 
A retrospective cohort study was conducted in the 5-
bed respiratory ICU of the Institute for Pulmonary Diseases 
of Vojvodina, Sremska Kamenica (Serbia). All adult patients 
diagnosed with VAP from January 2009 to December 2014, 
were included. This study was approved by the Hospital 
Ethics Committee. In order to evaluate changes in the 
incidence of infection with pathogens and changes in their 
resistance pattern, 6 year period was divided into two 
separate periods: period I (January 2009 to December 2011) 
and period II (January 2012 to December 2014). 
Definitions 
VAP was diagnosed in the presence of a new or persistent 
(≥ 48 hours) and progressive  radiographic infiltrate plus at least 2 
of the following: temperature of ≥ 38ºC or < 35ºC; purulent trac-
heal secretions or a change in characteristics of sputum; or 
leucocytosis (> 10.000 white blood cells/mm3) or leucopenia 
(< 4.000 white blood cells/mm3) 9, 10 . After clinical diagnosis of 
VAP had been established, quantitative culture of endotracheal 
aspirate (ETA) was performed to identify VAP pathogens. Only 
pathogens isolated at a concentration of > 106 colony-forming 
units (CFU/mL) was considered causative of VAP  9.  VAP was 
classified by the onset of the disease as early-onset VAP, which 
occurred within the first 4 days and late-onset VAP, which develo-
ped more than 4 days after starting mechanical ventilation (MV) 3. 
If patients met clinical criteria for VAP, antibiotic 
therapy was initiated empirically according to primary 
diagnosis, comorbidities, prior antibiotic exposure, duration 
of the previous hospitalization of the patient, and the result 
of the surveillance cultures. 
Multidrug resistance (MDR) was defined as acquired 
non-susceptibility to at least one agent in three or more anti-
microbial categories. Extensively drug-resistance (XDR) was 
defined as non-susceptibility to at least one agent in all but 
two or fewer antimicrobial categories (i.e. bacterial isolates 
remain susceptible to only one or two categories). Pandrug-
resistance (PDR) was defined as non-susceptibility to all 
agents in all antimicrobial categories 11. Standardized defini-
tions were used to determine the presence or absence of ICU 
complications including acute respiratory distress syndrome 
(ARDS) 10, severe sepsis and septic shock 12.  
Data collection 
Demographic data, comorbidities, Charlson 
comorbidity score, Simplified Acute Physiology Score II 
(SAPS II), Acute Physiology and Chronic Health Evaluation 
II (APACHE II), the Sequential Organ Failure Assessment 
(SOFA) score at ICU admission, admission diagnosis of the 
patients, reason for endotracheal intubation, prior antibiotic 
use, microorganisms of VAP, antibiotic susceptibility, 
lengths of ICU and hospital stays and duration of MV prior 
to VAP onset were recorded. All patients were followed-up 
for survival status until 60 days after the initial onset of VAP 
or until death (if patients died within 60 days). The overall 
30-day and 60-day mortalities were recorded.  Only the first 
VAP episode was evaluated. 
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The antibiotic susceptibility of clinical isolates was deter-
mined by the Kirby-Bauer disk diffusion method and, if required, 
E-test, and analyzed according to the Clinical and Laboratory 
Standards Institute 2013 document. Identification of pathogens 
and the antibiotic susceptibility was performed in the Center for 
Microbiology, Virology and Immunology, Institute for 
Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia. 
Statistical analysis 
Data entry and analysis were performed using IBM SPSS 
Statistics 22 (SPSS Inc., Chicago, IL, USA). A descriptive 
analysis was used to investigate patient demographics and ICU 
data. The median with range was employed for not-normally di-
stributed continuous variables, and mean ± standard deviation 
(SD) was used for normally distributed continuous variables. 
Numbers and percentages were used when applicable. The χ2 
test and Fisher’s exact test were employed for testing differences 
in values of dichotomous variables among study groups, Krus-
kal-Wallis and Mann-Whitney U tests were used for continuous 
variables with not-normal distribution. The level of significance 
was set at p < 0.05. 
Results 
During the study period, 844 adult patients were admitted 
to the ICU. VAP developed in 144 (17%) patients during the 
ICU stay. Twenty two patients were excluded from the 
analysis (lack of data). So, the final analysis of bacterial 
etiology included 122 patients/ETA samples (78 males and 44 
females) with 141 bacterial species isolated.  The incidence of 
VAP was 47.3 cases per 1,000 ventilator days. The mean age 
of the patients was 56.8 ± 14.6 years. The most common 
comorbidities of the VAP patients were hypertension (50.8%), 
other cardiovascular diseases (41.8%) and the chronic 
obstructive pulmonary disease (COPD) (28.7%). The major 
reasons for intubation were as following: ARDS (39.3%), 
pneumonia (34.4%), cardiac arrest (8.2%), and exacerbation of 
COPD (6.6%). Clinical characteristics of analyzed patients on 
admission at ICU are shown in Table 1. 
Median length of ICU stay was 19 days (4–85) and of 
hospital stay 30 (4–112) days. Out of 122 patients that 
developed VAP, 50 (41.0%) died. The patients who did not 
survive after 60 days were significantly older than the 
patients who survived (60.6 ± 14.5 years and 53.2 ± 13.8 
years respectively; p = 0.004). Monomicrobial infection 
occurred in 103 of 122 (84.4%) patients. Isolated pathogens 
and mortality rates are shown in Table 2. Almost all isolate 
were bacteria; the fungal infection (Candida albicans) was 
reported in one patient and Stenotrophomonas maltophilia 
was isolated in one patient (0.8%) in this study (Table 2). 
Early-onset VAP was diagnosed in 23 patients 
(18.9%) and median of onset was 4 (2–4) days of mechani-
cal ventilation. Late-onset VAP was diagnosed in 99 
(81.1%) patients and median of onset was 9 (5–27) days of 
MV. Mortality after 30 days (47.8% vs 39.4%; p = 0.46) 
and 60 days (47.8% vs 49.5%; p = 0.89) was not different 
in patients with early-onset and late-onset VAP, 
respectively. The pattern of isolates according to the type 
of VAP is shown in Table 3. 
Figure 1 demonstrates the proportion of drug 
susceptibility of each microorganism. 
Fig. 1 – Percentage of drug susceptibility patterns for each microorganism.  
MDR – multidrug resistant; XDR – extensively drug resistant; MRSA – methicillin-resistant Staphylococcus aureus. 
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Table 1 
Characteristics of ventilator-associoted pneumonia (VAP) patients at intensive care unit (ICU) admission 
Parameters  Value 
Number of patients (n) 122 
Age (year), mean ± SD 56.8  ± 14.6 
Gender, n (%) 
male 78 (63.9) 
Body mass index (kg/m2), n (%) 
underweight (< 18.5) 5 (4.5) 
normal weight (18.5–24.9) 44 (39.3) 
overweight (25–29.9) 35 (31.3) 
obese (> 30) 28 (25) 
Smoking habit, n (%) 61 (63,5) 
APACHE II score, mean ± SD 23.34 ± 7.03 
SAPS II score, mean ± SD 47.92 ± 13.87 
SOFA score, mean ± SD 8.39 ± 3.03 
Patient's location before ICU, n (%) 
emergency room  22 (18.0) 
ward in same hospital 55 (45.1) 
other hospital 45 (36.9) 
Duration of previous hospital stay if no direct ICU:  
admission (days), median (range) 2 (0–65) 
Comorbidities, n (%) 
hypertension 62 (50.8)
ischemic heart disease 16 (13.1) 
other cardiac diseases 51 (41.8) 
cerebrovascular diseases 4 (3.3) 
COPD 35 (28.7)
other chronic respiratory disease 22 (18) 
diabetes mellitus 30 (24.6) 
chronic renal disease 13 (10.7) 
chronic liver disease 8 (6.6) 
immunodeficiencya and cancer 17 (13.9) 
gastrointestinal diseases 25 (20.5) 
neurologic diseasesb 10 (8.2)
psychiatric diseases and addiction disorders 26 (21.3) 
other diseases 34 (27.9) 
Diagnosis at ICU admission, n (%) 
CAP 68 (55.7) 
HAP 15 (12.3) 
HCAP 9 (7.4) 
viral pneumonia 17 (13.9) 
exacerbation of COPD 13 (10.7) 
ARDS 53 (43.7)
pulmonary thromboembolism 4 (3.3) 
severe sepsis 118 (96.7) 
MODS 60 (49.2)
septic shock 44 (36.1) 
acute intoxication 4 (3.3) 
cardiorespiratory arrest  10 (8.2) 
H1N1 infection 19 (15.6) 
acute renal failure 16 (13.1) 
Charlson comorbidity index, median (range) 3 (0–11) 
Reason for MV, n (%) 
pneumonia 42 (34.4)
ARDS 48 (39.3)
COPD 8 (6.6) 
cardiorespiratory arrest 10 (8.2) 
pulmonary edema 3 (2.5) 
thromboembolism 3 (2.5)
intoxication 4 (3.3)
septic shock 5 (4.1) 
Prior antibiotic usec, n (%) 79 (69.3) 
cephalosporins 52 (45.6)
fluoroquinolones 24 (21.1)
macrolides 28 (24.6)
carbapenem (imipenem or meropenem) 10 (8.8) 
aminoglycosides 14 (12.3)
APACHE II – Acute Physiology and Chronic Health Evaluation II; SAPS II – Simplified 
Acute Physiology Score II; SOFA – Sequential Organ Failure Assessment; COPD – Chronic 
Obstructive Pulmonary Disease; CAP – community acquired pneumonia; HAP – hospital 
acquired pneumonia; HCAP – health care associated pneumonia; ARDS – acute respiratory 
distress syndrome; MV – mechanical ventilaton; MODS – multiple organ dysfunction 
syndrome, SD – standard deviation. 
aImmunodeficiency including acute rheumatoid arthritis, HIV+, Sjogren's syndrome and 
immunosuppressant; bOther commorbidities – fractures, thyroid gland diseases, 
osteoporosis and anemia; cAntibiotic treatment during the two weeks preceding ICU 
admission. 
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Table 2 
Pathogens of ventilator-associated pneumonia (VAP) patients and their susceptibility pattern compared between 
survivor and non-survivor groups after 30 and 60 days 
Mortality after 30 days Mortality after 60 days 
Organism types 
Number 
of patients 
(n = 122) 
non-survivors 
(n = 50) 
survivors 
(n = 72) p 
non-survivors 
(n = 60) 
survivor 
(n = 62) p 
Monomicrobial VAP, n (%) 103 (84.4) 42 (40.8) 61 (59.2) 0.91 52 (50.5) 51 (49.5) 0.50 
Gram-positive (MRSA) 5 (4.1) 3 (60.0) 2 (40.0) 0.40 4 (80.0) 1 (20.0) 0.20 
Gram-negative 98 (80.3) 39 (39.8) 59 (60.2) 0.59 48  (49.0) 50 (51.0) 0.93 
Acinetobacter spp 73 (59.8) 31 (42.5) 42 (57.5) 0.69 38 (52.1) 35 (47.9) 0.44 
Pseudomonas aeruginosa 14 (11.5) 4 (28.6) 10 (71.4) 0.32 5 (35.7) 9 (64.3) 0.28 
Klebsiella pneumoniae 10 (8.2) 3 (30) 7 (70) 0.46 4 (40) 6 (60) 0.54 
Polymicrobial VAP, n (%) 19 (15.6) 8 (42.1) 11 (57.9) 0.91 8 (42.1) 11 (57.9) 0.50 
Acinetobacter spp plus  
 Pseudomonas aeruginosa 8 (6.6) 3 (37.5) 5 (62.5) 1.00 3 (37.5) 5 (62.5) 0.72 
Acinetobacter spp plus  
 Klebsiella pneumoniae 5 (4.1) 3 (60.0) 2 (40.0) 0.40 3 (60.0) 2 (40.0) 0.68 
Acinetobacter spp plus  
  MRSA 3 (2.5) 1 (33.1) 2 (66.7) 1.00 1 (33.1) 2 (66.7) 1.00 
Klebsiella pneumoniae plus 
   Pseudomonas aeruginosa 2 (1.6) 0 (0) 2 (100) 0.51 0 (0) 2 (100) 0.50 
Susceptibility pattern 
susceptible 5 (4.1) 2 (40.0) 3 (60.0) 1.00 2 (40.0) 3 (60.0) 1.00 
MDR organisms 21 (17.2) 6 (28.6) 15 (71.4) 0.20 9 (42.9) 12 (57.1) 0.52 
XDR organisms 96 (78.7) 42 (43.8) 54 (56.2) 0.23 49 (51.0) 47 (49.0) 0.43 
MRSA – methicillin-resistant Staphylococcus aureus; MDR – multi-drug resistant pathogens; XDR – extensively drug-
resistant pathogenus. 
Table 3 
Bacterial species isolated from endotracheal aspirate (ETA) samples in ventilator-associated pneumonia (VAP) patients 
Bacterial species Total (n = 122) Early-onset VAP (n = 23) Late-onset VAP (n = 99) p 
Monomicrobial VAP, n (%) 103 (84.4) 18 (78.3) 85 (85.9) 0.37 
Gram-positive (MRSA), n (%) 5 (4.1) 1 (4.3) 4 (4.0) 0.95 
Gram-negative, n (%) 98 (80.3) 17 (73.9) 81 (81.8) 0.39 
Acinetobacter spp 73 (59.8) 13 (56.5) 60 (60.6) 0.72 
Pseudomonas aeruginosa 14 (11.5) 1 (4.3) 13 (13.1) 0.23 
Klebsiella pneumoniae 10 (8.2) 3 (13.0) 7 (7.1) 0.35 
Polymicrobial VAP, n (%) 19 (15.6) 5 (21.7) 14 (14.1) 0.37 
Acinetobacter spp plus  
 Pseudomonas aeruginosa 8 (6.6) 0 (0) 8 (8.1) 0.16 
Acinetobacter spp plus  
  Klebsiella pneumoniae 5 (4.1) 3 (13) 2 (2) 0.05 
Acinetobacter spp plus  MRSA 3 (2.5) 1 (4.3) 2 (2) 0.47 
Klebsiella pneumoniae plus  
 Pseudomonas aeruginosa 2 (1.6) 0 (0) 2 (2.0) 1.00 
MRSA – methicillin-resistant Staphylococcus aureus. 
The resistance of all Acinetobacter isolates was high to pipera-
cillin/tazobactam (99%), ciprofloxacin (97%), carbapenems 
(95% to imipenem and 96% to meropenem), ceftazidime 
(92%), cotrimoxazole (88%) and gentamicin (87%). Among 
the 4th generation of cefalosporins, the resistance was lower to 
cefepime (72%) and among aminoglycosides to netilmicin 
(67%). Acinetobacter spp was not tested for amikacin in 52 
(58%) cases, however, all isolates which were tested (38/90) 
were resistant to amikacin (42%). Thirty six percent of  Acine-
tobacter spp isolates were resistant to ampicillin-sulbactam. 
Monitoring of total resistance of isolates showed that there 
was no resistance to colistin, while resistance to tigecycline 
was 7%. Seventy three percent of  Pseudomonas aeruginosa 
isolates were resistant to gentamicin, 67% to ciprofloxacin, 
57% to meropenem, 55% to piperacillin, 42% to piperacil-
lin/tazobactam, 52% to ceftazidime, 41% to amikacin, 38% to 
cefepime and 35% to imipenem. The highest resistance of 
Klebsiella pneumoniae (K. pneumoniae) was observed against 
β-lactams (100% isolates were resistant to ampicillin and 94% 
to ampicilin/sulbactam); among 3rd and 4th generation cepha-
losporins 93% isolates were resistant to ceftriaxone, 89% to 
cefotaxime, 94% to ceftazidime and cefepime), and then aga-
inst ciprofloxacin (94%) and cotrimoxazole (93%). However, 
it was relatively less resistant to piperacillin-tazobactam 
(47%), gentamicin (44%) and amikacin (22%). Among carba-
penems, 38% isolates were resistant to ertapenem, 11% to 
imipenem and 11% to meropenem. In methicillin-resistant 
Staphylococcus aureus (MRSA) isolates no resistance was ob-
served against vancomycin, teicoplanin and linezolid. 
There were no differences in the incidence of infection 
with Acinetobacter spp, Pseudomonas aeruginosa and 
MRSA between period I (2009–2011) and period II (2012–
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2014), but there was a statistically significant increase in 
incidence of infection with K. pneumoniae from 8.9% in pe-
riod I to 25.6% in period II (p = 0.019). A significant increa-
se in resistance rates of Acinetobacter spp to ampicil-
lin/sulbactam in period II (2012–2014) was also found 
(30.2% vs 58.6%; p = 0.01). 
The resistance of Acinetobacter spp to other tested antibio-
tics did not change significantly between the two studied peri-
ods. The resistance of Pseudomonas aeruginosa to cefepime, 
piperacillin/tazobactam and amikacin increased between the two 
studied periods, without a statistically significant difference, but 
it increased significantly to imipenem (20% vs 71.4% 
respectively; p = 0.052). The resistance of K. pneumoniae incre-
ased, especially to carbapenems (ertapenem: 0% vs 54.5%; p = 
0.09), but due to the small sample statistical significance could 
not be detected. During the two studied periods there was no dif-
ference in incidence of infection with XDR (75.9% vs 83.7%; p 
= 0.317) and MDR strains (19% vs 14%; p = 0.482) in all isola-
ted bacteria. 
Discussion 
Multiresistant bacteria pose a great threat and challenge 
in everyday clinical practice. That is why regular monitoring 
of susceptibility of isolated bacteria to antibiotics in each 
ICU is essential. These data, as well as data regarding 
patient's characteristics on admission to ICU will help 
determine the most efficient empirical therapy for VAP. 
Empirical therapy based on data on local resistance has an 
impact on lowering morbidity and mortality, shortening of 
hospitalization, lowering of treatment expenses, and prevents 
the development of MDR bacteria in patients with VAP 13, 14. 
The overall incidence of VAP was 47.3 per 1,000 ventila-
tor-days. The incidence rate of VAP ranges from 13.2 to 51 per 
1,000 ventilator days 9. In a study performed in surgical and me-
dical ICUs in a tertiary hospital in China it was found that the 
incidence of VAP in the medical ICU was 29.7 cases per 1,000 
ventilator days 15. Differences in infection control practices and 
lack of established infection control programs may account for 
higher rates. 
VAP caused mortality varies (25%–50%) and greater 
mortality has been noticed in infections caused by Pseudo-
monas and Acinetobacter, in medical ICUs compared to sur-
gical ones, and with the administration of inadequate empiri-
cal antibiotic therapy 3. In our study, mortality in patients 
with VAP was 41.0% after 30 days, and 49.2 % after 60 
days. In a study by Song et al. 15 mortality in VAP patients in 
medical ICU was 41.9% after 30 days, and 53.5% after 60 
days. One of the significant characteristics of our patients on 
admission to ICU was a high incidence of ARDS (43.7%). A 
number of clinical studies have shown that pulmonary infec-
tion is very frequent in patients with ARDS (34–70%) and 
often leads to sepsis, multiorgan dysfunction and death 16. In 
a study by Forel et al. 17, mortality in patients with ARDS 
and VAP was 41.8%. 
According to American Thoracic Society, empirical an-
tibiotic therapy in VAP treatment should be based on VAP 
onset time (early-onset vs late-onset VAP) and on the presence 
of the risk factors for the development of MDR bacteria 3. In our 
study, most of the patients had late-onset VAP (81.1%) and the-
re was no difference among pathogens causing early-onset and 
late-onset VAP. These results were expected since most of our 
patients had a  number of risk factors which predispose to the 
colonization with MDR bacteria (69.3% of patients had received 
antibiotic treatment prior to admission, 82% was previously ho-
spitalized). Evidence suggests that resistance is a problem also 
in patients with early-onset VAP is growing. In a study conduc-
ted in Serbia in multidisciplinary ICU, no difference was shown 
among isolated bacteria in patients with early-onset and late-
onset VAP 18. It is interesting that prospective multicenter study 
in 27 ICUs in 9 European countries showed that even in patients 
who do not have classic risk factors for MDR bacteria, in 50.7% 
VAP was caused by multiresistant bacteria 5. These results spe-
ak in favor of the fact that microbiology does no longer follow 
model “early-onset vs late-onset VAP” what presents a new 
problem for empirical therapy 19. Our study also showed there 
was no difference in mortality in patients with early-onset and 
late-onset VAP after 30 days and 60 days suggesting that VAP 
onset time is not mortality predictor. Other researchers who 
compared mortality in patients with early-onset and late-onset 
pneumonia, came to the similar results 20–23.  
In our study, gram negative bacteria were the main pat-
hogens of VAP (80.3%) which is in correlation with the re-
sults from other recently published studies, especially from 
the developing countries. In a study by Chittawatanarat et 
al. 24 gram negative bacteria caused VAP in 94.7% of cases. 
During the past ten years, the significance of Acinetobacter 
spp has increased due to the rapid spreading of the strains re-
sistant to the most of the antibiotics, which was noticed thro-
ughout the world 25. One of the important features of Acino-
bacter baumannii (A. baumannii) is its ability to survive for 
a longer time period on the surfaces around patient from 
where is transmitted to patients in the direct or indirect way. 
In our study, Acinetobacter spp was the most frequent VAP 
pathogen (59.8%), and the most common XDR strain (89%). 
Studies in Asian countries have shown that A. baumanii was 
the most frequent pathogen in mixed medical-surgical ICUs 
where the incidence of infection was between 25% and 50% 
24, 26. In the neighboring countries, a high incidence of infec-
tion with MDR A. baumannii (85.6%) and XDR (14.4%) was 
also noticed 27. Having in mind risk factors for infections ca-
used by multiresistant Acinetobacter spp (ARDS, septic 
shock, severity of the disease, previous use of broad spec-
trum antibiotics, previous hospitalisation, duration of ICU 
stay and contamination of patient's surroundings) 28, 29, signi-
ficant presence of Acinetobacter spp in our ICU (frequency 
of ARDS – 43.7% and septic shock on admission – 36.1%, 
previous antibiotic therapy – 69.3%, previous hospitalisation 
– 82%) can be partially explained. Although carbapenems
are considered to be a basic therapy in the treatment of A. 
baumannii, during the last years reporting of strains resistant 
to carbapenems is increased throughout the world 30. In our 
study, Acinetobacter spp showed a high degree of resistance 
to carbapenems (more than 95%). According to the Annual 
Report of the European Antimicrobial Resistance Surveillan-
ce Network for 2014, resistance to carbapenems was from 
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0% (the Netherlands) to 93.2% (Greece) 31. Šuljagić et al. 32 in 
their study analyzed and compared the surveillance data on 
Acinetobacter spp nosocomial colonization/infection collected 
during the wartime with the data collected in peacetime in sur-
gical clinics of the Military Medical Academy in Belgrade 
(Serbia). Their data showed that resistance of Acinetobacter 
spp to imipenem was 0% during wartime (1999) and 18.6% 
during peacetime (2001), and to meropenem 4.6% and 27.1%, 
respectively. Having in mind these data, pronounced increase 
of Acinetobacter spp resistance to carbapenems in our region 
during the last 15 years is obvious. In the study by Šuljagić et 
al. 32 Acinetobacter spp resistance to ampicillin/sulbactam was 
30% what is similar to the results of our study. However, in 
our study the significant increase of resistance to ampicil-
lin/sulbactam was noticed between two study periods (30.2% 
vs 58.6%; p = 0.012). The increase of resistance was also mar-
ked in the neighboring countries. In Croatia, resistance of Aci-
netobacter spp to ampicillin/sulbactam increased from 13% 
(2009) to 19% (2012) 33. In our ICU resistance to colistin was 
not detected, although it was noticed during the last years in 
Europe (4%), and countries with the highest resistance to co-
listin were Greece and Italy 31. The assumed reason that resis-
tance to colistin was not detected in this study is that the colis-
tin was just approved in Serbia for hospital use in 2013, and in 
this paper data analyzed was ending with the year 2014. 
In our study the resistance of Pseudomonas aeruginosa 
to piperacillin/tazobactam, ciprofloxacin, ceftazidime and 
aminoglycosides was high in comparison with the latest data 
on resistance in other European countries. The highest resis-
tance of Pseudomonas aeruginosa was marked in Romania 
(62.2% to piperacillin/tazobactam, 55.4% to ciprofloxacin, 
59.1% to ceftazidime, 63.4% to aminoglycosides), and the 
lowest in Denmark, Iceland and Luxembourg (0%–4.4%) 31. 
Besides, the resistance of Pseudomonas aeruginosa to imipe-
nem was grown significantly between the two studied periods. 
The trend of resistance increase to carbapenems from 2011 to 
2014 was also noticed in Germany, Hungary and Slovakia 31. 
In our study significant increase in the incidence of 
infection with K. penumoniae as a pathogen of VAP 
between the two study periods was noticed (3.8% vs 16.3%; 
p = 0.02). This increase was due to the statistically 
significant increase of XDR strain of K. pneumoniae (3.8% 
vs 14.0%; p = 0.040). For the first time, XDR strain of K. 
pneumoniae (sensitive only to aminoglycosides and 
carbapenems) was noticed in December 2010. The resistance 
of  K. pneumoniae has also increased to imipenem, 
meropenem i ertapenem between the two studied periods 
(0% vs 18.2%; 18.2% vs 54.5%, respectively), but 
statistically significant difference could not be detected. The 
three European countries with the highest marked resistance 
to carbapenems in 2014 were Greece (62.3%), Italy (32.9%) 
and Romania (31.5%). In these countries the greatest percent 
of K. pneumoniae resistant to polymyxins was noticed, 
indicating that the situation is very worrying 31. 
All cases of MRSA caused VAP (5/122) were marked in 
2009 and all were sensitive to linezolid and vancomycin. Reports 
from other European countries also show a decrease of MRSA 
from 2011 to 2014 from 18.6% to 17.4%, respectively 31. 
Empirical treatment of VAP with the high probability of 
MDR pathogens is one of the greatest challenges met by the 
intensive care specialists. Having in mind the results of our 
study, adequate empirical therapy of VAP would be colistin 
(because of the high prevalence of XDR Acinetobacter spp) 
plus imipenem (because of Pseudomonas aeruginosa and K. 
pneumoniae) plus vancomycin (because of MRSA). But, due 
to the increased use of colistin PDR strains of Acinetobacter 
spp can develop, and that is why its use must be rational 29. 
After the short duration of broad spectrum antibiotic therapy 
and after the antibiogram is obtained, quick deescalation of 
antibiotic therapy should follow 34. 
The significance of this study is in a long monitoring 
period and therefore obtaining insight in resistance changes 
of VAP pathogens during the time. Besides, this is the first 
analysis of VAP pathogens in our ICU.  
There are several limitations of this study. The first one 
is that the bacterial isolates from the VAP cases may not re-
flect the true etiologic pathogens because more specific dia-
gnostic procedures, such as bronchoalveolar lavage, were not 
performed. The second limitation is that it was performed in 
one ICU of the tertiary health facility specialized in treating 
pulmonary patients. Therefore, the microbiological profile of 
the isolated strains of VAP pathogens reflects the local epi-
demiologic situation and it can not be extrapolated to other 
centres. That is why multicentric research that would help 
forming general recommendation is necessary. Also, it is 
necessary to continue regular monitoring of microbiological 
profile and susceptibility of the pathogens in our ICU in or-
der to timely detect changes, especially today when PDR 
strains are marked in southeast Europe. 
Conclusion 
According to results obtained in this study, gram nega-
tive bacteria were the main pathogens of ventilator associa-
ted pneumonia, out of which the most common was XDR 
strain of Acinetobacter spp with a high resistance to all tested 
antibiotics except for colistin and tigecycline. There was no 
difference in pathogens in patients with early-onset and late-
onset ventilator associated pneumonia.  Mortality in patients 
with VAP was 41.0% after 30 days and 49.2 % after 60 days 
of hospitalization, and there was no difference in mortality 
between patients with early-onset and late-onset VAP. 
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Abstract 
 
Background/Aim. Energy homeostasis is a balance 
between energy intake and energy expenditure. Leptin and 
ghrelin are two orexitropic hormones with opposite effect 
on energy homeostasis. We investigated fasting ghrelin and 
leptin serum levels in children with different nutritional 
conditions. Methods. In 30 obese children of both sexes, 
aged from 6 to 17.67 years (mean 13.04 ± 2.95 years), fas-
ting ghrelin and leptin levels were determined in the serum, 
along with auxological assessment and pubertal staging. Ob-
tained values were analyzed and compared with those of the 
same parameters in 33 lean and 25 undernourished (UN) 
children. Results. Mean ghrelin/body mass (BM) ratio was 
the lowest in obese children (21.75 ± 12.60 pg/mL/kg), 
which was significantly different in comparison with that in 
lean and UN subjects. Mean leptin/BM ratio of 0.62 ± 0.86 
pg/mL/kg in obese children was significantly higher than 
that in lean and UN children (p < 0.01 and p < 0.001, 
respectively). Ghrelin and leptin levels showed different 
profiles in obese, lean and UN children. An inverse relation-
ship was discovered among study groups in  ghrelin/leptin 
and leptin/ghrelin ratios. Conclusion. Obese children, 
compared to other children, have significantly higher values 
of leptin, and UN children have significantly higher values 
of ghrelin per kilogram of body mass. The results also illus-
trate the inverse ratio of ghrelin and leptin, which has been 
demonstrated as a clinically reliable marker of the status of 
obesity or undernutrition in children, with significant impli-
cations concerning rather large variations in the concentra-
tion of these hormones in relation not only to the body 
mass but also to the children’s age.  
 
Key words: 
nutritional status; child; leptin; ghrelin; obesity. 
Apstrakt 
 
Uvod/Cilj. Homeostaza energije je balans između ener-
getskog unosa i potrošnje energije. Leptin i grelin su dva 
oreksitropna hormona sa suprotnim efektom na homeo-
stazu energije. Ispitivane su vrednosti leptina i grelina u se-
rumu dece različititog tipa uhranjenosti. Metode. Kod 30 
gojazne dece oba pola, uzrasta od 6 do 17,67 godina 
(srednja vrednost 13,04 ± 2,95 godine), određivane su 
vrednosti leptina i grelina u serumu, uz određivanje aukso-
loških parametara i pubertetskog statusa. Dobijeni rezultati 
su analizirani i upoređivani sa vrednostima istih pa-
rametara kod 33 normalno uhranjene i 25 mršave dece. 
Rezultati. Vrednosti odnosa grelin/telesna masa (TM) 
bile su najniže kod gojazne dece (21,75 ± 12,60 
pg/mL/kg) što je statistički značajno različito u odnosu na 
vrednosti kod mršave i normalno ishranjene dece. Vred-
nost odnosa leptin/TM bila je statistički značajno veća 
kod gojazne dece (0.62 ± 0.86) u odnosu na normalno uh-
ranjene  (p < 0,01) i mršave (p < 0,001). Vrednosti leptina i 
grelina pokazale su različit profil kod gojazne, normalno 
uhranjene i mršave dece. U ispitivanim grupama dokazane 
su inverzne vrednosti odnosa grelin/leptin i leptin/grelin. 
Zaključak. Gojazna deca imaju značajno više vrednosti 
leptina, a mršava deca značajno više vrednosti grelina po 
kilogramu telesne mase u odnosu na ostalu decu. Rezultati 
ukazuju i na inverzni odnos grelina i leptina koji se poka-
zao kao klinički pouzdan pokazatelj prisustva gojaznosti ili 
neuhranjenosti kod dece, što je od velikog značaja, uzima-
jući u obzir velike varijacije u koncentraciji ovih hormona, 
ne samo prema telesnoj masi, već i prema uzrastu dece.  
 
 
Ključne reči: 
uhranjenost; deca; leptin; grelin; gojaznost. 
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Introduction  
The ghrelin-ghrelin receptor system is one of the most im-
portant mechanisms regulating energy balance and metabolism. 
Ghrelin, a 28-amino acid peptide, is mainly produced in the 
stomach from a distinct group of endocrine cells. It is discovered 
as potent growth hormone secretagogue and appetite stimulator 
by Kojima et al. 1 in 1999. Identified as a natural ligand for 
growth hormone secretagogue receptor (GHsR)  the small pep-
tide provoked a burst of new enthusiasm among scientists and 
clinicians. Many types of research were hunting for this hormo-
ne for years, but Kojima et al. 1 made great discovery  by 
switching  the search from the brain to the stomach 1–3. 
Ghrelin quickly demonstrated its  pleiotropic nature. Op-
posite to leptin, it stimulates food intake and rises body mass 
index (BMI) in rodents and humans. In fact, this hormone is one 
of the most important factors known for regulating appetite and 
energy expenditure. Ghrelin is also known as “starvation hor-
mone”, potent orexigenic signal acting via neuropeptide Y 
(NPY)/Agouti Related Peptide (AGRP)  and orexin neurons 
stimulation in nucleus arcuatus. Both peripheral and central 
administration of ghrelin potently promotes body weight gain 
and adiposity through the stimulation of food intake while dec-
reasing energy expenditure and body fat 4–8. 
Ghrelin which operates as a signal of energy 
insufficiency and functional antagonist of leptin may play a 
physiological, and eventual pathophysiological role in the 
regulation of puberty onset and gonadal function 9–11. 
Besides a role in energy homeostasis, growth and puberty,  
the influence of ghrelin on sepsis, atherogenesis, apoptosis, an-
giogenesis and addictional habits is among its most prominent  
effects with the potential of clinical application 8–12. 
Since the discovery of leptin in 1994, it has been assu-
med that adipose tissue is not just fat storage organ, but plays a 
role in many physiological and pathological processes, inclu-
ding appetite regulation, glucose homeostasis, immune res-
ponse, growth and differentiation, angiogenesis, hypertension, 
atherosclerosis and cancer. Finding that leptin signals to the 
brain that the stomach is full with consequent suppression of 
NPY production, a stimulator of food intake was among the 
first actions discovered in rats and confirmed in humans 13–18. 
It controls the start of puberty 19, stimulates sympathetic ner-
vous system activity and energy expenditure and influences 
thyroid, growth, and sex hormone axes 20, 21. 
Taking into account the influence of both hormones on 
appetite regulation and energy expenditure, we found that it 
would be of  importance to determine  and compare levels of  
ghrelin and leptin in children and adolescents with different 
nutritional status. Also, it was intriguing to investigate ghre-
lin/leptin and leptin/ghrelin ratios in these groups and to 
explore correlations of two hormones with auxological data 
in children with different nutritional conditions.  
Methods 
The study was designed as cross-sectional and conduc-
ted in Pediatric Clinic of University Clinical Centre Niš, in 
the south-east region of Serbia. 
Examinees 
Our sample included  88 children and adolescents  aged  
6 to 17.67 years, stratified as obese (30 subjects, 11 females), 
undernourished – UN (25 subjects, 19 females) and lean (33 
subjects, 24 females). Candidates for the study were selected  
from patients who were referred to the endocrinology 
examination due to obesity or consulted endocrinologist be-
cause of difficulties in gaining weight. Healthy and normal 
weight children, assigned as lean, with ideal weight for he-
ight, 33 of them, acted as controls. All these children 
underwent a complete physical examination by a pediatric 
endocrinologist in order to rule out organic disease or ab-
normalities in growth and development. 
In all participants height and weight measurements 
were performed and calculation of height percentile (P), he-
ight standard deviation score  (Height SDS) for chronologi-
cal age  (CA) and gender, body mass index (BMI kg/m²), 
percentiles of BMI and SDS of BMI for CA and gender, 
were established. Obesity was defined as BMI greater than 
P95 (+3SD) for their CA and gender. Undernutrition was de-
fined as BMI-P < 3 (-2SD) for CA.  
The informed consent was obtained from all partici-
pants and their legal representatives. The study was approved 
by the Ethical Committee of the Faculty of Medicine, 
University of Niš.   
Hormone assays 
Total ghrelin levels in the serum were measured using a 
commercial  Human Ghrelin Elisa Kit Cusabio Biotech 
Co.,LTD. The assay sensitivity was 0.156 pg/mL, and the in-
tra-assay coefficient of variation (CV) was < 8% and the in-
ter-assay CV <  10%. 
Serum leptin was measured using Quantikine Elisa 
Human Leptin Immunoassay USA&Canada. The assay 
sensitivity was 7.8 pg/ml with intra-assay CV of 3.3% and 
inter-assay CV of  5.4%. 
Children fasted for at least 8 hours before specimen col-
lection. 
Statistical analysis 
All statistical analyses were performed using SPSS ver-
sion 12 software. The data are presented as mean ± SD and 
comparisons among groups were conducted by independent 
t-test, or Mann-Whitney test, depending on normality of va-
riable distribution. The distributions of the continuous varia-
bles were assessed for normality by Shapiro-Wilk test. Pear-
son’s correlation coefficients and Spearman's rho were calcu-
lated to evaluate the relationships between hormones values 
and auxological data p < 0.05 was considered to be 
statistically significant. 
Results 
The mean age of the obese group was 13.04 ± 2.95 
(range 6–17.67) years and the mean puberty stage was 3.37. 
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 Table 1 
Auxological data of investigated children  
Parameters Obese UN Control 
Number 30 25 33 
Sex (M/F) 19/11bc** 6/19 9/24 
Age (years), mean  SD 13.04  2.95 12.08  3.70 13.23  3.01 
range 6.00 – 17.67 6.33 – 17.58 8.00 – 17.67 
Height (cm), mean  SD 160.66  15.78 b** 144.16  21.64 157.56  13.92 b* 
range 124.50 – 185.00 108.00 – 191.00 126.00 – 184.00 
 Height Percentile, mean  SD 78.30  22.22 b*** 38.99  33.23 66.98  31.42 b** 
range 4.60 – 99.90 0.70 – 99.90 0.80 – 99.90 
Height SDS, mean  SD 1.17  1.35 b*** -0.35  1.54 0.62  1.23b** 
range -1.70 – 6.50 -2.50 – 3.90 -1.28 – 3.00 
BM (kg), mean  SD 82.55  21.72 cb*** 31.69  11.56 50.95  16.43 b*** 
range 43.00 – 128.50 16.00 – 57.00 25.00 – 75.00 
BME (kg), mean  SD 27.45  11.33 bc*** -11.71  4.06 6.77  9.61 b*** 
range 10.00 – 52.00 -2.00 – 18.00 -3.70 – 11.10 
BMI (kg/m2), mean  SD 31.51  4.78 cb*** 14.65  1.39 19.81  3.37 b*** 
range 23.95 – 43.95 12.36 – 17.31 16.83 – 22.65 
  BMI z-score, mean  SD 3.11  0.18 cb*** -2.93  0.49 0.9  0.70 b*** 
range 3.00 – 4.70 -3.20 – 1.90 0.67 – 1.80 
Puberty stage, mean  SD 3.37  1.35 2.88   1.64 3.42  1.46 
range 1.00 – 5.00 1.00 – 5.00 1.00 – 5.00 
SDS – standard deviation score; BM – body mass; BME – body mass excess; M – male;  
F – female; BMI – body mass index; BMI z-score – standard deviation of relative weight ad-
justed for child age and sex. UN  Undernourished group; a  vs Obese group; b  vs UN 
group; c  vs Control group; * p < 0.05, ** p < 0.01, *** p < 0.001. 
 
Table 2 
 Orexitropic signaling proteins in investigated children  
Parameters Obese UN Control 
Leptin (pg/mL), mean  SD 56.12  96.94 c**b*** 6.92  8.10 20.96  12.74 b*** 
range 10.74 – 452.40 1.07 – 40.06 1.46 – 50.40 
Leptin/BM (pg/mL/kg), mean  SD 0.62  0.86 b*** 0.21  0.17 0.37  0.23 b** 
range 0.15 – 3.93 0.04 – 0.80 0.02 – 0.90 
Ghrelin (pg/mL), mean  SD 1,624.93  674.10 2,055.84  579.37*a 2,001.88  598.75*a 
range 196.00 – 3195.00 838.00 – 3073.00 342.00 – 3124.00 
Ghrelin/BM (pg/mL/kg), mean  SD 21.75  12.60 72.25  32.82 ac*** 38.68  19.98 a*** 
range 1.74 – 67.98 37.36 – 180.59 5.23 – 96.21 
Leptin/ghrelin ratio, mean  SD 0.0582  0.1536bc*** 0.0034  0.0033 0.0116  0.0079b*** 
0.0008 – 0.0342 range 0.0042 – 0.8472 0.0004 – 0.0141 
Ghrelin/leptin ratio, mean  SD 59.69  44.74 570.15  507.42 ac*** 194.36  262.90a*** 
range 1.18 – 238.43 70.74 – 2526.17 29.28 – 1297.95 
Obese children had lipomastia, genua valga, and boys (with 
only two exceptions) pseudo-hypogenitalism. 
 The mean BMI was very high in obese children being 
31.51 ± 4.78 kg/m², ranging from 23.95 kg/m² to 43.95 
kg/m². The mean height percentile was P78.30 (1.17 ± 1.35 
height SDS) and documented  optimal growth in obese chil-
dren. Mean height SDS of obese children was significantly 
higher than that of UN children. Children in the control gro-
up were also significantly taller than UN children. 
Overweight (body mass excess – BME),  reached abnormal 
values: mean overweight being 27.45 (ranging from 10 to 
52) kg (Table 1). 
When absolute values of ghrelin levels in studied groups 
were compared we found statistical significance (p < 0.05). UN 
children (2,055.84 ± 579.37 pg/mL) and lean children (2,001.88 
± 598.75 pg/mL) had higher ghrelin levels than obese ones 
(1624.674.10 pg/mL). After adjusting ghrelin levels by calcula-
tion of ghrelin/kg BM the value of 72.25 pg/ mL/kg was 
significantly higher in the UN group in comparison with the 
control and the obese children (p < 0.001). Mean ghrelin/BM ra-
tio was the lowest in the obese children, 21.75 (1.74–67.98) 
pg/mL/kg with high significance in comparison with the lean 
and UN subjects (Table 2). 
The highest values of leptin were observed in the obese 
children (56.12 ± 96.94 pg/mL), which was statistically 
significantly higher compared to those in the controls (p < 
0.01) and the UN children (p < 0.001). The values of leptin 
in normally nourished children (20.96 ± 12.74 pg/mL) were 
statistically significantly higher (p < 0.001) than those in the 
UN children (6.92 ± 8.10 pg/mL). 
BM – body mass; SD – standard deviation. UN  undernourished group; a  vs Obese group; b  vs UN 
group; c  vs Control group. * p < 0.05, ** p < 0.01, *** p < 0.001. 
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a) 
 
b) 
Fig. 1 – a) Leptin/BM and b) Ghrelin/BM ratios in children with different nutritional status. 
BM – body mass; UN – undernourished group. 
 
 
a) 
 
b) 
Leptin/BM ratio was highest in the group of obese chil-
dren (0.62 ± 0.86 pg/mL/kg) – statistically significantly hig-
her compared to that in the UN children (p < 0.001). Furt-
hermore, the value of this ratio was statistically significantly 
higher in the group of normally nourished children compared 
to the UN children (p < 0.01) (Table 2). 
Leptin/ghrelin ratio was highest in the group of obese 
children (0.0582 ± 0.1536), with a statistical significance 
compared to that in the UN children (p < 0.001) and the con-
trols (p < 0.001). The value of leptin/ghrelin ratio was 
statistically significantly higher in the controls, compared to 
that in the UN children (p < 0.001). Ghrelin/leptin ratio was 
highest in the group of lean children (570.15 ± 507.42 
pg/mL/kg), with a statistically significant difference when 
compared with the controls (p < 0.001) and the obese chil-
dren (p < 0.001). The value of ghrelin/leptin ratio in the gro-
up of controls (194.36 ± 262.90 pg/mL/kg) was statistically 
significantly higher than that in the obese children (p < 
0.001) (Table 2). 
Leptin and ghrelin levels calculated per kilogram of 
BM showed different profiles in obese, lean and UN children 
(Figures 1a and 1b). An inverse relationship in leptin/ghrelin 
was found in the obese and UN children ghrelin/leptin ratios 
(Figures 2a and 2b).  
Leptin levels significantly positively correlated with BM, 
BMI and high SDS (p < 0.001) (Figure 3), while ghrelin levels 
correlated  significantly negatively with BM and BMI (p < 
0.01), and nonsignificantly with high SDS (Figure 4). 
Fig. 2 – a) Leptin/ghrelin and b) Ghrelin/leptin ratios in children with different nutritional status. 
UN – undernourished group. 
 
Fig. 3 – Leptin correlations with BM, BMI and SDS in children with different nutritional status. 
BM – body mass; BMI – body mass index; SDS – standard deviation score. 
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Fig. 4 – Ghrelin correlations with BM, BMI and SDS in children with different nutritional status. 
BM – body mass; BMI – body mass index; SDS – standard deviation score; n.s. – non significant. 
 
Discussion 
We intended to compare serum ghrelin and leptin levels 
in children with different nutritional status. These two hor-
mones were chosen as potent appetite influencers in the op-
posite way. It was not surprising that we found the 
statistically significant difference among studied groups. In 
our study, the values of ghrelin were highest in the group of 
UN children. In the controls and in the UN children the valu-
es of ghrelin were statistically significantly higher compared 
to the group of obese children. The value of ghrelin/BM ratio 
was highest in the group of UN children, with a statistically 
significant difference compared to those of the obese chil-
dren and controls, since ghrelin values were highest in the 
group of UN children with, at the same time, lowest BM, 
which suggested that in addition to the hunger/satiety status, 
the concentration of this hormone was also affected by BM, 
in agreement with the above-mentioned studies. The value of 
this ratio in the control group was statistically significantly 
higher compared to that in the obese children. 
Mean ghrelin/BM level was more than tripled in the UN 
children in comparison with the same parameter in the obese 
ones. Modulatory effect of both forms of ghrelin, acylated and 
nonacylated on adipogenesis is well documented. It has been 
shown  that both forms of ghrelin directly promote adipogenesis 
in rat bone marrow adipocytes 22, 23. Although the orexigenic ac-
tion of ghrelin itself predicts the impact on weight gain, ghrelin 
has also been shown to be able to directly act at the level of en-
docrine pancreas, liver and adipose tissue, thus modulating glu-
cose and lipid metabolism 4, 5, 7. In humans, ghrelin concentrati-
ons progressively decrease during childhood and adolescence, as 
well as with advancing puberty. In adolescents, similar to adults, 
ghrelin concentrations are inversely related to BMI and to circu-
lating insulin 24. One notable exception is the presence of eleva-
ted ghrelin concentrations in subjects with Prader-Willi 
syndrome, raising the possibility that ghrelin could be part of the 
etiology of excess food intake in this condition. The present 
study also shows that levels of  ghrelin inversely correlated with 
BM and BMI.  
In children with obesity, the decreased ghrelin and inc-
reased leptin levels suggest a possible adaptive process to 
positive energy balance. However, studies of ghrelin in chil-
dren are scarce. Recently published study of Wali et al. 25 on 
ghrelin and obestatin level in obese children and children 
with failure to thrive showed significantly lower total ghrelin 
levels in children with obesity. In another study Shen et al. 26 
investigated changes in ghrelin and obestatin levels before 
and after a meal in children with simple obesity (15 children) 
and anorexia (25 children). Their results confirmed the nega-
tive correlation between BMI and ghrelin,  while the 
anorexia group had the highest values of obestatin and ghre-
lin. Recently Arrigo et al. 27 found that weight loss in prepu-
bertal children was associated with a significant change in 
leptin, ghrelin and obestatin concentrations. They concluded  
that levels of these hormones are closely associated with 
obesity in childhood and might take part, as consequence but 
not as a cause, of weight changes. 
Although well known as GHs (growth hormone secre-
tagogue), ghrelin level was low in our group of obese chil-
dren exerting optimal growth. We can conclude indirectly 
that our obese children growth because of insulin and/or via 
leptin stimulated conversion of T4 to T3 what is already do-
cumented in obese children 28, 29. 
Plasma leptin concentrations correlate with the amount 
of energy stored as fat, and obese individuals express higher 
levels of leptin than lean individuals 14, 17. Our study confir-
med this positive correlation between leptin concentrations 
and BM and BMI. Also, our results demonstrated that leptin 
values were highest in the group of obese examinees, compa-
red to the UN children and the controls. Moreover, lep-
tin/BM ratio was lowest in the UN children in whom indivi-
dual values of leptin and BM were lowest, while it was hig-
hest in the group of obese children, in whom individual valu-
es of leptin and BM were highest. Leptin/BM ratio was 
statistically significantly higher in the obese and control 
children, compared to the UN ones. This suggested a direct 
dependence of leptin values on BM, as shown by previously 
mentioned studies as well. 
The height of investigated obese children was optimal 
(mean percentile being P78.30). High caloric and protein in-
take in overfed children provide full energy stores, high lep-
tin values, and stimulation of growth hormone secretion and 
T4 to T3 conversion. This could explain the excellent growth 
in our study group. In addition, leptin per se stimulates T4 to 
T3 conversion and leptin receptors are identified in the 
thyroid gland 30. Leptin, GH, insulin and thyroid hormones, 
acting synergistically, may be responsible for stimulation of 
growth in children with exogenous obesity 14, 17, 31. 
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The study was limited by small sample sizes and wide 
age range of investigated children. We avoided further divi-
ding of study groups according to pubertal development, due 
to relatively small number of pubertal participants. The 
majority of studied children were in mid-puberty. We also 
recognize that boys dominated in the obese group and girls in 
the UN one, but the data about gender difference in 
orexitropic signals are still biased 28, 29. 
Suppressed levels of ghrelin in our group of obese chil-
dren and more than tripled in the UN children are in favor of 
the significant influence of this hormone on adaptation in 
conditions of overfeeding and starvation. Leptin levels were 
inversely regulated among study groups when compared to 
ghrelin. It is important to establish a healthy balance between 
these two hormones. In this interplay, genetic and environ-
mental influencers are certainly of great importance, but this 
must be further investigated.  
Leptin/ghrelin ratio was highest in the group of obese 
children, with statistical significance compared to the UN 
children and the controls. The value of leptin/ghrelin ratio 
was statistically significantly higher in the control group 
compared to that in the UN children. Leptin values were hig-
hest in the group of obese children, with the simultaneous 
presence of lowest ghrelin values, which could be possibly 
interpreted as the process of adaptation to a positive energy 
balance. Children with higher BMI had more adipose tissue, 
i.e. more leptin per kg of BM, as shown in the study. At the 
same time, leptin/ghrelin ratio was able to identify distinctly 
the obese children, and it can thus be used as an indicator of 
the status of obesity, supplementing BM and BMI. 
Ghrelin/leptin ratio was highest in the group of UN 
children, with a statistically significant difference compared 
to that in the control group and the obese children. The value 
of ghrelin/leptin in the controls was statistically significantly 
higher than that in the obese children. The values of ghrelin 
were highest in the group of UN children, with simultaneous 
lowest leptin values; this association demonstrated that there 
was a mechanism of adaptation in the UN children to a nega-
tive energy balance. Ghrelin/leptin ratio clearly identified the 
UN children, and this relationship could be used as a sup-
plemental indicant of undernutrition, in addition to the 
already known indicants (BM, BMI). 
Such data are scarce for the children aged up to 12 
years 27, 32, as those enrolled in this study. Moreover, there 
have been no studies involving all three groups of children 
(UN, normal weight and obese). This shows that in children 
of different ages a characteristic profile of secretion of these 
hormones is kept, as well as its association with BM, BMI 
SDS, and BMI-P. 
Conclusion 
The obese children, compared to other children, demon-
strate significantly higher values of leptin, and the UN chil-
dren demonstrate significantly higher values of ghrelin per 
kilogram of body weight. The results also illustrate the inver-
se ratio of ghrelin and leptin, which has been demonstrated 
as a clinically reliable indicator of the status of obesity or 
undernutrition in children, with significant implications con-
cerning rather large variations in the concentration of these 
hormones not only with body mass but also with children 
age. The results provide a better understanding of hormonal 
regulation in different nutritional conditions. The important 
difference in appetite targeting hormones and their ratios 
(ghrelin/leptin and leptin/ghrelin profile) between the obese 
and the UN children was found. 
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Abstract 
 
Background/Aim. C-reactive protein (CRP) is a systemic 
inflammatory marker associated with risk for cardiovascular 
disease (CVD). Some risk factors for CVD are associated 
with normal tension glaucoma (NTG), but the association 
between CRP and NTG has not been well defined yet. The 
aim of our study was to compare high-sensitivity CRP (hs-
CRP) levels in plasma between patients with NTG and 
normal controls. Methods. We studied 20 patients (4 males 
and 16 females) with the NTG diagnosis and compared 
their CRP values to those obtained in 25 controls (5 males 
and 20 females) with no ocular disease. Both groups had 
similar demographic parameters (age, sex, body mass index 
– BMI) and similar vascular risk profile. Results. Plasma 
CRP levels were comparable between patients with NTG 
and controls (mean values 4.99 ± 0.77 mg/L, median 4.50 
mg/L, range 2.50–18.90 mg/L and mean value 4.19 ± 0.30 
mg/L, median 3.50 mg/L range 2.20–8.50 mg/L, respec-
tively, p > 0.5. Conclusion. The results obtained in this 
study suggest that CRP levels are not altered in NTG pa-
tients. 
 
Key words:  
low tension glaucoma; c-reactive protein; 
atherosclerosis. 
Apstrakt 
 
Uvod/Cilj. C-reaktivni protein (CRP) je sistemski inflamatorni 
marker koji je povezan sa rizikom od nastanka 
kardiovaskularnih bolesti (KVB). Određeni faktori rizika od 
KVB su ujedno i faktori rizika od razvoja normotenzivnog 
glaukoma (NTG), ali povezanost između CRP I NTG još uvek 
nije jasno definisana. Cilj ove studije bio je da se ispita 
povezanost između vrednosti visokosenzitivnog CRP u plazmi 
kod bolesnika sa NTG i u kontrolnoj grupi. Metode. Ispitano 
je ukupno 20 bolesnika sa NTG (4 muškaraca i 16 žena) i 25 
osoba iz kontrolne grupe (5 muškaraca i 20 žena). Obe grupe 
ispitanika imale su približno iste demografske karakteristike 
(godine, pol i indeks telesne mase) i kod obe grupe bili su 
prisutni vaskularni faktori rizika u istom procentu. Rezultati. 
Vrednosti CRP u plazmi bolesnika sa NTG i u kontrolnoj 
grupi bile su poredive: srednja vrednost iznosila je 4.99 ± 0.77 
mg/L, mediana 4.50 mg/L, opseg 2.50–18.90 mg/L kod 
bolesnika sa NTG, dok su te vrednosti u kontrolnoj grupi bile: 
4.19 ± 0.30 mg/L, 3.50 mg/L, odnosno 2.20–8.50. Zaključak. 
Rezultati dobijeni u ovoj studiji pokazuju da vrednosti CRP 
nisu povećene kod bolesnika sa NTG. 
 
Ključne reči: 
glaukom, normotenzivni; c-reaktivni protein; 
ateroskleroza. 
 
Introduction 
Glaucoma is a group of diseases characterized by pro-
gressive optic neuropathy and loss of retinal nerve fiber layer 
with corresponding visual field defects. Elevated intraocular 
pressure (IOP) has been identified as the most important risk 
factor, but not the only one 1. 
Normal tension glaucoma (NTG) is a special type of 
primary open angle glaucoma characterized by intraocular 
pressure levels in normal statistical range, but resulting in a 
progressive optic neuropathy 2, 3 . This type of glaucoma is 
associated with vascular risk factors such as vascular 
dysregulation with systemic hypotension and vasospasm 4, 5. 
In the optic nerve head (ONH) in these patients, disk hemo-
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Table 1 
Characteristics of normal tension glaucoma (NTG) cases and controls 
Characteristics NTG cases (n = 20) Control group (n = 25) 
Age (years), mean ± SD 64 ± 8.9 62.8 ± 5.9 
Male/Female, n 4/16 5/20 
BMI (kg/m2), mean ± SD 25.9 ± 4.9 26.1 ± 3.4 
Hypotension, n (%) 3 (15) 4 (16) 
Hypertension, n (%)  10 (50) 12 (48) 
Migraine, n (%) 2 (10) 2 (8) 
Vasospastic diathesis, n (%) 2 (10) 2 (8) 
Coronary artery disease, n (%) 2 (10) 3 (12) 
Diabetes mellitus, n (%) 2 (10) 2 (8) 
CRP (mg/L), median (range)  4.50 (2.50–18.90) 3.50 (2.20–8.50) 
CRP (mg/L), mean ± SEM 4.99 ± 0.77 4.19 ± 0.30 
rrhages, notching of the neuroretinal rim and peripapillary 
atrophy are often encountered 6. Patients with NTG have an 
increased endothelin-1 plasma level 7, 8. 
C-reactive protein (CRP), an important serum marker of 
inflammation, the levels of which increase in response to 
acute inflammatory processes, is synthesized in the liver and 
regulated by cytokines 9. CRP has recently been proposed as 
a marker of chronic inflammatory processes such as atheros-
clerosis 10. Epidemiological studies show that an elevated 
CRP level is a strong predictor of cardiovascular risk 11. 
Some risk factors for cardiovascular disease are asso-
ciated with NTG, but the association between CRP and NTG 
has not been well defined yet. While some studies found ele-
vated levels of CRP in patients with NTG 12, 13, other studies 
suggest that CRP levels are not altered in NTG patients 14–17. 
The purpose of this study was to investigate CRP levels by 
using a highly sensitive CRP kit in NTG patients and to 
compare them to normal controls. 
Methods 
This study included 20 consecutive NTG patients who 
presented in our glaucoma consultations. The diagnosis of 
NTG was based on a clinical examination, including intrao-
cular pressure measurements at 2-hour intervals from 8 am to 
6 pm with the values consistently below 22 mmH, open 
chamber angle, optic nerve head damage typical of glaucoma 
and glaucomatous visual field defects. There was no history 
or signs of other eye disease or steroid use. Control subjects 
also underwent clinical eye examination including measure-
ments of intraocular pressure at two hour intervals from 8 am 
to 6 pm, fundoscopic and optic nerve head examination and 
OCTOPUS visual field analysis, program full threshold (Oc-
topus 900, Haag Streit AG, Koeniz, Switzerland). Based on 
the value of the mean defect (MD), all visual fields were di-
vided into three groups. The first group consisted of patients 
with initial changes in the visual field (MD ≤ 6 dB). The se-
cond group consisted of patients with moderate changes in 
the visual field (6 dB < MD < 12 dB), while the third group 
consisted of patients with advanced changes in the visual fi-
eld (MD ≥ 12 dB). 
In both NTG and control groups, the detailed medical 
history was obtained. The patients and control subjects with 
the known systemic inflammatory disease, malignancy 
and/or steroid use were excluded from the study. 
Hypertension, hypotension, migraine, ischemic heart disease, 
vasospastic diathesis (positive history of cold hand and feet), 
cerebrovascular disease and diabetes mellitus were identified 
from the medical charts and history taking in each patient 
and subject. The control group consisted of the subjects of 
similar gender and age, with no ocular disease. 
The quantitative determination of plasma CRP levels in 
all study participants was done using a highly sensitive CRP 
kit (Abbot AEROSET, Illinois, USA). 
The study was approved by the relevant ethics commit-
tee and all the participants gave written informed consent ac-
cording to the Declaration of Helsinki. 
The results were analyzed by t-test, χ2 test, ANOVA 
and Mann-Whitney U test. A value of p < 0.05 was conside-
red significant. 
Results 
A total of 20 NTG cases (4 males, 16 females, mean 
age 65 ± 9 years) were compared with 25 controls (5 males, 
20 females, mean age 63 ± 6 years) (Table 1). Both groups 
had similar demographic parameters (age, sex, BMI; all p-
values > 0.05). Systemic vascular disorders identified from 
charts and medical history in the NTG patients were: 3 
(15%) patients had hypotension, 10 (50%) had hypertension, 
2 (10%) had a migraine, 2 (10%) had positive history of cold 
hands and feet, 2 (10%) had an ischemic heart disease and 2 
(10%) had diabetes mellitus. Systemic vascular disorders that 
were identified in the control group were: 4 (16%) patients 
had hypotension, 12 (48%) had hypertension, 2 (8%) had a 
migraine, 2 (8%) had positive history of cold hands and feet, 
3 (12%) had an ischemic heart disease and 2 (8%) had diabe-
tes mellitus. No patient from both groups had the history of 
cerebrovascular disease. 
Plasma CRP levels were comparable in NTG patients 
and controls [median (range) 4.50 2.5–18.9] mg/L compared 
with 3.50 (2.2–8.5) mg/L; Mann-Whitney (p = 0.233)]. Also, 
SD – standard deviation; BMI – body mass index; SEM – standard error of the mean;  
CRP – C-reactive protein. 
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the mean values (± standard error) were not significantly diffe-
rent between the patients with NTG and the controls (4.99 ± 
0.77 mg/L compared with 4.19 ± 0.3 mg/L), t-test p = 0.302. 
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Table 2  
Mean defect (MD) and C-reactive protein (CRP) values among the 3 groups 
 of normal tension glaucoma (NTG) patients and controls 
 
Parameters 
 
Group I 
(MD < 6 dB) 
Group II 
(6 dB < MD < 12 dB) 
Group III 
(MD > 12 dB) Controls 
Number of patients, n (%) 7 (35) 11 (55) 2 (10) 25 (100) 
MD ± SD (dB) 4.06 ± 1.02  8.64 ± 1.65  15 ± 2.54  2.72 ± 0.60 
CRP (mg/L), mean ± SEM 4.10 ± 0.34 4.13 ± 0.32 5.30 ± 0.96 4.19 ± 0.32 
NTG – normal tension glaucoma; SD – standard deviation; SEM – standard error of the mean.                                           
The values of mean defect of sensitivity were 
significantly higher in the patients with NTG than in the con-
trol group (p < 0.01). Most of the patients, 18 out of 20 
(90%), belonged to the group with early and moderate chan-
ges in visual field (Table 2). The number of patients with ini-
tial changes in the visual field was 7 (35%), MD = 4.06 ± 
1.02: Moderate changes in the visual field were noted in 11 
(55%) patients, MD = 8.64 ± 1.65, while only 2 (10%) pati-
ents had advanced changes in visual field, MD = 15 ± 2.54. 
Also, CRP values were not significantly different among the 
3 groups of the NTG patients and the controls, ANOVA 
(oneway) p = 0.347 (Table 2). 
Discussion 
The results of this study show that CRP levels are not 
altered in patients with NTG as compared with the control 
group with no ocular disease, but with similar demographic 
parameters and similar vascular risk profile. 
Previous researches on the connection between CRP 
and NTG were controversial. Our results are consistent with 
the findings obtained by Su et al. 15 and Choi et al. 16, even 
though they excluded patients with cardiovascular disease. 
That CRP is not elevated in patients with NTG when compa-
red with normal controls, after exclusion of patients with 
cardiovascular and other systemic diseases has also been fo-
und by Lee et al. 17 in their study. Since NTG is a multifacto-
rial disease in which the vascular risk factors independent of 
IOP take increasing importance, we did not exclude from our 
study patients with cardiovascular disease. Taking that into 
consideration we tried to match NTG patients and controls 
well. However, our results are contrary to the prior report by 
Leibovitch et al. 12 who showed significantly higher levels of 
CRP in 20 NTG patients, when compared to the control gro-
up (mean 3.21 ± 0.6 to 0.85 ± 0.17 mg/dL, p > 
0.001). Leibovitch et al. 12 also did not exclude patients with 
cardiovascular disease, but, obviously, characteristics of the 
patients in the control group differed from those in our con-
trol group (CRP level in their control group was lower than 
in our controls). A possible explanation for the different re-
sults in our and in Leibovitch's study may be the fact that pa-
tients with NTG in our study belong to the same or a similar 
disease stages (initial and moderate loss of the visual field). 
It is possible that CRP values vary in the different stages of 
the disease. Further research is needed so that this factor co-
uld be taken into account, and that should include a larger 
number of subjects. 
C-reactive protein is not only an important serum mar-
ker of inflammation but may have a direct role in the patho-
genesis of atherosclerosis. CRP has been found in atheroscle-
rotic plaque 18, and has an important role in cell adhesion 
molecular expression in human endothelial cells 19. There are 
strong associations between the levels of CRP and the inci-
dence of vascular atherosclerotic events such as myocardial 
infarction and stroke 11. 
A number of studies dealing with the connection of gla-
ucoma and systemic cardiovascular disease, despite some 
positive findings, did not find a strong link between atheros-
clerotic changes in blood vessels and the development of 
glaucoma 20–24. Neither the Rotterdam study on a sample of 
3,842 subjects after 6.5 years of follow-up found an associa-
tion between CRP and atherosclerosis, with the prevalence of 
glaucoma in a relatively healthy population 14. 
To the contrary, vascular dysregulation rather than athe-
rosclerotic changes in blood vessels appears to cause reduced 
perfusion in the optic nerve head 25. 
In research on NTG, vascular risk factors, in general, were 
considered as especially important. Interestingly, however, athero-
sclerosis itself and its risk factors are of minor importance. 
Systemic hypertension, dyslipidemia and diabetes mellitus are 
weak risk factors, if they are risk factors at all. Vascular 
dysregulation causing abnormal blood flow to the optic nerve se-
ems to be a major risk factor. Such dysregulation may lead to 
systemic hypotension and to local vasospasms, but also to a dis-
turbed autoregulation of blood flow in the optic nerve head 26–28. 
Potential limitations of our study are relatively small group sizes 
of NTG subjects and normal controls. The selection process of pa-
tients must be strictly controlled to avoid all of those factors and 
systemic inflammatory disease that may affect the level of CRP.  
Patients with different types of open-angle glaucoma but at the 
same stage of the disease should be involved in future research. 
Conclusion 
Our findings suggest that CRP levels are not associated 
with NTG, in line with an assumption that the risk profile of at-
herosclerotic patients, which includes an increase in CRP, is not 
identical to the risk profile of NTG patients. 
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Introduction 
Hemostatic system has been developed to preserve the 
integrity of circulation. Main components of hemostasis are: blo-
od vessel wall, plasma proteins (coagulation and fibrinolytic fac-
tors), platelets and other blood elements such as monocytes, red 
blood cells, etc. 1. All system components function interconnec-
ted. Coagulation plasma proteins normally circulate in its 
biologically inactive forms as proenzymes. Coagulation is the 
process which leads to formation of blood clots and turning from 
liquid to solid. It is very important, since if it does not work, it 
may cause bleeding disorders and if it works in excess it can lead 
to thrombosis. The whole process of clotting is based on many 
parts, each component performing a small but vital role. The clot-
ting cascade  details this (Figure 1), but in essence, damaged ves-
sel walls cause platelets to get joined together by fibrin, forming 
a tight clot. Thus, the three main components of the coagulation 
process are: platelets, fibrin, and the damaged endothelium. 
Whilst platelets are naturally present in blood, fibrin is formed 
through the clotting cascade. There are two pathways: the contact 
activation pathway (also known as the intrinsic pathway) and the 
tissue factor pathway (known as the extrinsic pathway). The pro-
cess of activation of platelets and fibrinogen in inappropriate blo-
od vessel can end in thrombus formation, so that thrombosis may 
be considered excessive hemostasis in the wrong place 2–4. 
Thrombi can occur in any part of the vascular system as a result 
of imbalance between the hemostatic system. The sequence of 
events in thrombus formation depends on the velocity of circula-
tion: arterial (fast) and venous (slow). 
 
 
 
Fig. 1 – Coagulation cascade. 
HMWK – high molecular weight kininogen; PK – prekallik-
rein; F – factor; TFPI – tissue factor pathway inhibitor  
 (https://sh.wikipedia.org/wiki/Zgru%C5%A1avanje_krvi) 
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The causes of arterial thrombosis can be atherosclero-
sis, coagulation disorders such as antiphospholipid antibod-
ies syndrome, protein C resistance (factor V Leiden), the 
lack of protein C or S, heparin induced thrombocytopenia, 
essential thrombocytopenia and hyperhomocysteinemia 5–7. 
Pulmonary thromboembolism (PTE) and deep vein 
thrombosis  (DVT)  is  almost  impossible  considered sepa-
rately, and is often together referred as venous thromboem-
bolism (VTE). One or more factors of Virchow’s triad (he-
modynamic changes, endothelial injury/dysfunction and hy-
percoagulability of blood) are almost always the cause of 
VTE. Thrombotic process begins in the venous valve cusps, 
spreads and can lead to complete occlusion of the lumen and 
venous  tributaries  and  embolization 8, 9. The  incidence  of 
DVT is common in surgical and other disease in which there 
is inactivation of the muscle venous pump. Other causes may 
include: external obstruction, strictures, scars, pressures from 
surrounding structures, often tumor mass. PTE is a common, 
serious and potentially fatal complication that occurs when a 
clot from the deep vein, usually the lower limb or pelvic, 
cause embolisation of pulmonary arterial circulation. Rarely 
the source of emboli can be of the vena cava thrombus, deep 
veins of the upper extremities and the right heart. 
New thrombolytic technique 
EkoSonicTM Mach4 (EKOS® Corporation, Bothell, WA) 
endovascular system with rapid pulse modulation (RPM) is de-
signed for the dissolution of vascular blood clots. EkoSonicTM 
is the only endovascular system that can deliver microsonic en-
ergy and thrombolytic drug simultaneously, providing safer, 
faster and more complete thrombus removal by accelerating dis-
solution. It is intended for controlled and selective infusion of 
thrombolytic drugs into the peripheral vasculature and pulmo-
nary arteries. EkoSonicTM device obtain access for standard 
percutaneous endovascular procedures, 6F sheath is preferred. 
The system consists of a reusable and single use parts. The reus-
able parts are the control unit which provides ultrasound energy 
and the user interface, with his own connector interface cable 
(CIC). Single use parts of this device are:  intelligent drug deliv-
ery catheter (IDDC) and microsonic device (MSD) (Figure 2). 
Ekosonic control system generates ultrasonic energy 
waves at the treatment zone through  piezoelectric transduc-
tion of  radiofrequency (RF) energy generated by the control 
unit. The device frequency ranges from 2.05 to 2.35 MHz 
pulse modulated. The maximum output power is 50 W (30 
W average), maximum temperature is 43°C. The control unit 
monitors output power and temperature of the endovascular 
unit. It has the safeguard circuits to prevent deviation of the-
se parameters from preset range. If there is a disorder, the 
system automatically turns off. 
Infusion catheter (IDDC) has a unique design (Figure 3) 
with two separate lumens, one for the drug delivery through 
the side holes, and the central lumen for the exchange of the 
guide wire and MSD, as well the delivery of saline for coo-
ling the ultrasound probes. The IDDC catheter has two mar-
kers on the distal end between which are located side holes – 
treatment zone of the catheter. Infusion of the drug and sali-
ne are administered via a standard infusion clinical pump. 
The MSD device has 30 fully isolated, radiopaque marked 
probes in  its  distal  part. Both  catheters exist in  different 
length for different vessel localization and thrombus length. 
The available lengths are: 106 cm working length with the 
treatment zone 6, 12, 18, 24, 30, 40, 50 cm and 135 cm 
working length with the treatment zone 12, 30, 40, 50 cm. 
How it works? 
When it comes to the formation of thrombus in periphe-
ral blood vessels that obstruct the lumen and prevent normal 
blood flow or in PTE as the clot forms, plasminogen is in-
corporated into  the  fibrin 11.  In  order  to  resolve  the  clot 
thrombolytic agent must reach the receptor sites on the plas-
minogen. The EkoSonicTM  endovascular system facilitates 
this process. It simultaneously releases thrombolytics and ul-
trasound energy within the thrombus 12, 13. Delivering drug 
without ultrasound may limit its dispersion, as the drug will 
follow the path of least resistance along the side holes of non 
ultrasound catheter. By contrast activating the EkoSonicTM 
endovascular system it generates a radial pressure within the 
treatment zone around the catheter 14. The pressure 
effectively drives the drug into the thrombus and 
Fig. 2 – EkoSonicTM device 10. 
 
 
Fig. 3 – Cross section of the intelligent drug delivery 
catheter 10. 
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immediately accelerates the dispersion of the drug. At the 
same time acoustic energy conditions the clot by thinning fi-
brin into individual strands. This increases the pore size and 
allows more effectively delivery of the drug deep inside the 
thrombus. As the drug moves further in the fibrin mesh, it 
surrounds each fibrin strand and bounds with newly exposed 
plasminogen activator receptor sites. The fibrin strands begin 
to dissolve releasing red blood cells and other blood compo-
nents trapped into the fibrin matrix. 
Our initial experiences 
Using this method patients have been treated in 
Radiology Institute in Military Medical Academy in Belgra-
de since 2013 untill February 2017, co working  with clinici-
ans from Cardiac Surgery Clinic, Vascular Surgical Clinic 
and Clinic for Emergency and Internal Medicine. Purpose of 
the report is to show efficiency of method for dissolving 
thrombus in targeted blood vessel.  All patients had signs of 
arterial or venous system thrombosis. The diagnosis of 
thrombosis of the vessel was established on the basis of cli-
nical examination, laboratory findings, echocardiography, 
multidetector computed tomography (MDCT) angiography 
or conventional angiography. Following the established dia-
gnosis all the patients were subjected to treatment with ultra-
sound accelerated thrombolysis by the assigned protocol. 
Four patients had thrombosis of femoropopliteal bypass 
graft, one had thrombosis of the superior mesenteric artery, 
one with thrombosis of vena cava and twenty patients with 
PTE. Depending on the location of thrombosis and its durati-
on clinical symptoms were different. The duration of 
symptoms in patients varied from rapid onset up to six 
months. There had been treated acute (< 14 days), subacute 
(15–28 days) and chronic (> 28 days) old thrombosis. After 
abovementioned examination all the patients were presented 
to the Catheterization Laboratory. 
Device and procedure description 
Percutaneous transfemoral or transjugular approach was 
used. After the angiography of the occluded vessel, through 
the 6F sheath guide wire was introduced into the blood ves-
sel that was necessary to treat passing through the entire 
length of the clot under the control of fluoroscopy. 
Hydrophilic guide wire of 0.035 inch was used. Then the 
IDDC catheter was inserted over the guide wire until the tip 
of the catheter passes entirely through the clot with the tip in 
healthy part of the vessel. The guide wire was then pulled out 
and replaced by the MSD with positioning of the radiopaque 
probes within the proximal and distal marker on the IDDC. 
After connecting drug solution and saline with the adequate 
ports and attaching the CIC with IDDC and MSD, treatment 
procedure was started. The duration of the therapeutic proce-
dure depended on thrombus maturity and its size. The time 
ranged from 6 to 24 hours. Thrombolytic therapy [recombi-
nant tissue plasminogen activator-tPa (rtPA) – alteplase] was 
given at the dose of 1–3 mg per hour. The solution was made 
as follows: 50 mg alteplase inserted into 500 mL of saline. 
The drug was running through the standard infusion pump 5–
15 mL per hour (depending on the required dose), saline so-
lution for cooling the probe went 35 mL per hour. Upon 
completion of the therapy procedure the device was pulled 
out. Final angiography was made and MDCT angiography 
was made next day. Further monitoring of the patient's was 
clinical. 
Views of individual patients performed 
There were 4 patients 1–2 years after surgical revascu-
larization of the lower limbs, femoropopliteal bypass grafts 
(due to occlusion of superficial femoral artery), with the pre-
sentation of symptoms that indicated graft occlusion. In 3 pa-
tients according to the medical history graft occlusion was 
subacute (up to one month), while one was chronic (up to 6 
months). They all had clinical symptoms of chronic lower 
limb ischemia as they already had ischemic arterial disease, 
but they all complained on intermittent claudications, distan-
ce shortening. Claudication is defined as fatigue, discomfort 
or pain that occurs during exercise in a particular group of 
legs muscles. People with claudication have enough blood 
supply  so  in  rest  symptoms  disappear 15, 16.  Patients  with 
typical claudication described: pain, itching, pressure, cram 
ping or fatigue in one or more muscle groups of the lower 
extremities. The symptoms are usually caused by exertion 
and subside during resting. Localization of claudications oc-
currence was distal to the diseased segment of the artery. 
Anatomic site of the lesion is usually associated with pain in 
the leg at a certain point. Patients complained of pain in the 
region below the knee, which is typical for the femoropopli-
teal or tibial artery disease. After confirmed diagnosis of 
thrombosis  of   femoropopliteal  graft   they   received   the 
therapy (ultrasound accelerated thrombolysis) which lasted 
for 6 hours at a dose of 1 mg per hour. After reestablishing 
perfusion in all four patients were detected stenosis at 
proximal or distal anastomosis which was solved by stent 
implantation (Figure 4). All given results refer to immediate 
founding after the intervention. The prognostic outcome of 
patients limb salvage in spite of complete resolution of 
thrombus depends on the condition of distal microvascular 
circulation. 
Acute occlusion of the superior mesenteric artery appe-
ar in the patient on the third   postoperative   day   after 
coronary artery bypass grafting (CABG) for myocardial re-
vascularisation. The patient had strong, tearing pain in the 
abdomen, bowel peristaltic was not audible. After MDCT 
examination the occlusion of the superior mesenteric artery 
was found. First thrombus aspiration was done, by using the 
right coronary guiding catheter 7F (due to the larger lumen 
width) with no results. Then the ultrasound accelerated 
thrombolysis was applied for 6 hours at the dose rtPA 1 
mg/hour. Near complete dissolution of the thrombus was ac-
hieved, soon after peristalsis was restored and the patient 
fully recovered (Figure 5). 
Acute vena cava inferior thrombosis appeared after re-
section of the right liver lobe due to hepatocellular carcino-
ma. During the surgery, there was an iatrogenic lesion of the 
Kostić J, et al. Vojnosanit Pregl 2017; 74(10): 974–981. 
Vol. 74, No 10 VOJNOSANITETSKI PREGLED Page 977 
 
Fig. 4 – a) Occlusion of the right femoropopliteal graft; b) EkoSonicTM device into the graft; c) and d) Control angiograph 
by findings; e) Stent placement at the site of distal anastomosis. 
 
Fig. 5 – a) Occlusion of arteria mesenterica superior; b) and c) Attempt of aspiration; d) EkoSonicTM device;  
e) Final angiogragram. 
inferior vena cava that was resolved surgically. On the third 
postoperative day the patient developed symptoms of acute 
renal failure.  MDCT examination showed thrombosis of the 
inferior vena cava, which starts from the hepatic vein stret-
ching down and capturing the renal veins. Ultrasound accele-
rated thrombolytic therapy was applied for 24 hours with the 
dose of thrombolytic 1 mg/hour. Control angiography revea-
led reestablished venous drainage. The patient recovered 
uneventfully with no further renal insufficiency. 
There were twenty patients with PTE, treated with this 
method. Most of them had high risk for bleeding or were resis-
tant to conventional therapy. In all patients were registered 
significant improvement of symptoms, decrease of systolic 
right ventricular  pressure and decrease of thrombus burden on 
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control MDCT pulmoangiography. There were no intrahospi-
tal deaths in PTE patients treated with EKOS (Figure 6). 
Comparison to other techniques 
EkoSonicTM Mach4 (EKOS® Corporation, Bothell, 
WA) infusion system with an ultrasound probe was designed 
in 1996. The Food and Drugs Administration (FDA) and Eu-
ropean Community mark (CE mark) for therapeutic use in 
peripheral blood vessels was received in 2004.  
For systemic administration of rtPA doses are 0.6–0.9 
mg/kg for 2 hours in infusion, with a starting bolus of 10 mg 
previously, but not exceeding 100 mg in total. This way of 
giving carries a high risk of bleeding and contraindications 
for administration are hemorrhagic stroke or stroke of 
unknown etiology anytime, ischemic stroke in the previous 6 
months, central nervous system damage or neoplasm, recent 
trauma and/or surgical intervention, gastrointestinal bleeding 
in preceding month and positive hemorrhagic diathesis. Rela-
tive contraindications are: transitory ischemic attack in the 
preceding 6 months, oral anticoagulant therapy, pregnancy or 
the first week postpartum, advanced liver disease, infective 
endocarditis, active peptic ulcer, refractory hypertension 
(systolic pressure greater than 180 mmHg). 
The total dose of the given thrombolytic therapy using 
the ultrasound accelerated thrombolytic device is 50–70% 
smaller comparing to the systemically given. 
Classic transcatheter delivering of the drug entails the 
necessary long time, leaving intraluminal catheter 48 hours 
or more, which carries more than 10% higher risk of blee-
ding 17. This method increases the length of time of therapy, 
which brings along delivering greater total dose and thus a 
higher risk of bleeding. According to the recommendations 
of the American College of Chest Physicians (ACCP) from 
2008, in order to reduce the period of drug administration 
through a catheter, proposed was combining with mechanical 
method for faster removal of thrombus and thereby shorte-
ning the duration of the procedure and the total given dose 18. 
Pharmacomechanical thrombolysis involves a longer time of 
exposal to radiation to patients and staff, the risk of residual 
thrombus. Those methods mechanically remove a clot only 
from the place where the aspiration is made or clot is remo-
ved in another manner, therapy is usually continued with 
thrombolytic. There is always hemolysis, high risk of distal 
remobilization 19 as well as mechanical injury of the vessel 
wall and vein valves 20, 21. The difference in protocols and 
duration of procedures and last but not the least important is 
that the success rate of the three most common methods that 
are in use are very different. The protocol for the use of the 
EKOS® system is as follows: image occlusion, passing a gu-
ide wire through the thrombus, catheter insertion IDDC, re-
placement guide wire catheter MSD, release therapy 
(thrombolysis plus ultrasound) (Figure 7). The protocol for 
the use of the trellis system is quite complicated and time-
 
Fig. 6 – a) and b) Thrombus in the left pulmonary artery; c) EkoSonicTM device; d) Final multidetector computed tomo-
graphy with pulmonary angiography. 
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Fig. 7 – Ultrasonic pressure waves encompass entire vessel. 
 
consuming and involves: image occlusion, passing a guide 
wire through the thrombus, place trellis device into clot, in-
flate the first balloon, infuse contrast to confirm flow is oc-
cluded, inflate second balloon, infuse treatment dose of 
thrombolytic, insert dispersion wire, attach trellis device unit 
and activate, manually control drive speed (maximum ballo-
on inflation time: 15 minutes per position), deflate proximal 
balloon, advance introducer sheat to near distal balloon, aspi-
rate residual thrombus, the distal balloon deflation, image 
vessel and assess progress. If there is a residual thrombus, 
the entire procedure is repeated (Figure 8). The entire proce-
dure should not take longer than 60 minutes. If it still persists 
thrombus applies to any other method 22. 
The protocol for the AngioJet® system: occlusion seen, 
cross clot  with  guide  wire,  system setup (8  step  the  old 
system, the new ultra 3 steps AngioJet®), set up system for 
power-pulse mode (unspike saline and exange for thrombolytic), 
place AngioJet® at proximal end of thrombus formation, activa-
tion of the release of thrombolytic in the dose of about 10–20 
mg tPA while AngioJet® moves forward/backward through the 
thrombus, waiting for about 30 min., excludes the thrombolytic, 
includes a saline solution, cross clot with AngioJet® while aspi-
rating residual material, image vessel and assess progress, if the-
re is residual thrombus entire procedure is repeated (maximum 
run time is 8–10 minutes depending on the model) (Figure 9). If 
it still persists thrombus applies to any other method. The advan-
tage of ultrasound accelerated resolution of a thrombus over 
classical catheter for drug release is: reduced recanalization 
time, significantly lower risk of bleeding, shortness of in-
hospital time. The advantage of ultrasound accelerated reso-
lution of thrombus, over pharmacomechanical thrombolysis 
is using just one system, no hemolysis, minimal risk of distal 
embolization, no injuries of blood vessel wall and vein val-
ves, complete resolution of the thrombus, significantly lower 
exposed dose to radiation of patients and staff. 
Considering all the abovementioned EkoSonic® endo-
vascular device imposes as the simplest, safest and most 
comfortable. 
Fig. 8 – Trellis system. 
 
Fig. 9 – AngioJet system. 
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We may ask why is so difficult to dissolve the throm-
bus? The fibrin network that is formed (the matrix) does not 
permit thrombolytic agents to penetrate inside of the throm-
bus, and thus is limited to access to plasminogen receptors 
sites. The reason is that they are embedded deep into throm-
bus during formation 23. Speed of thrombolysis depends on 
ability to access the abovementioned receptor sites. EkoSo-
nicTM Mach4 ultrasound energy leads to the dissolution of fi-
brin network, exposing sites for plasminogen receptors, lea-
ding to increased permeability of the thrombolytic and ultra-
sound waves reaching all the way to the vessel wall and the 
venous valves, not allowing thrombolytic to migrate into the 
circulation, thus the dissolution process is accelerated with a 
lower risk of unwanted bleeding 12 (Figure 10). A study by 
Francis et al. 12 shows that in relation to ultrasound accelera-
ted thrombolysis, the dosage of given tPA is 48% greater af-
ter hour, 84% after 2 hours and 89% after 4 hours. 
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Fig. 10 – Fibrin network dissolution by: a) Only thrombolytic therapy; b) Only ultrasound;  
c) Ultrasound and thrombolytic therapy. 
 
Fig. 11 – Dispersion of thrombolytic with a standard infusion catheter vs EkoSonicTM system. 
The difference in penetration of thrombolytic using an 
ordinary infusion catheter and EkoSonicTM  system with the 
identical amounts of tPA for 15 minutes is as follows: 38% 
more penetrated with thrombus EkoSonicTM  system compa-
red to 17% with regular infusion catheter (Figure 11). Com-
parative overview of the thrombus dissolution with recombi-
nant urokinase through a standard drug delivery catheter 23 
and EkosonicTM system 10, 24 with the percentage of bleeding 
demonstrated that more than 26% of patients treated with 
EkoSonicTM  system had a complete dissolution of the 
thrombus, more than 82% reduction in bleeding and more 
than 75% of the dissolution of thrombus formation in pati-
ents resistant to conventional therapy in a shorter period of 
time vs drug delivery catheter. 
Conclusion 
Our initial experience shows that all the patients achieved 
complete dissolution of the thrombus. There were no complica-
tions as bleeding, distal embolization, mechanical injury of the 
vessel wall, including the vein valves. The total dose of the gi-
ven rtPA treatment in ultrasound accelerated thrombolysis ran-
ged from 6 to 24 mg in the infusion that lasted from 6 to 24 ho-
urs. All the patients successfully achieved complete thrombus 
dissolution and established normal circulation immediately after 
the intervention. The prognostic outcome of patients limb salva-
ge in spite of complete resolution of thrombus depends on the 
condition of distal microvascular circulation. 
EkoSonicTM Mach4 is a minimally invasive method that 
carefully and completely dissolve thrombus in the arterial 
and venous system leading to reestablishment of the circula-
tion (blood flow), with low risk of complications. The dose 
of tPA is 50–70% less than the implementation in protocols 
for systemic administration or other application of the above 
methods, which gives minimal risk of bleeding, shortens the 
time of infusion and exposing time to radiation and length of 
in-hospital stay also. In patients who had recent surgery or 
trauma, thrombocytopenia, or other contraindications to 
systemic administration of thrombolytic therapy, or are 
refractory to conventional therapy, EkoSonicTM  system has 
no alternative. 
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Abstract 
 
Introduction. Juxtaglomerular cell tumor (JGCT) or reni-
noma is a very rare cause of curable hypertension among 
young people. The early diagnosis is the most important 
based on the clinical presentation, hormonal and radiological 
findings observed on computed tomography (CT) and/or 
magnetic resonance imaging (MRI). The final confirmation of 
the JGCT is the lateralization of the plasma renin activity 
(PRA) during the selective renal venous sampling. Case re-
port. This report presents a typical case of young women 
with JGCT which was manifested for the first time with se-
vere hypertension during the pregnancy and was the reason 
of fetal death. After the miscarriage, the diagnosis of JGCT 
was made by the CT scanning and confirmed by the selective 
renal venous sampling. After the partial nephrectomy, the 
blood pressure and serum potassium normalized without the 
medications. Conclusion. Reninoma should be considered in 
the differential diagnosis as a cause of severe hypertension in 
pregnancy and also should be suspected in young hipertensi-
ves (especially females) with hypokalemia and secondary hy-
peraldosteronism after the exclusion of other causes 
particularly renal artery stenosis. A dynamic contrast-
enhanced CT, MRI and selective renal venous sampling are 
the most important tools in the diagnosis of JGCT.  
 
Key words:  
juxtaglomerular apparatus; kidney neoplasms; 
hypertension; fetal death; diagnostic techniques and 
procedures; diagnosis, differential; urologic surgical 
procedures. 
Apstrakt 
 
Uvod. Jukstaglomerularni ćelijski tumor (JGĆT) ili reninom 
је veoma redak uzrok hipertenzije kod mladih ljudi. Najvaž-
nija je rana dijagnoza koja se postavlja na osnovu kliničke 
prezentacije, hormonskih i radioloških nalaza, pre svega 
kompjuterizovane tomografije (KT) i magnetne rezonance 
(MR). Finalna potvrda dijagnoze JGĆT je prisustvo laterali-
zacije plazma reninske aktivnosti (PRA) tokom selektivnog 
uzorkovanja krvi iz renalne vene. Prikaz slučaja. Prikazan 
je tipičan slučaj mlade žene sa JGĆT koji se prvi put mani-
festovao ozbiljnom hipertenzijom tokom trudnoće i bio uz-
rok smrti ploda. Nakon pobačaja dijagnoza JGĆT postav-
ljena je na osnovu CT pregleda i potvrđena je selektivnim 
uzorkovanjem krvi iz renalne vene. Nakon parcijalne nefre-
ktomije došlo je do normalizacije vrednosti krvnog pritiska i 
vrednosti kalijuma u serumu. Zaključak. Na JGĆT treba 
misliti u diferencijalnoj dijagnozi ozbiljne hipertenzije to-
kom trudnoće kao i kod mladih ljudi (naročito žena) sa hi-
pokalijemijom i sekundarnim hiperaldosteronizmom nakon 
isključenja drugih uzroka kao što je renalna arterijska steno-
za. Dinamski kontrastni KT, MR i selektivno uzorkovanje 
krvi iz renalne vene najvažnije su procedure u postavljanju 
dijagnoze JGĆT. 
 
 
Ključne reči: 
jukstaglomerularni aparat; bubreg, neoplazme; 
hipertenzija; fetus, smrt; dijagnostičke tehnike i 
procedure; dijagnoza, diferencijalna; hirurgija, 
urološka, procedure. 
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Introduction 
Juxtaglomerular cell tumor (JGCT) or reninoma is a 
very rare cause of curable hypertension among young peo-
ple. It is typically presented with hypertension, hypokalemia, 
and hyperaldosteronism secondary to excessive renin secre-
tion by tumor cells 1. Approximately 119 cases were publis-
hed and the majority of the reported cases were benign tu-
mors, except in four cases 2–5. However, its clinical behavior 
can be malignant as a result of severe systemic complications 
of hypertension. The early diagnosis is the most important 
based on clinical presentation, hormonal and radiological 
findings observed on computed tomography (CT) and/or 
magnetic resonance imaging (MRI). The final confirmation 
of the JGCT is the lateralization of the plasma renin activity 
(PRA) during the selective renal venous sampling 6, 7. 
However, patients with JGCT can be misdiagnosed due to 
the small size of the tumor which can not be visualized 
and/or the lack of the lateralization of PRA during the selec-
tive renal venous sampling. The usual treatment consists of 
partial or complete nephrectomy which results in normaliza-
tion of blood pressure. 
This report presents a typical case of young women 
with JGCT WHO manifested for the first time severe 
hypertension during the pregnancy, which was the reason of 
fetal death. After the miscarriage, the diagnosis of JGCT was 
made by using CT scanning and confirmed by the selective 
renal venous sampling. 
Case report 
A 20-year old female patient was referred to our hospital 
for a further examination of persistent and severe hypertension 
and hypokalemia lasting for over one year. The diagnosis of 
severe hypertension was established at 20th gestational weeks 
at 19 years of age. Antihypertensive therapy was started with 
methyldopa (500 mg two times daily). Except for occasional 
headache, the patient denied any other symptoms. PRA and 
plasma aldosterone concentration (PAC) were elevated (PRA 
23.6 ng/mL/h, normal range 0.2–2.8 ng/mL/h; PAC 949 ng/L, 
normal range 42–201.5 ng/L). The pregnancy was discontinu-
ed at 24th gestational week when fetal death was diagnosed. 
Pathoanatomical diagnosis of the fetus and pathohistological 
diagnosis of the placenta showed the fetal mass of 425 g which 
was adequate for the 22 weeks of gestation. In the placental 
bed and in the intervillous space recent hemorrhage and fibrin 
deposits were seen. Significant syncytial nodules and villous 
fibrosis were present. Thickened walls of fetal blood vessels 
were also present.  
Few months after the miscarriage she was still 
hypertensive and because of the hypertensive crisis (blood 
pressure – BP 240/120 mmHg) she was hospitalized in the 
regional clinical center. The renal vascular stenosis and aor-
tic coarctation were excluded using renal angiography and 
cardiac ultrasound, but severe hypokalemia (2.6 mmol/L) 
was noticed. The antihypertensive therapy was changed to 
captopril (50 mg three times a day), bisoprolol (5 mg twice a 
day), amlodipine (10 mg once a day) and potassium chloride 
(1 g twice a day) in the local hospital. After that, she was re-
ferred to our hospital for further investigation of 
hypertension and hypokalemia. On admission, her blood 
pressure was normal (115/70 mmHg) and the physical 
examination showed no significant findings. The serum po-
tassium level was normal on the substitution therapy and the 
results of other routine laboratory tests were within the nor-
mal ranges. The endocrine examination was performed after 
washout period of two weeks (taking amlodipine 10 mg 
only) and it revealed elevated PRA (27.6 ng/mL/h, normal 
range 0.2–2.8 ng/mL/h) and PAC levels (1,633.7 ng/L, nor-
mal range 42–201.5 ng/L) indicating secondary 
hyperaldosteronism. Adrenocorticotropin (ACTH), cortisol, 
dehydroepi-androsterone-sulfate (DHEA-S), thyroid-
stimulating hormone (TSH), thyroxine (T4), catecholamines 
and chromogranin were normal. Fundoscopy demonstrated 
hypertensive retinopathy grade II. 
A dynamic contrast-enhanced CT image revealed a 
small renal tumor (10 mm in diameter) (Figure 1, A and B). 
On the other hand, there was no evidence of renal artery ste-
nosis and the adrenal glands were normal. However, conside-
ring the findings of dynamic contrast-enhanced CT we could 
not completely exclude the possibility that the renal tumor 
was not JGCT, but rather some other tumor of the kidney and 
the possibility that renin was being secreted by an ectopic 
extrarenal tumor. Therefore, we performed selective renal 
venous sampling to assess the level of PRA and direct renin 
secretion by the tumor of the left kidney described on CT 
scan. We did not perform a strict low-sodium diet four days 
before the test nor did apply the intravenous fast acting angi-
otensin converting enzyme (ACE) inhibitors during the ve-
nous sampling. The only preparation for the test was discon-
tinuation of potentially interfering medications 4 weeks befo-
re the test (the patient was on amlodipine therapy 10 mg on-
ce daily). The renal venous sampling was done in the early 
morning after overnight recumbency. Consequently, the PRA 
level was 37.9 ng/mL/h  in the left renal vein, 3.1 ng/mL/h in 
the right renal vein and 31.7 ng/mL/h in the low inferior vena 
cava. This indicated the clear lateralization of PRA on the 
left side as the lateralization rate was 12.2 (the accepted rate 
of lateralization is > 1.5). At the same time, the renin concen-
tration was measured. At first, we got the same high values 
in both veins (> 500.0 μIU/mL, normal range 2.8–39.9 
μIU/mL, CLIA). After dilution, the renin concentration in 
left vein was 2,796.0 μIU/mL and in the right vein 520 
μIU/mL. Taken together, we strongly suspected that the tu-
mor in the left kidney was JGCT and the patient was prepa-
red for the operation with the spironolactone (50 mg twice a 
day) and fosinopril (20 mg once daily) having achieved 
excellent control of blood pressure and potassium level. The 
open partial nephrectomy with intraoperative ultrasound was 
done and no complications were observed (Figure 1, C and 
D). The histological examination and immunohistochemistry 
confirmed the diagnosis of JGCT (Figure 2). After the opera-
tion, the measured levels of PRA and PAC were in the nor-
mal ranges (PRA 0.74 ng/mL/h, PCA 74.2 ng/L). The blood 
pressure and serum potassium normalized without the medi-
cations. 
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Fig. 1 – A) Contrast enhanced multidetector computed tomography (MDCT) of the left kidney, cortical phase. 
Frontal multiplanar reformation. Picture shows discrete rounded 10 mm lesion, that appears izodense with 
surrounded medulla of the upper third of the left kidney (arrow). Renal cortex is normal; B) Contrast enhanced 
MDCT of the left kidney, nephrographic phase. The lesion is well bordered with kidney during nephrographic 
phase, nonenhanced, low attenuated and hypovascular (hypodense), typical for reninoma (arrow). Contour of the 
kidney is not altered, no distortion of the renal hilum; C) Intraoperative ultrasound of small renal tumor – 
reninoma (arrow); D) Operative finding of small tumor imunohistochemically confirmed as reninoma. 
 
Fig. 2 – A) Reninoma: the tumor is highly cellular, composed of round, polygonal or spindle cells with granular 
eosinophilic cytoplasm and distinct cell borders, in the background  of minimal mixomatous stroma, some of them 
forming the walls of small vessel (arrow) hematoxylin and eosin staining; B) the cytoplasmic granules react with  
periodic acid-schiff (PAS); C) Immunohistochemical positivity of the tumor to CD34.  
Original magnification 400. Scale bar = 100 µm. 
 
Discussion 
Herein we presented the case of a typical JGCT in a 
young woman with severe hypertension in pregnancy, 
hypokalemia and secondary hyperaldosteronism diagnosed 
with JGCT after poor fetal outcome by using the CT and se-
lective renal venous sampling. 
Diagnosis of hypertension was made during the 
pregnancy which was terminated at 24th gestational week 
due to fetal death. To the best of our knowledge this is the 
fourth case of JGCT complicating pregnancy 8–10. Secondary 
aldosteronism in pregnancy is a normal physiologic response 
to estrogen-induced increases in circulating levels of renin 
substrate and PRA and to the anti-aldosterone actions of pro-
gestagens. The pregnancy might be the trigger for aggravati-
on and manifestation of  existing hypertension and secondary 
aldosteronism in JGCT. As it was mentioned above the pati-
ent has high PRA and aldosterone levels measured at 20th 
gestational weeks. 
JGCT primarily affects adolescents and young adults, 
with peak prevalence in the second and third decades of life, 
and it is twice as common in women. Haab et al. 11 described 
eight JGCT among 30,000 hypertensive patients, the largest 
series in the literature. Average age at diagnosis was 22 years 
(range: 7 to 58 years). Our patient was 19 years old women 
when the diagnosis of hypertension was made, and she was 
in the typical age group for the diagnosis of JGCT. Accor-
ding to the clinical presentations, laboratory and imaging 
examinations and pathologic results the JGCT can be classi-
fied into 3 types: typical, atypical and non-functioning 
type 12. The typical JGCT is characterized by marked 
hypertension, severe hypokalemia and hyperaldosteronism 
secondary to tumor renin secretion. The typical variant is the 
most common type of JGCT. Our patient is the example of 
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the typical JGCT with all the mentioned features and with 
the excellent control of severe hypertension on the ACE in-
hibitor and spironolactone therapy using small doses. The 
clinical presentation of atypical JGCT includes marked 
hypertension with normal serum potassium and renin secre-
tion. The clinical presentation of the non-functioning JGCT 
includes renal tumor with normal blood pressure and potas-
sium 12, 13. A non-functioning variant is the rarest and is tho-
ught to produce inactive renin 13. 
In our case, the suspicion of JGCT was made after the 
exclusion of the other causes of hypertension in young adults 
such as renal artery stenosis, aortic coarctation, 
pheochromocytoma and causes of primary aldosteronism. 
MRI and CT are generally able to identify renal tumors 
accurately and can be equally effective in the detection of 
JGCT with rates of detection approaching 100% in some se-
ries 1, 14. However, JGCT tumors smaller than 5 mm can cau-
se severe hypertension and can not be seen using standard 
imaging techniques 15. JGCT usually appears isodense or 
hypodense to the renal medulla. If the tumor is small and iso-
dense to the renal medulla on non-enhanced CT, it may not 
be detected. Taken together, the use of enhanced CT should 
be considered in all cases of suspected JGCT 6. In our case, 
CT revealed small tumor and in combination with secondary 
aldosteronism, it was obvious that JGCT can be the cause of 
hypertension. However, considering the findings of CT we 
could not completely exclude the possibility that the renal 
tumor was not JGCT but rather another type of tumors such 
as angiomyolipoma or renal cell carcinoma and that renin 
was being secreted by an extrarenal tumor (lung carcinomas, 
pancreatic adenocarcinomas, fallopian tube adenocarcino-
mas, ovarian leiomyosarcoma) 16, 17. Therefore, we perfor-
med selective renal venous sampling to evaluate direct PRA 
and renin secretion from the tumor and we got the clear late-
ralization rate of 12.2. A previous study of 50 cases of renal 
venous sampling reported that the sensitivity and specificity 
were 56% and 94%, respectively for the lateralization rate of 
1.5 1. However, the variable success of this procedure in ac-
hieving accurate lateralisation of the JGCT has been publis-
hed in the literature. Haab et al. 11 reported that 3 of 8 pati-
ents with JGCT were unable to be diagnosed by the selective 
renal venous sampling despite repeated attempts and its visu-
alization on CT. Although the detailed reasons for the failure 
of previously reported cases of renal venous sampling are 
unclear, one proposed that the tumors are primarily located 
on the surface of the kidneys and most of the venous supply 
of the tumors is collected into the perivascular veins instead 
of the main renal vein 11, 18. Precise details for preparing pati-
ents  for the selective renal venous sampling still do not exist 
but there are some recommendations as the administration of 
dietary salt restriction (40 mmoL/day) for 4 days before the 
sampling. In addition, cessation of potentially interfering 
medications is recommended (diuretics, beta blockers, ACE 
inhibitors, angiotensin II receptor blockers, spironolactone) 
where it is possible for at least 4 weeks before the test. The 
overnight recumbency is also proposed 7. The administration 
of a rapidly acting ACE inhibitors during the sampling can 
be beneficial improving the sensitivity of the test 19. In our 
case, we did not perform dietary salt restriction before the 
sampling and we did not use ACE inhibitors during the pro-
cedure but we got the clear lateralization of the PRA and re-
nin. As there are many cases of unsuccessful renal venous 
sampling we suggest careful patient preparation.  
Clinical behavior of JGCT can be malignant due to se-
vere systemic complications of hypertension, especially in 
cases with a delayed diagnosis of the tumor. Retinopathy, re-
nal insufficiency and left ventricular hypertrophy have been 
reported in 24%, 3% and 7% of cases, respectively 1. Cereb-
rovascular accident and intestinal ischemia have been also 
reported 20, 21. Our patient had hypertensive retinopathy grade 
II and it significantly resolved few months after the operati-
on. 
Because JGCT is mostly benign, partial nephrectomy is 
the proposed treatment with successful outcomes reported. 
Laparoscopic partial nephrectomy is particularly recommen-
ded as the tumor is usually small 1, 11. 
Conclusion 
This case of JGCT was diagnosed during the pregnancy 
and was the reason of poor fetal outcome. This tumor should 
be considered in the differential diagnosis as a cause of seve-
re hypertension in pregnancy. The tumor had the typical pre-
sentation and after the exclusion of the other causes of 
hypertension in young adults, particularly renal artery steno-
sis, the investigation was directed to the JGCT. A dynamic 
contrast-enhanced CT, MRI and selective renal venous sam-
pling are the most important tools in the diagnosis of JGCT.  
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Alveolar bone defect regeneration after bilateral periapical cyst 
removal with and without use of platelet rich fibrin – A case report 
Zarastanje koštanog defekta nastalog enukleacijom bilateralnih periapikalnih 
cista sa i bez upotrebe fibrina obogaćenog trombocitima  
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Abstract 
 
Introduction. Periapical inflammatory lesions are local bone 
responses around the apex of a tooth that occur after necrosis 
of the pulp tissue. The ultimate goal of reconstructive surgical 
techniques in the treatment of the intra-bone defects is a re-
generation of lost bone tissue. The aim of this report was to 
evaluate clinical and radiographic outcome following the re-
moval of two big, periapical lesions, approximately of the same 
size, located around maxillary lateral incisors, in the same per-
son at the same time, using two different regenerative ap-
proaches. Case report. A healthy, 21-year-old female pre-
sented with two large periapical lesions around both upper lat-
eral incisors, and a surgical treatment was indicated. One resid-
ual defect (tooth #12) was filled with the mixture of bovine-
derived hydroxyapatite xenograft and platelet rich fibrin (PRF) 
gel and covered with PRF membrane, while the other (tooth 
#22) was filled with bovine-derived hydroxyapatite xenograft 
only and covered with a resorbable collagen membrane. Clini-
cal and radiographic examinations were performed seven 
months after the surgery. All clinical and radiographic parame-
ters were significantly improved after the treatment on both 
sites; however, a newly formed bone around the tooth 12 
showed a higher bone density. Conclusion. The use of PRF 
significantly speeded up filling of the defect compared to bo-
vine-derived hydroxyapatite xenograft. 
 
Key words:  
oral surgical procedures; platelet rich plasma; bone 
regeneration. 
Apstrakt 
 
Uvod. Inflamatorne periapikalne lezije su posledica širenja 
infekcije iz kanala korena zuba. Cilj moderne periapikalne 
hirurgije je uklanjanje lezija u celosti, kako bi se omogićila 
potpuna restitucija periapikalnog, sa težnjom da se povrati 
izgubljeno koštano tkivo. Cilj  ovog  prikaza bolesnika bio je da 
se klinički i radiografski proceni rezultat  zarastanja koštanog 
defekta nakon uklanjanja  dve velike periapikalne ciste kod iste 
osobe u isto vreme, koristeći dva različita regenerativna pristupa. 
Prikaz bolesnika. Kod zdrave, dvadesetjednogodišnje bolesnice 
dijagnostivane su dve periapikalne ciste gornjeg levog i desnog 
lateralnog sekutića i indikovano njihovo hirurško uklanjanje. 
Jedan koštani defekt je popunjen mešavinom serumskog 
eksudata dobijenog kompresijom plazme obogaćene fibrinom 
(PRF) ugruška i govedjeg koštanog ksenografta, a zatim 
prekriven  membranom od PRF. Drugi defekt popunjen je 
korišćenjem samo hidratisanog govedjeg koštanog ksenografta i 
prekriven resorptivnom kolagenom membranom. Kliničko i 
radiografsko ispitivanje izvršeno je sedam meseci posle hirurškog 
tretmana. Svi klinički i radiografski parametri bili su značajno 
poboljšani posle tretmana na oba mesta. Međutim, 
novoformirana kost oko zuba br. 12 imala je veću koštanu 
gustinu. Zaključak. PRF je značajno ubrzao zarastanje koštanog 
defekta. 
 
 
Ključne reči: 
hirurgija, oralna, procedure; plazma bogata 
trombocitima; kost, regeneracija. 
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Introduction 
Periapical inflammatory lesions are local bone respon-
ses around the apex of a tooth that occur after necrosis of the 
pulp tissue caused by dental caries, mechanical or thermal 
trauma and chemical agents. Modern periapical surgery aims 
to remove periapical lesions to achieve complete wound hea-
ling and aid regeneration of bone and periodontal tissue. Sin-
ce natural healing takes a relatively long period of time for 
the bone to fill the residual cavity 1, regenerative approaches 
that help restore lost tissue and speed up regeneration have 
been introduced 2, 3. Regeneration is the process of reproduc-
tion or reconstitution of a lost or injured part of the body in 
such a way that the architecture and function of the lost or 
injured tissues are completely restored, and it is a natural 
process of wound healing. The ultimate goal of reconstructi-
ve surgical techniques in the treatment of intra-bone defects 
is a regeneration of lost bone tissue. 
Many regenerative techniques, utilizing bone grafts and 
barrier membranes, were introduced to help the optimal healing 
of the residual defects after the removal of intra-bone lesions, 
especially large cysts 4–6. Lately, the use of platelet rich fibrin 
(PRF) showed very promising results in regenerative surgical 
procedures 7, although autologous platelet concentrates and their 
advantages are already very well-known 8. The PRF technique 
was developed in 2001 by Joseph Choukroun and associates 
with the idea to combine characteristics of both platelets and 
growth factors into a fibrin clot in order to accelerate healing 
and remodeling of bone and soft tissue 9. 
So far, there has been no consensus on whether or not 
alveolar bone defects left after large periapical cysts removal 
should be filled with bone grafts or other healing inducing 
derivate 10, but the positive effects these techniques have on 
alveolar bone formation are undisputed 11. The aim of this 
report was to show clinical and radiographic outcome 
following the removal of two big periapical lesions, 
approximately of the same size, located around maxillary la-
teral incisors, in the same person at the same time, using dif-
ferent regenerative approaches.  
Case report 
A healthy, 21-year-old female patient complaining of 
the pain in the upper left anterior region presented to the De-
partment of Conservative Dentistry and Endodontics, Faculty 
of Dentistry in Pančevo. During the intraoral examination, a 
slight discoloration of upper left lateral incisor was observed; 
tooth was mobile and sensitive to vertical percussion, with 
non-exudative swelling in the apical region. The patient was 
provided with the first aid dental treatment and sent to the 
Department of Radiology. The panoramic radiograph revea-
led the presence of periapical intrabony defects around api-
ces of teeth #12 (approximately 13 mm in diameter) and #22 
(11 mm in diameter) and inadequate endodontic treatment of 
the tooth #12 (Figure 1).  
Root canal treatment of teeth #12 and #22 was perfor-
med just before surgery. The PRF was prepared in accordan-
ce with the standard protocol. Just prior to surgery, 30 mL  
 
Fig. 1 – The panoramic radiograph before the treatment. 
 
intravenous blood was collected in a 10-mL sterile tube and 
immediately centrifuged in centrifugation machine (A-PRF 12, 
APRF, Nice, France) at 3,000 revolutions per minute for 10 mi-
nutes. This protocol of blood centrifugation allows the forming 
of a 3D fibrin structured clot in the middle of the tube, just 
between the red corpuscles at the bottom and acellular plasma 
(platelet-poor plasma) at the top. PRF was easily separated from 
red corpuscles base (retaining a small red blood cell layer) using 
sterile tweezers (Figure 2) and scissors just after the removal of 
the tube and then transferred to a sterile dish. 
 
 
Fig. 2 – The platelet rich fibrin (PRF) clot. 
 
After administration of local anesthetic, buccal angular 
incisions were made and full thickness mucoperiosteal flap 
was elevated. Labial cortical plate around the apex of the to-
oth #12 was removed, revealing the periapical intrabony de-
fect in evident relation to the tooth. The cystic lining was 
enucleated and sent for a biopsy which identified the lesions 
as radicular cysts.  Using tapered fissure bur, tooth root was 
resected and mineral trioxide aggregate (MTA) (ProRoot 
MTA; Dentsply, Tulsa, OK, USA) was used as the root end 
filling material. Bovine-derived hydroxyapatite xenograft 
(Bio-Oss®, GeistlichPharma AG, Switzerland) was sprinkled 
over the PRF gel and the whole mixture was placed into the 
defect (Figure 3). PRF membrane was prepared with com-
presses and placed in two layers over the edge of the defect 
(Figure 4). The mucoperiosteal flap was repositioned using 
3-0 non-absorbable black silk surgical simple interrupted su-
tures. The same surgical technique was used for the removal 
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Fig. 3 – BioOss mixed with platelet rich fibrin (PRF) gel 
and placed into the defect. 
 
Fig. 4 – Platclet rich fibrin (PRF) membrane placed 
over the defect previously filled with the mixture of 
BioOss and PRF gel (upper right lateral incisor). 
 
 
Fig. 5 – The panoramic radiograph after the treatment. 
 
 
Fig. 6 – Region of the former defects filled up with newly formed bone above the root of the tooth #12 (left) 
 and the tooth #22 (right) (Ez3D plus software, Vatech Global, Hwaseong-si, Gyeongii-do, Korea). 
of the tooth #22 periapical lesion, but this time bovine-
derived hydroxyapatite xenograft mixed with a physiological 
solution was placed into bone defect and resorbable collagen 
membrane (Bio-Gide® COLLAGEN – GeistlichPharma AG, 
Switzerland) was placed to cover the edge of the defect. 
Clinical and radiographic examinations were perfor-
med seven months after the surgery. The following parame-
ters were evaluated: bone density, alveolar ridge width at 
the place of residual defect and mobility of the teeth. All 
clinical and radiographic parameters were significantly im-
proved after the treatment on both sites; however, a newly 
formed bone around the tooth 12 showed a higher bone 
density (Figures 5–8). No mobility of teeth was observed at 
both sites. 
 
Vuković N, et al. Vojnosanit Pregl 2017; 74(10): 987–991. 
Page 990 VOJNOSANITETSKI PREGLED Vol. 74, No 10 
Vuković N, et al. Vojnosanit Pregl 2017; 74(10): 987–991. 
 
Fig. 7 – Bone density measured in Hounsfield units and alveolar ridge width 3 mm above resected root of the tooth 
#12 (measured in Ez3D plus software, Vatech Global, Hwaseong-si, Gyeonggi-do, Korea). 
 
 
Fig. 8 – Bone density measured in Hounsfield units and alveolar ridge width 3 mm above resected root of the tooth 
#22 (measured in Ez3D plus software, Vatech Global, Hwaseong-si, Gyeonggi-do, Korea). 
 
Discussion PRF is a derivate of patient’s own blood, and as such 
does not trigger an immune response and minimize chances 
of infectious disease transmission 14. Preparation of PRF is 
easy and fast and is done in the dental office immediately be-
fore the intervention, which simplifies the procedure and sa-
ves the patient of blood harvesting in the hospital 14.  
After periapical surgery, large bone defects may be created, 
which sometimes cannot be adequately filled on their own, so the 
use of suitable graft material is required. PRF is a matrix of auto-
logous fibrin which contains a lot  of platelets and intrinsic 
cytokines within the fibrin mesh, allowing their gradual release 
over time (7–11 days), correlating with the resorption of fibrin 
network 9. The use of PRF grafting offers several advantages: 
PRF clot and membrane play mechanical role by protecting and 
linking the grafted biomaterials with themselves and with bone 
tissue, fibrin network accelerates cellular migration (endothelial 
cells) necessary for the neo-angiogenesis, platelet cytokines (plate-
let-derival growth factor – PDGF, transforming growth factor alp-
ha – TGF-α, insulin like growth factor – IGF-1) are released, hel-
ping the process of healing, and leukocytes and cytokines in the 
fibrin network play a significant role in the regulation of 
inflammatory and infectious processes during wound healing 12, 13.  
In this case report, we analyzed the clinical efficacy of 
PRF autologous graft comparing it with heterologous graft in 
the treatment of intrabony defects. It was shown that the use 
of PRF speeds up the filling of the defect compared to bovi-
ne-derived hydroxyapatite xenograft. 
Conclusion 
This case report indicates that the use of PRF should 
be considered as a promising solution for a successful au-
gmentation of large bone defects in everyday dental surgi-
cal practice. 
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Sneezing – a symptom of respiratory or psychogenic superposition of 
illness in a teenager? 
Kijanje – simptom respiratorne ili psihogene superpozicije bolesti u tinejdžera?  
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Abstract 
 
Introduction. The coincidental combination of allergic 
respiratory diseases and psychogenic or psychiatric illness is 
possible but rarely associated in a female teenager. Case re-
port. A girl aged 12.5 years was admitted to the Pediatrics 
Clinic in the Clinical Centre Kragujevac with the main diffi-
culty of sneezing as 10 sneezes in each of the 500–600 series 
a day, only in the waking state. Working diagnoses were tic 
disorders associated with Allergic rhinitis, asthma and bio-
chemically determined rickets. The patient was treated with 
chlorpromazine, desloratadine, montelukast, fluticasone 
propionate, vitamin D, azelastine hydrochloride along with 
the elimination diet. After a year and a half, the patient 
rarely sneezed, but periods without sneezing were not 
longer than 3 months, and she ‘cleared her throat’ occasion-
ally. Although her clinical condition is less severe now and 
without additional motor tics or symptoms of Tourette's 
disorder, because of its length we suspect the tic turned into 
a chronic vocal tic disorder. Conclusion. We reported a 
case of rare association between allergic rhinitis and condi-
tion of tic-related conversion in a female teenager and em-
phasized the necessity of revising the systematisation for the 
tic disorders and protocol for the allergic rhinitis in terms of 
their association. 
 
Key words:  
adolescent; rhinitis, allergic; tic disorders. 
Apstrakt 
 
Uvod. Udruženost alergijskih respiratornih oboljenja i 
psihogene ili psihijatrijske bolesti je moguać, premda se 
javlja retko kod devojčica u tinejdžerskom uzrastu. Prikaz 
bolesnika. Devojčica uzrasta 12,5 godina primljena je u 
Pedijatrijsku kliniku Kliničkog centra Kragujevac sa 
glavnom tegobom kijanje, po 10 uzastopnih kijanja u 
serijama od 500–600 dnevno i to samo u budnom stanju. 
Radne dijagnoze bile su tik poremećaj udružen sa 
alergijskim rinitisom, astmom i biohemijski utvrđenim 
rahitisom. Tinejdžerka je lečena hlorpromazinom, 
desloratadinom, montelukastom, flutikazon propionatom, 
vitaminom D, azelastin-hidrohloridom, sa pratećom 
eliminacionom ishranom. Posle perioda od godinu i po 
dana, bolesnica je ređe kijala, periodi bez kijanja nisu bili 
duži od 3 meseca i povremeno je „čistila grlo“. Mada je sada 
klinička slika bila blaža i bez dodatnog motornog tika ili 
simptoma Tourette poremećaja, zbog dužine trajanja tegoba 
postoji sumnja da se tik preobratio u hronični glasovni tik 
poremećaj. Zaključak. U radu je prikazana retka 
udruženost alergijskog rinitisa i stanja tik-srodne konverzije 
kod tinejdžerke i istaknuta je potreba za reviziju 
sistematizacije tik poremećaja i protokola za alergijski rinitis 
u smislu njihove udruženosti. 
 
Ključne reči: 
adolescenti; rinitis, alergijski; tik poremećaji. 
 
Introduction 
Sneezing in children is the most common symptom of 
allergic and infective rhinitis. Sneezing (or blowing) pro-
vides a high-velocity ejection from the mucosal surface 1. 
Sneezing is an involuntary reaction, and a protective reflex 
that starts in the nasal mucosal lining travels to the medulla 
oblongata, from which many muscles are stimulated to take a 
deep breath 2. After that the breathing stops for a short time, 
the soft palate rises and closes the inner nasal opening. At the 
same time, the respiratory muscles, participating in the exha-
lation, are strained, and the pressure in the lungs rises. The 
soft palate lowers, and the air penetrates into the nose under 
high pressure, goes through the nasal passages removing all 
foreign and harmful substances from the nose. 
As a sudden, strong and uncontrollable expulsion of the 
air through the nose and mouth, sneezing is rarely a serious 
health issue in children. The infective rhinitis and allergic 
Correspondence to: Andjelka Stojković, Clinical Centre "Kragujevac", Pediatric Clinic, Zmaj Jovina 30, 34 000 Kragujevac, Serbia. 
Phone: +381 34 505 175; E-mail: andja410@mts.rs  
Vol. 74, No 10 VOJNOSANITETSKI PREGLED Page 993 
rhinitis are, logically, first suspected in primary health care 
and the treatment begins without testing protocols 3, which 
turns out in this case as a reason for potentiating the health 
problem of a patient. Sneezing is, also, a common symptom 
of nonallergic-noninfective rhinitis, acute and chronic rhi-
nosinusitis and the like. 
It is rare that, among the multiple common triggers of 
sneezing in children, a strong emotion is associated with al-
lergic rhinitis, resulting in frequent and exhausting sneezing 
prolonged over several days, weeks and even months. As it is 
presented in this case report, such hardships were put for-
ward for the consideration as a particular disorder, among 
various psychiatric and psychological disorders in a child or 
teenager 4. 
Tic, in medicine, does not imply any voluntary action 
of a body part when a person is excited, stressed, anxious, 
and after an excessive intake of caffeine or alcohol 5. In that 
case, the human body shows that it is under stress or tired, al-
though it was not always so easy to discern, especially dur-
ing the teenage period. At this age, the frequent mood swings 
are part of growing up. During puberty, teenagers begin to 
change physically – most girls get their first period and a 
beard begins to grow in boys. For teenagers, these changes 
are very important and not easy to accept. While maturing, 
teenagers have to deal with a lot of things in their mind, 
which can contribute to their anxiety, irrational fear or soma-
tization of an organic disease such as the allergic rhinitis. In 
this case report, the treatment of the allergic rhinitis symp-
toms in a teenager was difficult, time-consuming and on the 
edge of being unsuccessful due to the lack of information, 
about somatization of allergic rhinitis or possible association 
with tic in the ARIA (the Allergy Rhinitis and its Impact on 
Asthma) approaches 6. 
Case report 
We considered the unusual tic related to sneezing in a 
12.5-year old female teenager associated with the allergic 
rhinitis, mild asthma 7 and rickets. The girl was hospitalized 
because of sneezing, headache, and constipation in the early 
winter period. She sneezed in approximately 500–600 daily 
series of ten sneezing each, and exclusively while being 
awake. The order of all clinical findings, related to this case, 
is shown in Table 1. After 3 days of the treatment with 
chlorpromazine, the teenager sneezed 42 series of 10 sneez-
ing each. Chlorpromazine was taken during following 5 
months with a gradual dose reduction. Currently, after a year 
and a half, the patient rarely sneezes, periods without sneez-
ing have not been longer than 3 months, and she ‘clears her 
throat’ occasionally. She had no symptoms of conjunctivitis. 
At the beginning, sneezing was accompanied with the 
fever up to 38.5°C during 10 days, and the therapy was ap-
plied in the school infirmary, including xylometazoline nose-
drops, paracetamol and ascorbic acid, desloratadine and 
mometasone furoate nasal spray. Because of the protracted 
sneezing, pharyngeal and nasal swabs were taken, so that in 
accordance with the antibiogram, amoxycillin with clavu-
lanic acid was administered over 7 days. Since the teenager 
kept on sneezing despite her good general health, she was 
sent to the General Hospital for examination. 
On admission to the Department of Pediatrics, in the 
General Hospital in the countryside of Serbia, main reasons 
for the hospitalization were sneezing, headache and constipa-
tion, despite normal physical findings. Diagnostic findings 
are shown in Table 1. During a 7-day monitoring and exami-
nation, the girl sneezed in approximately 200 series of ten 
sneezing each, suffered from substernal chest pain and con-
stipation. Electroencephalography (EEG) showed the follow-
ing:  irritant activity was noted bilaterally at well-expressed 
and regular OA 12Hz in the frontal-central-temporal region 
(FCT). Due to the EEG findings and performed analyses, the 
patient was empirically treated with diazepam 5 mg tablets 
for 5 days. However, sneezing continued with variable inten-
sity and frequency, exclusively during the state of wakeful-
ness. As a consequence of constipation, a fissure appeared in 
the anal region and it was treated with policresulen and cin-
chocaine ointment and benzydamine solution. She was dis-
charged from the General Hospital with the recommended 
therapy: omeprazole 20 mg capsule once a day, metronida-
zole 750 mg daily, lactulosa syrup 30 mL daily and policre-
sulen and cinchocaine ointment. 
During 9 days at home, the girl continued to sneeze 
even more intensely, 10 sneezes in each of the 500–600 se-
ries a day, only while being awake, during the following 
month and a half. 
Because of this, the girl was sent to the additional ex-
amination to the Pediatrics Clinic in the Clinical Centre Kra-
gujevac. On admission, the girl was eutrophic, complained 
about fatigue and exhaustion; the pharynx was hyperemic; 
livid nasal mucosa was without edema; diffuse expiratory 
wheezing was noted, and other physical findings were nor-
mal. Diagnostic findings are shown in Table 1.  Detected vi-
tamin D deficiency with elevated alkaline phosphatase and a 
high total IgE level suggested the association of allergic dis-
ease and rickets. Skin prick test clearly showed characteris-
tics, potential risk factors and triggers of allergic diseases. 
Pulmonary function tests showed moderately constricted 
small airways along with moderately elevated total and spe-
cific airway resistance, mild “air trapping”, and a positive 
bronchodilator response. The female teenager did not have 
asthma symptoms (a cough, wheezing, shortness of breath, 
chest tightness) and asthma was diagnosed using functional 
assessment of airflow limitation and airflow reversibility 7. 
The above mentioned pulmonary and other examinations 
confirmed the following diagnoses that were intertwined: 
asthma (organic), rhinitis (both allergic and, predominantly, 
psychogenic superpositioned), the condition of tic related 
conversion and biochemically confirmed rickets. 
The female teenager was discharged from the Clinic 
with recommended therapy: chlorpromazine 25 mg at every 
8 hours over a month and parents were requested to keep 
evidence of the number of tics (sneezing) during the day. At 
the same time, the patient received therapy for asthma, aller-
gic rhinitis and rickets including vitamin D3 2000 IJ daily, 
desloratadine 2.5 mg daily, montelukast 5 mg daily, fluti-
casone propionate 100 mcg inhaled daily, and she was given  
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advice on the elimination diet (without freshwater fish, cow's 
milk, tomatoes, seafood). After a month of the treatment, the 
girl still sneezed up to 15 series per day, the lung function 
was normal, with vitamin D insufficiency detected and nor-
mal alkaline phosphatase activity in the serum. 
Chlorpromazine, as a phenothiazine neuroleptic, was 
taken during 5 months with a gradual reduction of the dose. 
In the same period allergic rhinitis and asthma were treated 
(desloratadine, montelukast, fluticasone propionate) and after 
that, in the following six months only prophylaxis of allergic 
rhinitis continued (desloratadine, mometasone furoate). After 
a year and a half period of time, the patient rarely sneezed, 
periods without sneezing were not longer than 3 months, and 
she ‘cleared her throat’ occasionally. Prophylaxis of allergic 
rhinitis continued using topical antihistamine azelastine hy-
drochloride along with the elimination diet. Given that the 
number of tics (sneezing and “throat clearing”) was small, 
psychological treatment, in the form of a counseling and 
conversation, was also recommended before the next check 
up in 4 months. Then, we suspected that there was a “hidden 
anxiety” which with available psychological (projective 
techniques, Beck Hopelessness Scale, Children’s Depression 
Inventory) and psychiatrist (katamnestic) tests was not estab-
lished. 
The data from the personal history should also be men-
tioned: 5 months prior to the hospitalization, the female teen-
ager was admitted to the Pediatric Surgical Care because of 
the episodes of belching and pain in the stomach which were 
successfully cured with ranitidine. Personal medical history 
revealed that she was prone to sneezing during the spring and 
autumn since she was 9 years old, but she not been tested or 
treated for allergic rhinitis so far. 
There was no information on the use of psychoactive 
substances and drugs or exposure to toxic and other sub-
stances or about the similar problems identified in family 
members. 
Discussion 
In this paper, we described the case of an unusual tic re-
lated to sneezing in a female teenager associated with the al-
lergic rhinitis and asthma. We considered this as “the condi-
tion of tic related conversion”, what was working diagnosis. 
Accordingly, we did a differential diagnostic consideration. 
Tic disorder is, as suggested by the American Academy 
of Child and Adolescent Psychiatry, a neuropsychiatric dis-
order associated with other psychiatric disorders, including 
attention deficit disorder, hyperactivity and obsessive-
compulsive disorder 5, 8, 9. Simple vocal tics indicate person-
ality development disorder, indeed; that usually disappears 
because of its transient nature and is more common in male 
children. It is most commonly manifested as a cough, grunt-
ing, throat clearing and sniffling. It is transient if it lasts be-
tween 4 weeks and 12 months in children under 18 years of 
age, but if not due to the effects of psychoactive substances 
or other drugs, and not meeting the criteria of Tourette's dis-
order or other chronic motor or vocal tic disorders 8, 9. Tic 
disorder is a neuropsychiatric disorder associated with other 
psychiatric disorders, including attention deficit disorder, 
hyperactivity, and obsessive-compulsive disorder 5, 7, 10. 
From patient's medical history we were not informed 
about her or her family suffering from Gilles de la Tourette’s 
syndrome 9 and we excluded the influence of the various sub-
stances and drugs. However, tic-related sneezing in our teen-
ager is not of transient nature (the simple vocal tics) 5, 8, 9 be-
cause it has lasted for year and a half, and although its clinical 
picture is less severe now and without additional motor tics, or 
symptoms of Tourette's disorder, because of its duration, we 
reflect the tic turns into a chronic vocal tic disorder. 
The psychologist and psychiatrist did not find the reason 
for the teenager’s emotional instability or excessive depend-
ence on her parents and the fear of her parental deprivation, 
especially in receiving love and any exposure to punishment. 
There is a disorder marked as a psychogenic superposition of 
allergic rhinitis. Then, the “hidden anxiety” was not estab-
lished with the available psychological and psychiatrist tests. 
The symptoms as a headache, constipation, retrosternal pain 
(with normal physical findings) were perceived as somatic 
symptoms because they have manifested at the same time with 
intense sneezing. This was the reason to think about "hidden 
psychological factors" that affected other medical condition 
but was not recognized by the Diagnostic and Atatistical Man-
ual of Mental Disorders, Fifth Edition (DSM-5). 
After this, a neurologist, as a treating physician, however, 
prescribed chlorpromazine. The low-potency, typical antipsy-
chotic effect of chlorpromazine 10 was achieved in this patient. 
The treating physicians have had in mind the favorable cir-
cumstance that chlorpromazine acts as an antagonist on differ-
ent postsynaptic and presynaptic receptors (dopamine-D1‚-
D2,-D3,-D4, serotonin-5HT1,-5HT2, histamine H1, α1- and 
α2-adrenergic, M1- and M2-muscarinic acetylcholine) 10, as 
used here. Chlorpromazine reduced the anxiety and annulled 
psychogenic superposition of allergic rhinitis. Here is imple-
mented dual therapy of sneezing. 
On the other hand, the prevalence rates of allergic rhinitis 
are highest in school-age children 2, 3, 6, 7. Thus, allergic rhinitis 
and infective rhinitis are logically first suspected in primary 
health care where, usually, the treatment begins without testing 
protocols. We were thinking about other types of rhinitis but we 
did not fit any of the known clinical pictures and received addi-
tional diagnostic findings, including sneeze on a full stomach 11. 
It is known that the treatment of moderate/severe persistent al-
lergic rhinitis according to the approach titled the ARIA 6 guide-
lines, and the patient should be checked in 2–4 weeks in primary 
health care. And, in the end, if there is no improvement, a sur-
geon should be consulted and specific immunotherapy consid-
ered. The treatment of allergic rhinitis according to the ARIA 
protocol 6 involves stepwise approach 3 but without established 
order of application of decongestant, oral H1-antihistamine, in-
tranasal H1-antihistamine, intranasal corticosteroids (INS), an-
tileukotriene and cromolyn for any severity of intermittent rhini-
tis and mild persistent rhinitis lasting up to 4 weeks. If there is 
no improvement, INS dose should be gradually increased or ip-
ratropium bromide or oral corticosteroids should be intro-
duced 3, 10. Conditions of controlled persistent allergic rhinitis 
can be achieved by the treatment of the ARIA approach 6. 
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However, the ARIA approach 6 implies neither the pos-
sibility that allergic rhinitis may be associated with psycho-
genic or psychological disorders or the attention deficit-
hyperactivity disorder (ADHD), nor that the allergic rhinitis 
is less controlled in the teenagers with tic or ADHD or psy-
chological factors that affect rhinitis. It does not say whether 
these diseases deteriorate each other, providing no guideline 
whether the patients should be treated by the ARIA ap-
proach 6 or by the DSM-5 protocol 8 first or simultaneously 
by both approaches. 
It is known that low level of vitamin D is associated 
with the increased frequency of asthma exacerbations, in-
creased allergy markers and asthma severity in children 12, 
and that vitamin D3 supplementation may modulate respira-
tory mucosa. Vitamin D has a role in immunological modu-
lation, aging, gene regulation, brain homeostasis, and neu-
rodevelopment. But, at this moment we do focus on just the 
condition of tic related conversion associated with allergic 
rhinitis. 
For the doctors in the primary health care, as well as for 
other doctors, it is important to have the correct initial guide-
lines for the treatment of a certain disorder in teenagers, 
which affects the cost of treatment. 
Conclusion 
This case report emphasizes the necessity of revising the 
systematization of tic disorders, the DSM-5 protocol and the 
ARIA approach in terms of their association, emphasizing each 
other, and clearer diagnostic/treatment/prognostic approaches of 
these associated disorders with the age of teenagers. 
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Introduction  
The period after the First world war (FWW) is conside-
red as one of the most intensive periods of hospital openings in 
the Vardar Region of Macedonia as part of Serbia. Vardar Ma-
cedonia (today's Republic of Macedonia) was part of the Kingdom 
of Serbia in the period 1912–1915, the province of Serbia within 
the Yugoslav Kingdom until 1929, and Vardar Banovina within 
the Kingdom of Yugoslavia from 1929 to 1941.* 
Because the situation was unsatisfactory as a result of the 
lack of hospitals, minimalistic capacities and the low hospital 
equipment the hospital’s opening started with the new country 
formation and the foundation of the Ministry of National Health.  
If we follow some chronological order we should mention 
first the hospitals in the cities that existed before the war but beca-
use the Vardar Region of Macedonia was practically ruined there 
was no evidence of them. That is why we use the term new hospi-
tals not the old ones. When we say new hospitals, in the period af-
ter the war we do not think of building new hospitals but forming 
hospitals in places where they did not exist before.  
According to the data given in the telegram sent by the 
Head of the Sanitary to the Management of all hospitals in 
the Kingdom of Serbs, Croats and Slovenes (SCS), of 14 May 
1919, by which it was called on purchasing products and 
equipment for the hospitals, in the Vardar Region in 1919, four 
public hospitals only existed in Skopje, Štip, Bitola and Tetovo 1. 
                                                          
* Vardar Macedonia (today's Republic of Macedonia) was part of 
the Kingdom of Serbia in the period 1912–1915, the province of 
Serbia within the Yugoslav Kingdom until 1929, and Vardar 
Banovina within the Kingdom of Yugoslavia from 1929 to 1941. 
According to some other reports from 1920 in the Var-
dar Region, besides the public hospitals, there were also hos-
pitals of the American mission in Veles, Prilep, Ohrid, Stru-
mica and Gostivar 2. 
There were whole areas, as for example the area of 
Kumanovo, where there were no hospitals at all. Also in Ser-
bia, Montenegro and the Vardar Region of Macedonia at that 
time, there were no hospitals. In the places where war hospi-
tals did not exist like Štip, Veles, and Ohrid, the injured were 
treated in the regional hospitals 3. 
Hospitals which worked after the war had a status of ‘Per-
manent’ or ‘Temporary’ hospitals. In the Kingdom of SCS the 
hospitals were public and private depending on the investors.  
Public hospitals were divided into state, regional, local 
and municipal hospitals which later, after regions were for-
med, became regional hospitals. In the Vardar Region of 
Macedonia only regional and local hospitals existed without 
having the status of public hospitals until 1929.  
Regional hospitals covered a range of few municipalities 
and were settled in the centre of the region, while the local hos-
pitals were formed in few villages. That was the situation till 
1929 when all hospitals were renamed as regional hospitals.  
Regional hospitals were hospitals in Skopje, Bitola, Štip, 
Tetovo and Ohrid, and the local in Veles, Prilep and Gevgelija.  
Besides the regional and local ambulances in the municipali-
ties, there were public ambulances which were free of charge.  
There were also hospitals in the Vardar Region that were 
private and founded by the foreign humanitarian missions.  
According to the professional and organizational set up, 
the hospitals could be common treating all diseases as well 
as special hospitals where only one disease was treated.  
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The Sanitary Law of the Kingdom of SCS imposed on 
the state and its bodies to build a hospital at their own 
expense. When they were not in condition to do that the state 
must have helped them or finance the building of the hospi-
tals. Thus, to 1930 when the Skopje’s hospital became regio-
nal, there were no hospitals with public status in the Vardar 
Region, although, as a result of bad financial conditions, the 
state fully covered the expenses for the hospitals openings 3. 
The hospital staff did not satisfy the hospital needs. 
There was a lack of doctors and professionals. According to 
the law, one doctor should cover 25 hospital beds, and in 
Vardar region he/she covered 32 3.  
Great working difficulty represented the post of a hospi-
tal manager and a house keeper which the law did not stipula-
te. In the regional hospitals, with a few exceptions, the duty 
manager of the hospitals was led by epidemiologists. The sa-
me happened with the local hospitals where the duty of a ma-
nager was performed by the local doctor. In places where hos-
pitals were bigger, two doctors were posted as managers. The 
law had other negative side and that was the administrative 
work which was manager’s duty. That prevented the manager 
to dedicate himself/herself to the professional and real hospital 
work. That was the reason for imposing the need for opening 
the post of a manager with professional qualifications and le-
gal responsibility. The Sanitary Law predicted posts such as a 
chief of ward, secondary doctor, or honorary doctor. These 
doctors received free home for living in the hospital surroun-
dings, food, energy and heating materials. Secondary doctors 
should have spent 3 years in one ward and worked under a su-
pervision of the chief of the ward and after that, they could run 
the ward by themselves. The greatest difficulty in hospitals 
was the equipping of helping professional staff, doctor’s assis-
tant, and nurses 3. That was why schools for necessary profes-
sional profiles were opened.  
According to the Law, for a normal functioning of a ho-
spital, the following was needed: a manager, secondary doc-
tor, honorary doctor, doctor’s assistant, nurses, midwives, 
laboratory assistant, pharmacist, recorder, procurement clerk, 
technician, electrician, priest and hospital service for hygiene 
maintenance, preparation of hospital food, bedding and hos-
pital clothes, ironing, and laundering of the clothes 3. 
According to the report of the president of the perma-
nent hospital commission and assistant to the minister of na-
tional health Dr. Dobrivoje Ger. Popovic, since 1923, all ho-
spital buildings in the Vardar Region of Macedonia, except 
for the hospital in Veles, did not provide for the hospital ne-
eds. For them, the Ministry of National Health (MNH) paid 
rent because they were placed in private property buildings, 
except for the hospital building in Skopje which was a state 
one. Without an exception, for all of them, it was given a re-
commendation that a new hospital should be built 4. 
After 1929, with the division of Kingdom of SCS on 9 
regions, so called banovina, all state hospitals as well as the 
public ones were under the supervision of the region where 
they belonged to. The centres of the regions were appointed 
as state hospitals. So, the hospital in Skopje became the State 
hospital. It was actually the unique state hospital in the Var-
dar Region.  
The municipality of the cities managed  the municipal 
hospitals, under which authority were  the hospital expenses.  
The state was in charge of building new hospitals and 
their opening for regions and municipalities with over 20,000 
citizens. But, at some private hospitals, under special condi-
tions, the minister could give them the right to charge a 
number of hospital expenses.  
Regional hospitals from 1918 to 1929 
Regional hospital in Bitola  
The regional hospital in Bitola existed from  December 
1, 1916 and it was placed in an old Turkish building which 
was a private property the state paid a rent for.  
The hospital building was placed in the centre of the town. 
Besides the main building, the hospital had one smaller building 
and  barracks with 137 beds. The buildings were so destroyed in 
the last explosion that it was very difficult to readapt them.  
Bitola Regional Hospital was reopened in 1919 and it 
functioned with 3 wards: internal, surgical, and venereal 
ward. The following posts were fulfilled: a manager, chief – 
sergeant, 2 secondary doctors, 1 honorary doctor, 1 pharma-
cist, 1 midwife, 1 procurement clerk, 1 recorder, 11 nurses, 
other services 6, 1 technician, and 1 priest. According to the 
stipulations in the law there were no medical assistants, 
laboratory assistant, supervisor, and electrician.  
Professional staff in the regional hospital - Bitola in 
1924 was as follows 5: manager: Dr. Vasilije (Vasa) Petrovic, 
duty manager -regional physiotherapist; secondary doctors: 
Dr. Ego Nikolaric, Dr.. PreDr.ag Pop – Simeon, Dr.. Desan-
ka Kirkovic, pharmacist: AnDr.ija Timofejev; procurement 
clerk: Lazar Premovic. 
The hospital, according to the grade given in the Dr. 
Popovic's report, was not adequate for the hospital needs and 
it was recommended to build a new one with 125 beds at le-
ast, and about 10 million denars should have been provided 
for it. As cited in the report, it was an old, half ruined buil-
ding, a property of the ex-Greek hospital called ‘Evangeliz-
mos’ which should, according to the doctor Popovic's opini-
on, be rebuilt and transformed into a new hospital.  
Those hospital capacities could not satisfy the city ne-
eds. In addition to those claims, there was the article in the 
local newspapers ‘Novi Sjaj’ 6 in which it was stated: “It can 
freely be said that Bitola even today does not have its own 
hospital. The comfort and hospital accommodation should 
correspond to all hygiene rules. The current hospital capaci-
ties should be significantly increased. We had two major ho-
spitals during the war and now we have only one. Because of 
that, the issue of a hospital in Bitola does not stop to be actu-
al and necessary for the citizenship.” 
Besides many initiatives, the problem of the hospital 
remained unsolved. Since 1920, when the regional manager 
of the hospital was Dr. Vasa Petrovic, an initiative for reno-
vation of “spitaljeto” was raised and as a result the hospital 
capacities were significantly increased. Unfortunately, this 
was not realized because ‘.... one pure philanthropic move-
ment was raised in a political issue 7. 
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The conditions did not change even though the need for 
the children ward instead of the internal in the hospital in Bi-
tola, and the gynecology ward instead of the surgical was se-
en. What was essential in the Bitola hospital, was to open an 
ophthalmology ward, and to place venereal ward in the bar-
racks as it is today. It was also important to have a tuberculo-
sis ward because it was very difficult to admit people ill with 
tuberculosis in the hospital. A high percentage of tuberculo-
sis affected in our villages was a result of not having a place 
in the hospitals where they could have been treated 6. 
In the period after 1920, the citizens were convinced 
that a new hospital in Bitola would be built as a result of the 
manager’s intervention, Dr. Dragoljub G. Popovic. The loca-
tion was the place ‘Devejani’ at today’s Ohrid Street. It was 
predicted to have a pavilion system in the hospital and to bu-
ild one pavilion per year. The idea remained unrealized and 
the city was forced to be satisfied with the small inadequate 
hospital.  
Because of this, the poor suffered the most, and the rich 
solved their problems in private hospitals.  
In such hospital conditions, the city entered World War 
II and faced the Bulgarian administration8–10†. 
 
Regional hospital in Skopje  
 
Right after World War I, the Minister of National He-
alth of the Kingdom of SCS, approved the English Mission 
‘Lady Paget’ to form a hospital in Skopje by a decision 
number 15517.  At that time, Skopje had a population of 
144,848 inhabitants. The hospital was opened on September 
1st 1919 at the state property buildings in the barracks ‘King 
Petar’ at the Skopje fortress. The first venereal ward was 
formed then and it was led by Dr. Nikola Megeri, a native 
from Vojvodina, gynecology ward was led by Dr. Ante Ani-
cin, X-ray ward by Dr. Nikola Nastic, and surgical ward was 
led by Dr. Vladimir Rojic. The manager of the hospital was 
Dr. Etta Gray, an „American Women's Hospitals“ represen-
tative 1.  
                                                          
                                                          
† Right after setting the Bulgarian management in the Vardar 
Region of Macedonia the conditions did not change, and it was 
similar to the previous one. The absurd lies in the fact that there 
was a promise of building two hospitals in Bitola and one of 
them should have been workers hospital. The hospital was 
planned to be built with all the necessary wards in it with 200 
beds. (Petar Bojadzievski, Health service in Bitola during the 
Bulgarian reign, Scientific thought, Bitola, 1981, 577–598.) The 
municipality provided a place for building the hospital, the al-
lotement of 30 acres in the Bair area. (Newspaper. „Pelistersko 
eho“, number 8, 21 February 1942, Bitola). The other hospital 
which was promised to the citizens of Bitola by the Mayor of 
Bitola, Ilija Nencev, the Minister of Health, P. Gabrovski and 
the head manager of the National Health of Bulgaria, doctor, I. 
Balkanski, should have been a modern and big state hospital, lo-
cated in Arnaut place near the war hospital and hygiene labora-
tory (n. „Pelistersko eho“, number. 35, 30 August 1942, Bitola). 
Unfortunately the hospital was left to be built some other time. 
The hospital had 80 beds, without a sanitation system, 
and rooms did not correspond to the needs of a hospital. In 
Dr. Popovic's report it was alerted that a new building should 
be built with a capacity of 300 beds and a sum of 20 million 
dinars to cover the expenses 8.  
The hospital was moved to the barracks of the War ho-
spital in the 2nd army area ‘Half-moon’ in 1920. It was re-
named in Skopje Regional hospital and placed into two new 
pavilions, seven Decker’s barracks, five wooden houses;  one 
part was set up in the army hospital. It had 200 beds, 7 
wards: internal ward (56 beds), surgical ward (27 beds), 
gynecology and lying –in ward (16), venereal ward (33), 
ophthalmology ward (33), children ward (50 beds) and X-ray 
ward 1.  
The hospital was financed by the English mission and a 
small amount of the state budget was allocated. Its manager 
was a regional physicist in Skopje 1. 
Staff in Skopje’s regional hospital in 1920 were: the ma-
nager, Dr. Zivojin Milenkovic, a regional physicist; Venereal 
ward: the chief Dr. Nikola Megeri, and at the same year doctor 
Valentin Ivanivic Zarubin was employed, Russian immigrant, 
temporary honorary doctor ‡: Surgical ward: Vladimir Rojic 
was its chief to 1925, when the Minister appointed the surgeon 
doctor Josif-Jozo Pulizovic, and then Dr. Milisic; Gynecology 
ward: chief Dr. Kosta Cohadzic. The secondary doctor, doctor 
Radmila Milicevic-Smiljanic was working with him, and since 
1926 the ward was under supervision of Dr. Andre Stojanov 
from Ohrid; Internal ward: chief was Dr. Ante Anicin, then 
doctor Sarinka Jovanovic–Najdic, secondary doctor; X-ray 
ward: chief Dr. Nikola Nastic; Otorhinolaryngology ward: 
chief Dr.. Petar Zdravkovic, and since 1926 the ward was un-
der supervision of Dr. Bozidar Sekulic; Children ward: Dr. 
Marija Fjodorovna-Siebold§, temporary honorary doctor; 
Pharmacist: Dr. pharmacist Krsta Stavric; Midwife: Katerina 
Veljkovic; Procurement clerk: Milosav Stojanovic. 
Besides doctor staff, 22 nurses, 1 laboratory assistant, 2 
recorders, and 7 helping assistants worked in the hospital. 
There were no doctor assistants 1. 
Besides the venereal ward, in the Regional Hospital in 
1921, as a result of increased prostitution, a unit  for venereal 
diseases was opened and the sick were treated for free.  
In 1923, Skopje Hospital got its own manager, and the 
regional physicist was released from that obligation. Milan 
Zankovic was appointed as the manager of the hospital and 
performed this duty for 9 years.  
Initiated by Dr. Etta Gray, who provided the financial 
part, a chilren pavilion with 80 beds was built the same year.  
‡ Since receiving Yugoslavian citizenship, all Russian immi-
grants no matter of the education, after employment received 
status of temporary honorary doctor. 
 
§ Dr. Marija Fjodorovna-Siebold (1849-1939), German origin, 
married to Russian, sanitary mayor of the Serbian Army in 
1876. She worked as a war doctor during the Balkans wars and 
the FWW. She received many awards from the Red Cross, Ss 
Sava, Courage award and White Erl award. Since the FWW she 
worked in the Skopje’s hospital till her death. 
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Since 1927, the hospital was transferred in Dolno Vod-
no where it is today, and it was renamed as Regional Skopje 
Hospital.  
Since 1929, when a new reorganization in the Kingdom 
was done, the hospital was renamed as Regional Hospital.  
Skopje Regional Hospital covered a territory where 2 
million citizens lived, and that is from Leskovac to Gevgeli-
ja, from Albanian to Bulgarian border, the whole Vardar Re-
gion and one part of the Zeta Region.  
Since 1930 it was renamed as State or Country Hospi-
tal. The State Hospital in Skopje had opened new wards sin-
ce 1930: tuberculosis ward, isolation ward, neurology ward 
and ophthalmology ward. The staff who worked there were: 
Manager, Dr. Radovan Milutinovic; chief of the internal 
ward, Dr. Andra Stojanovic; chief of the gynecology ward, Dr. 
Valentin Zarubin; chief of the venereal ward, Dr. Dusan Anas-
tasijevic; assistant of the venereal ward, Dr. Nikola Guknic; 
chief of the surgical ward, Dr. Dragoljub Katanic; surgical 
doctor, Dr. Ilija Bojanic; pathologist, Dr. Bozidar Sekulic; chi-
ef of the otorhinolaryngology ward, Dr. Klementije Krstic; 
chief of the children ward, Dr. Zdravko Jeftanovic; chief of the 
X-ray ward, Dr. Budimka Milojkovic; assistant doctor, phar-
macist Dr. Kosta Stavric; Midwife Katerina Veljkovic; manci-
ple Milosav Stojanovic; 18 nurses and 18 servants. 
The Great Pavilion for the surgical and gynecological 
ward started to be built in 1931. Besides the beds for the sick 
in the building, there was a space for the central laboratory, 
physical therapy and x-ray diagnosis and a therapy. The 
schedule of the interior parts, in pavilion, apparatus, and 
everything else corresponded to the modern technological-
medical rules.  
Even after having built the new pavilion in 1938 
(today’s building of the gynecology ward) the space prob-
lems were partially solved 11. 
All names of the Skopje Hospital from 1919 to 1947 are 
given below: 
1919 – Lady Paget 
1920 – 1927 Regional Skopje Hospital 
1927 – 1929 Territorial Skopje Hospital 
1929 – 1930 Banovina (Regional) Hospital in Skopje 
1930 – 1947 State Hospital 
Since 1947, with the opening of the Faculty of Medical 
Sciences in Skopje, until today, the State Hospital has tran-
sferred into Clinical Hospital as a scientific base of the 
Faculty of Medical Sciences.  
 
Managers of the Skopje Hospital from 1919 to 1941  
1919–1920 Dr. Etta Gray 
1921–1923 Dr. Zivojin Milenkovic 
1923–1925 Dr. Milan Zerajic  
1926–1932 Dr. Milan Zankovic 
1932–1937 Dr. Radovan Milutinovic 
1937–1941 Dr. Viktor Sosic 
 
A report dated May 1, 1941 sent by the administrator of 
the hospital, taken over by the Bulgarian government to the 
Chief Directorate of National Health in Sofia can serve as a 
testimony about the Skopje Hospital. In this report, among 
other things, it is said that the Skopje Hospital was the lar-
gest hospital in the “newly liberated country” and that it had 
500 beds. It was situated in four hospital buildings: 
Administration Building, a two storey massive building 
built in 1928 with funds from the mission of American women 
from New York; a three storey massive central building with a 
basement in the form of a letter “H” built in 1938 with state 
funds; Infectious Diseases building, a two storey massive buil-
ding in which the Department for Lung Diseases is situated. It 
is located 200 meters from the administrative building; pavili-
on for the mentally ill, one-storey small building. 
The Administrator gives a comprehensive description 
of the apparatus found in the radiology ward. He says that 
the department is very well established and it has three X-ray 
apparatuses: one apparatus for diagnosing - a Siemens model 
"Tuto Heliofos" with four valves and equipped with full au-
tomation, an X-ray apparatus for diagnostics, type Galon-
Pilon-Pariz, about 16 years old, and a Siemens X-ray appara-
tus for treatment of the type "Tuto Multi-Volt 12. 
 
Regional hospital in Štip  
 
Štip’s Regional Hospital was opened on April 1, 1919 
(it was formed in 1914), with 30 beds as one hospital without 
dividing the wards. A motive for the urgent opening of the 
hospital was the epidemic of typhus fever in the city. The ho-
spital was in the centre of the city in the so called Ceramid-
sko neighbourhood, in privately owned buildings, and sup-
plied with water from the city pipe line. The buildings were 
not appropriate for the hospital needs but they were adapted 
by the MNH.  
According to Dr. Popovic recommendation, it was 
necessary to build a new hospital** for which 6 million de-
nars were needed.  
 
Staff in the Regional Hospital in 1922 were: manager, 
Dr. Franjo Navratil; temporary honorary doctor, Dr. Ljudmi-
la Smirnova; procurement clerk, Kosta Ristic; midwife, Pa-
raskeva Jokanovic; 1 recorder, 1 laboratory assistant, 4 nur-
ses and 4 helping staff. 
 
Regional hospital in Tetovo  
 
Tetovo Hospital was opened on July 16, 1919 by the 
sanitary mission ‘Scottish women’ located right to the object 
                                                          
** The project for the Stip’s Hospital was done in 1931 and the 
building started in 1936 when a credit from the bank was taken 
for the costs. In 1941 the hospital was completely equipped, and 
before it was opened it should have been connected to the 
sanitary system. But, on April 6, 1941 when Stip was bombar-
deded  all windows of the hospital were destroyed. Right after 
the bombardement , the city was a victim of robbery and a large 
number of the equipment was robbed. When the Bulgarians ca-
me in Stip, it was started with new reequipping of the hospital 
and on  July 5, 1943 it was prepared to receive the first patients. 
Hospital capacity was 100 beds and its manager was Dr. Georgi 
Rahlij (Russian immingrant). 
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where recently was the geodetic management, in the old pri-
vate buildings (one of them was the house of Scanderbeg 
Bey) with 10 rooms, 50 beds which did not correspond to the 
needs 14. That was why Dr. Popovic recommended that a 
new building should be built with 75 beds, which would cost 
around 5 million dinars 15. 
The hospital had one two-storey building, and a smaller 
building in which was the manager's office, the ambulance 
and maternity hospital with 10 beds 16.  
Its staff were: a manager, Dr. Stojan Stefanivic; regio-
nal physicist, Dr. Edit Harley17, 18†† who was the manager of 
the hospital pharmacy which was supplied with all the 
necessary medicaments by the sanitary mission 13; procure-
ment clerk, Janikije Davinic; midwife, Mara Todorovic; 5 
nurses and 4 clerks. 
 
Regional hospital in Ohrid 
 
The Ohrid’s Hospital was opened on September 27, 
1920 in two privately owned buildings and one building 
which was the property of the Ministry of the Army. The ho-
spital had 80 beds and 4 hospital wards: surgical, infective, 
and the ward for internal diseases. The buildings partially 
corresponded to the hospital needs. As one of the main prob-
lems in the hospital was the lack of hospital clothes and bed-
clothes.  
According to Dr. Popovic's report recommendations a 
new hospital should have been built and for that occasion 4 
million dinars was needed. This hospital admitted soldiers 
because there was no other hospital in the city.  
Its staff were: a manager, honorary doctor, 1 doctor as-
sistant, 6 nurses, 1 midwife, procurement clerk, hospital pri-
est and 5 clerks (manager: Dr. Gura Martinovic; regional 
physicist; temporary honorary doctor, Dr. Sofija Larinova – 
Leskova; Doctor assistant, Milan Nedeljkovic; Procurement 
clerk, Aleksandar Siljak). 
                                                          
                                                          
†† Edit Harley and her sister Flora, came to Macedonia in 1915, 
as representatives of the ‘Scottish Women's Hospitals Motor 
Ambulance Column’ together with their mother Catherine.  
Dr. Catherine Mary Harley, 1853-1917, Scottish origin, 
was sister of the Field marshal Sir John French, executive com-
mander of the English troupes in France. The mission „the Scot-
tish Women's Hospitals Motor Ambulance Column” known as 
‘Transport Unit’ based in England as special unit with 18 mem-
bers, 6 Fords, came in Macedonia as chief administrator of the 
most modern ambulance service with sanitary column. She ad-
ministrated the Dr.iving department and beside the Dr.ivers the 
workers were equipped for mechanics of their Dr.iving vehicles. 
In her unit, beside her two daughters, were many famous women 
from the English and Scottish circles. She also took care of the 
wounded, injured, and hungry people after the bombing in Bito-
la in 1917. She was hit in her head on  March 7, 1917 and died 
immediately while doing that mission. Her tomb is in Serbian 
cemetery in Zejtinlik (Thessaloniki) as unique woman between 
all other dead soldiers. Her daughters continued with her work. 
Right after the Great War Edit Harley worked in the Tetovo Ho-
spital 
Territorial hospitals in the period from 1918 to 1929 
Territorial hospital in Strumica 
 
In 1919, in the Bey Inn, at the same place where the 
Bulgarian hospital was from 1912‡‡ hospital of the American 
women mission was formed. Professional and assistance sta-
ff were all women at the hospital. The head of the hospital 
was Dr. Etta Gray, a specialist for surgical and ophthalmolo-
gical diseases, and miss Teppi, a doctor specialist internal, 
miss Eliot, a general practicioner and two nurses. There were 
also staff nurses and translators from English into Macedoni-
an: Vasil Panov and Zaev from Strumica. The whole medical 
help was free and people from distant towns came to be trea-
ted here. Koce Pesev from Novo Selo, Stip, had a plastic 
surgery on his eyebrow.  
Unfortunately, the Hospital of the American women did 
not work long. In 1921, it was burned by a forgery, leaving 
behind a beautiful memory of one professional team that ga-
ined all sympathy of the population in Strumica region 19.  
 
Territorial hospital in Veles 
 
The Veles’s Hospital was opened on March 21, 1922, in 
the buildings of the Children hospital of the American mission 
which was formed in 1919 and its manager was Dr. Etta Gray.  
It was placed in buildings, the property of the Ministry 
of War and in Dr. Popovic's report, it was evaluated as a ho-
spital appropriate for the hospital needs, but because it did 
not have its own building it was recommended to build a 
new hospital for 4 million dinars.  
It was placed in a two-storey house on the upland of Veles. 
The hospital had two helping or in total three buildings: building 
for patients, building for the staff nurses, washing machine, in-
fective ward, and the other building for the dead.  
The hospital had the adult ward, children ward, and the 
infective ward. Besides the civilians, soldiers were also trea-
ted because there was no other hospital in the city.  
Of the total amount of 100 beds, 50 were used for 
adults, 41 for children, and 9 for the zymotic disease. It was 
connected to the sanitary system. The hospital was financed 
by MNH except for the children’s ward which was financed 
by the American mission. The whole equipment was suppli-
ed by Dr. Etta Gray who was the manager of the hospital un-
til 1922.  
Staff that worked in the Territorial Hospital in Veles in 
1922 were: a manager, Dr. Antun Saso; honorary doctor, Dr. 
Stanislava Simonovic – Ilic; procurement clerk, Spasoje Os-
tojic; 9 nurses and 5 clerks.  
‡‡ During the presence of the Bulgarian authorities a war hospi-
tal was formed where the population received prevention. The 
hospital was in the Bey Inn and it was equipped with modern 
medical equipment. Two doctor s worked in it: Dr. Kambacev 
and Dr. Mircev, and two pharmacists: Ivan Stojanov and Nikola 
Petrov. Sava Kovaceva worked on the sterilization ward and sta-
ff nurses were Zora Trendafilova and Danka Mirceva. This hos-
pital existed to 1918. 
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The largest number of patients from the hospital in 1922, 
according to Dr. Popovic's report, were ill with malaria (n = 
166), and tuberculosis infected (n = 48). The number of patients 
who were injured was 49. They completed 21 surgery and 3 au-
topsies and made 84 ambulance’s medical check ups 4.  
On August 27, 1922 the American mission left Veles 
and went to America. Dr. Whiste was the only person that 
stayed there, one surgeon and a medical nurse.  
In the annual report for 1923 the manager Anton Saso 
gave a description of the hospital: ‘...the hospital is placed on 
the hill above the barracks, one kilometre distant, with three 
buildings, one for the hospital wards, the other for the infective 
ward, staff nurses and washing machine, and the third building 
is a chapel. There are three hospital wards with 100 beds, the 
children ward with 41 bed and infective ward with 9 beds. The 
heating in the building is with metal stoves on wood, lighting 
by kerosene, sanitary system. The laundry washing is made 
manually. The hospital needs hospital equipment (laundry, set-
ting, bed equipment) laboratory and laboratory assistant. There 
is a pharmacy without a pharmacist, and there is no duty doc-
tor 20. In this hospital workers who built the railway Veles-
Prilep and Veles- Štip were received.  
In the annual report to the territorial inspection in Skopje, 
Dr. Saso reported for the malaria outbreak in 1923. Out of 560 
infected people, 46 were infected by malaria quartana, 147 terci-
ana, 201 of tropic malaria and 156 of chronical malaria. Most of 
the infected were between 20 and 30 years old, and a smaller 
number was from 1 to 20 years old. In the second half of 1924, 
the number of the malaria infected increased to 761 21. 
Veles Hospital did not manage to find the appropriate place 
for its dislocation and the ministry could afford money for a new 
one. It was at the same place in the Second World War (SWW).  
 
Territorial hospital in Prilep 
 
Territorial hospital in Prilep functioned from 1919, under 
the management of the American mission ‘Hospitals of the 
American women’. Since January 23, 1922, the management 
was taken by the Territorial sanitary management. The hospi-
tal had only 30 beds and was placed in a private building, loca-
ted between the house of Pance Magar and the Evangelic 
church, and water was supplied from the hospital well.  
In Dr. Popovic's report, it was noted that the hospital 
was not the adequate for the needs of a hospital and it was 
necessary to build another hospital with at least 50 beds and 
3 million dinars for building it 4.  
Its staff were: a manager, Dr. Cvetko Gorgevic; territo-
rial doctor, temporary honorary doctor, Dr. Lujza Bihari; 
procurement clerk, Omilj M. Radovanovikc; 4 nurses; 3 
clerks and 1 priest. 
 
Territorial hospital in Gevgelija 
 
A Hospital in Gevgelija was opened in 1920 in the old bu-
ilding, which was in a private property of the recent catholic–
unite pension). The rent was paid by MNH for a sum of 400 di-
nars monthly. It had three hospital rooms with 15 beds, an am-
bulance, office and kitchen. The lighting was with kerosene, he-
ating by wood stoves, and water supply by street taps and wells. 
There were no enough blankets and sheets, dividers and setting.  
The rooms did not correspond to the hospital needs and 
that is why Dr. Popovic recommended that a new hospital 
should be built and the amount for it was 3 million dinars.  
Its staff consisted of: the manager, territorial doctor, Dr. 
Milos Jakovlevic; procurement clerk; Rafajlo Petrovic, 3 
nurses and 2 servants. 
As a conclusion to this report, Dr. Popovic recommen-
ded that a new hospital should be built in Kumanovo with a 
capacity of 100 beds and amount of 10.500 million dinars. 
Also he recommended that another hospital should be built 
in Strumica with 30 beds and amount of 3 million dinars 4.  
The hospitals in the Vardar Region of Macedonia were 
financed by the American charity mission which did succes-
sful work with its staff. The work of Dr. Etta Gray should be 
mentioned who had Children Hospital in Veles. The Ameri-
can mission gave 10.000 dollars to support the building of a 
children’s pavilion in Skopje with 80 beds 22. 
Besides the fact that hospitals were opened as temporary at 
first, with recommendation that they were not the adequate for 
hospital needs, and that new hospitals should be built, many ho-
spitals waited the WW II in this condition.  
 
Hospital in Kumanovo 
 
Kumanovo Hospital was built with resources of Nikola 
Spasic’s fund; he was a respectable merchant and philanthropist 
from Belgrade. The hospital building was a modern edifice and 
the amount for its construction was 1,382,022 dinars. Fully 
equipped with 60 beds, it was opened on July 11, 1935. Today, 
this building is a part of the hospital in Kumanovo 23. 
Conclusion 
The opening and construction of hospitals in Vardar Ma-
cedonia located within the South Serbia during the Kingdom of 
SCS/Yugoslavia, in the period between the two world wars were 
carried out with great intensity because of the urgent need. The 
fact is that the state budget allocated huge funds to build hospi-
tals that were built by all regulations of the modern architecture 
of the time. The quality of these buildings was high and many of 
them are still operational. As an example, I will mention the 
Hospital in Stip built in 1936, which after 80 years still 
works in the same premises, all the time as a Regional Hos-
pital and, most recently with the opening of the Faculty of 
Medicine of the University "Goce Delchev", it has grown in-
to a Clinical Hospital - Štip. As for the provision of experts, 
particularly from specialist activities, the shortage of these 
was very obvious because the conditions were incredibly 
complex and difficult. Mostly, staff was taken on by recruit-
ment and civil mobilization but also by sending doctors on a 
regular job in order to open new departments and services. 
The Ministry of Public Health of the Kingdom of SCS / 
Yugoslavia always took care about the quality of professio-
nal staff enabling them to handle difficult and responsible 
tasks, especially in the areas where infectious diseases, 
primarily malaria, reigned. 
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S C I E N T I F I C  M E E T I N G  R E P O R T    
Third International Congress of Cardionephrology and Hypertension 
(Pirot, Serbia, May 11–13, 2017) 
Treći međunarodni kongres kardionefrologije i hipertenzije  
(Pirot, Srbija, 11–13. maj, 2017) 
 
Milica Petrović 
Military Medical Academy, Clinic of Nephrology, Belgrade, Serbia
 
The third International Congress of Cardionephrology 
and Hypertension, “KARNEF” was a gathering of cardiolo-
gists and nephrologists of South-Eastern Europe. The Con-
gress was organized by the authorities of the city of Pirot in 
cooperation with the Serbian Cardionephrology Association 
and the Serbian Medical Association. 
The role of the Serbian Cardionephrology Association 
in educational and scientific research work in the field of 
kidney and heart diseases, as well as in the organization of 
such meetings has been recognized by major world associa-
tions. Our organization has been an associate member of the 
World Association of Nephrologists since March 2016. 
Beside nephrologists and cardiologists, the three-day 
International Congress of Cardionephrology, was also atten-
ded by pathologists, clinical biochemists, pharmacologists, 
endocrinologists, vascular surgeons, cardiac surgeons, and 
for the first time – pharmacists, chemists and biologists. Mo-
re than 315 participants attented the Congress; 260 came 
from the host country and 55 from abroad. There were  33 
participants who presented researches from the host country 
and 16 participants  from abroad. 
There were 54 lectures in total, out of which 44 were by 
invitation. The Meeting was organized on the basis of mini 
symposiums, educational seminars, thematic sessions and 
plenary lectures. 
Thirty five eminent experts in the field of cardiology 
and nephrology presented their lectures. Apart from the lec-
turers from Serbia, the experts from the: USA, Canada, 
Switzerland, Israel, Spain, Italy, Macedonia and Slovenia 
shared their knowledge and experience, too. 
The complex etiopathogenetic mechanisms of formati-
on and development of associated heart and kidney diseases, 
the multidisciplinary approach to patients suffering from the-
se diseases is of paramount importance for early detection, 
prevention and treatment. 
Abstracts of the presented communications at the Third 
International Congress of Cardionephrology and 
Hypertension “Cardionephrology Up To Date” have been 
published in the book “Cardiology 2017”. 
The seven chapters present the latest findings, from the 
etiopathogenetic mechanisms of associated heart and kidney 
diseases, to diagnostic and therapeutic procedures. The grea-
test attention was paid to cardiovascular complications in pa-
tients with end-stage of renal disease, with an emphasis on 
combined heart, lung and kidney damage. 
Special attention was also paid to studies related to 
experimental cardiology and medical chemistry. 
The book is aimed at educating young doctors, doctors 
in specialist and subspecialist studies in cardiology and 
nephrology, as well as students of doctoral studies. The edi-
tors of the book are Prof. dr Sonja Radenković and Prof.  
Andrija Šmelcerović. 
There was a ceremony organized at the official opening 
of the Congress on the occasion of the fifteenth anniversary of 
the existence and work of the Cardiovascular Association of 
Serbia, and the awards were given to President of the Europe-
an Cardionephrology Association, Prof. Mario Timio, Prof. 
Luca Di Lullo, President of KARNEF Serbia Prof.  Sonja Ra-
denković, Mayor of Pirot, Mr. Vladan Vasić, and President of 
the Serbian Medical Association in Pirot, Dr. Aleksandar Lilić. 
The Serbian Cardionephrology Association also presen-
ted awards for the three best papers in the field of 
cardioneprology, published in scientific journals in 2016. 
The first prize was awarded to Anderluh Marko and as-
sociates, for the paper “Cross-talk between dipeptidyl pepti-
dase-4 and stromal cell derived factor-1 in stem cell homing 
and myocardial repair: potential impact of dipetidyl peptida-
se-4 inhibitors“ published in the pharmacology and Therape-
utics 2016; 167: 100-107 (Impact factor 11.00). 
Second prize was awarded to Di Lullo Luca and associa-
tes for the paper “Cardiorenal acute kidney injuries: 
Correspondence to: Milica Petrović, Military Medical Academy, Clinic of Nephrology, Crnotravska 17, 11 000, Belgrade, Serbia.  
E-mail: drmilicapetrovic@gmail.com 
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Epidemiology, presentation, causes, pathophysiology and trea-
tment” published in the International Journal of Cardiology 
(doi: 10.1016/j.ijcard. 2016.11.156) (impact factor 4.638). 
Third prize was given to Dr. Petrović Milica and asso-
ciates for the paper “Blood concentrations of B-type natriure-
tic peptide and N-terminal prohormone B-type natriuretic 
peptide as markers of left ventricular diastolic function in pa-
tients with chronic renal failure” published in the Vojnosani-
tetski Pregled (DOI: 10.2298 / VSP151019079P) Online Ap-
ril 1st, 2016 (impact factor 0.367). 
The participants of the Congress had the opportunity to 
get acquainted with the natural beauties and rich cultural he-
ritage of the host city, Pirot, which was previously known as 
„little Jerusalem“ 
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INSTRUCTIONS TO THE AUTHORS 
The Vojnosanitetski pregled (VSP) is an Open Access Journal.  
All articles can be downloaded free from the web-site 
(http://www.vma.mod.gov.rs/sr/vojnosanitetski-pregled) with the use of li-
cense: the Creative Commons — Attribution-ShareAlike (CC BY-SA)  
(http://creativecommons.org/licenses/by-as/4.0/). 
The VSP publishes only papers not published before, nor submitted to any 
other journals, in the order determined by the Editorial Board. Any attempted 
plagiarism or self-plagiarism will be punished. When submitting a paper to 
the VSP electronic editing system (http://aseestant.ceon.rs/index.php), the 
following should be enclosed: a statement on meeting any technical require-
ments, a statement signed by all the authors that the paper on the whole 
and/or partly has not been submitted nor accepted for publication elsewhere, 
a statement specifying the actual contribution of each author, no conflict of 
interest statement that make them responsible for meeting any requirements 
set. What follows subsequently is the acceptance of a paper for further editing 
procedure. The manuscripts submitted to the VSP pass in-house and external 
peer review. All authors pay “Article Processing Charge” for coverage all ed-
iting and publishing expenses. Domestic authors pay 5,000 RSD, and those 
from aboard 150 euros. The editing and publishing fee is required for sub-
stantive editing, facts and references validations, copy editing, and publishing 
online and in print by editorial staff of the Journal. No additional fees, other 
than stated above, are required even if an author who already paid the fee 
would have more articles accepted for publishing in the year when fee was 
paid. All authors who pay this fee may, if want, receive printed version of the 
Journal in year when fee is payed. Please note that the payment of this charge 
does not guarantee acceptance of the manuscript for publication and does not 
influence the outcome of the review procedure. The requirement about pay-
ing “Article Processing Charge” does not apply to reviewers, members of the 
Editorial Board and the Publisher’s Council of the Journal, young researchers 
and students, as well as any of the subscribers of the Journal.  
The VSP publishes: editorials, original articles, short communica-
tions, reviews/meta-analyses, case reports, medical history (general or 
military), personal views, invited comments, letters to the editor, reports 
from scientific meetings, book reviews, and other. Original articles, short 
communications, meta-analyses and case reports are published with ab-
stracts in both English and Serbian. 
General review papers will be accepted by the Editorial Board only if 
the authors prove themselves as the experts in the fields they write on by 
citing not less than 5 self-citations. 
Papers should be written on IBM-compatible PC, using 12 pt font, and 
double spacing, with at least 4 cm left margin. Bold and italic letters should 
be avoided as reserved for subtitles. Original articles, reviews, meta-analyses 
and articles from medical history should not exceed 16 pages; current topics 
10; case reports 6; short communications 5; letters to the editor and com-
ments 3, and reports on scientific meetings and book reviews 2. 
All measurements should be reported in the metric system of the 
International System of Units (SI), and the standard internationally 
accepted terms (except for mmHg and °C).  
MS Word for Windows (97, 2000, XP, 2003) is recommended for 
word processing; other programs are to be used only exceptionally. Il-
lustrations should be made using standard Windows programs, Micro-
soft Office (Excel, Word Graph). The use of colors and shading in 
graphs should be avoided. 
Papers should be prepared in accordance with the Vancouver Convention.  
Papers are reviewed anonymously by at least two editors and/or in-
vited reviewers. Remarks and suggestions are sent to the author for final 
composition. Galley proofs are sent to the corresponding author for final 
agreement. 
Preparation of manuscript 
Parts of the manuscript are: Title page; Abstract with Key words; Text; 
Acknowledgements (to the authors’ desire), References, Enclosures. 
1. Title page 
a) The title should be concise but informative, while subheadings 
should be avoided; 
b) Full names of the authors signed as follows: *, †, ‡, §, ||, ¶, **, ††, ... .   
c) Exact names and places of department(s) and institution(s) of af-
filiation where the studies were performed, city and the state for any au-
thors, clearly marked by standard footnote signs; 
d) Conclusion could be a separate chapter or the last paragraph of the 
discussion; 
e) Data on the corresponding author. 
2. Abstract and key words 
The second page should carry a structured abstract (250-300 words for 
original articles and meta-analyses) with the title of the article. In short, 
clear sentences the authors should write the Background/Aim, major 
procedures – Methods (choice of subjects or laboratory animals; meth-
ods for observation and analysis), the obtained findings – Results (con-
crete data and their statistical significance), and the Conclusion.   
It should emphasize new and important aspects of the study or observa-
tions. A structured abstract for case reports (up to 250 words) should 
contain subtitles Introduction, Case report, Conclusion). Below the 
abstract Key words should provide 3–10 key words or short phrases that 
indicate the topic of the article. 
3. Text 
The text of the articles includes: Introduction, Methods, Results, and 
Discussion. Long articles may need subheadings within some sections to 
clarify their content. 
Introduction. After the introductory notes, the aim of the article should be 
stated in brief (the reasons for the study or observation), only significant data 
from the literature, but not extensive, detailed consideratuion of the subject, 
nor data or conclusions from the work being reported. 
Methods. The selection of study or experimental subjects (patients or 
experimental animals, including controls) should be clearly described. 
The methods, apparatus (manufacturer's name and address in parenthe-
ses), and procedures should be identified in sufficient detail to allow 
other workers to reproduce the results. Also, give references to estab-
lished methods, including statistical methods. Identify precisely all drugs 
and chemicals used, with generic name(s), dose(s), and route(s) of ad-
ministration. State the approval of the Ethnics Committee for the tests in 
humans and animals. 
Results should be presented in logical sequence in the text, tables and 
illustrations. Emphasize or summarize only important observations. 
Discussion is to emphasize the new and significant aspects of the 
study and the conclusions that result from them. Relate the observations 
to other relevant studies. Link the conclusions with the goals of the 
study, but avoid unqualified statements and conclusions not completely 
supported by your data. 
References 
References should be superscripted and numerated consecutively in the 
order of their first mentioning within the text. All the authors should be 
listed, but if there are more than 6 authors, give the first 6 followed by et 
al. Do not use abstracts, secondary publications, oral communications, un-
published papers, official and classified documents. References to papers 
accepted but not yet published should be cited as ”in press“.  Information 
from manuscripts not yet accepted should be cited as ”unpublished data“. 
Data from the Internet are cited with the date of citation. 
Examples of references: 
Jurhar-Pavlova M, Petlichkovski A, TrajkovD, Efinska-Mladenovska O, 
Arsov T, Strezova A, et al. Influence of the elevated ambient temperature 
on immunoglobulin G and immunoglobulin G subclasses in sera of Wis-
tar rats. Vojnosanit Pregl 2003; 60(6): 657–612. 
DiMaio VJ. Forensic Pathology. 2nd ed. Boca Raton: CRC Press; 2001. 
Blinder MA. Anemia and Transfusion Therapy. In: Ahya NS, Flood K, 
Paranjothi S, editors. The Washington Manual of Medical Therapeutics, 30th 
edition. Boston: Lippincot, Williams and Wilkins; 2001. p. 413-28.  
Christensen S, Oppacher F. An analysis of Koza's computational effort 
statistic for genetic programming. In: Foster JA, Lutton E, Miller J, 
Ryan C, Tettamanzi AG, editors. Genetic programming. EuroGP 2002: 
Proceedings of the 5th European Conference on Genetic Programming; 
2002 Apr 3-5; Kinsdale, Ireland. Berlin: Springer; 2002. p. 182-91. 
Abood S. Quality improvement initiative in nursing homes: the ANA 
acts in an advisory role. Am J Nurs [serial on the Internet]. 2002 Jun 
[cited 2002 Aug 12]; 102(6): [about 3 p.]. Available from: 
http://www.nursingworld.org/AJN/2002/june/Wawatch.htm 
Tables 
Each table should be typed double-spaced 1,5 on a separate sheet, 
numbered in the order of their first citation in the text in the upper right 
corner and supplied with a brief title each. Explanatory notes are printed 
under a table. Each table should be mentioned in the text. If data from 
another source are used, acknowledge fully. 
Illustrations 
Any forms of graphic enclosures are considered to bi figures and 
should be submitted as additional databases in the System of Assistent. 
Letters, numbers, and symbols should be clear and uniform, of sufficient 
size that when reduced for publication, each item will still be legible. 
Each figure should have a label on its back indicating the number of the 
figure, author's name, and top of the figure (Figure 1, Figure 2 and so 
on). If a figure has been published, state the original source. 
Legends for illustrations are typed on a separate page, with Arabic 
numbers corresponding to the illustrations. If used to identify parts of 
the illustrations, the symbols, arrows, numbers, or letters should be iden-
tified and explained clearly in the legend. Explain the method of staining 
in photomicrographs.  
Abbreviations and acronyms 
Authors are encouraged to use abbreviations and acronyms in the 
manuscript in the following manner: abbreviations and acronyms must 
be defined the first time they are used in the text consistently throughout 
the whole manuscript, tables, and graphics; abbreviations should be used 
only for terms that appear more than three times in text; abbreviations 
should be sparingly used. 
An alphabetical list of all abbreviations used in the paper, followed by 
their full definitions, should be provided on submission. 
Detailed Instructions are available at the web site: 
    www.vma.mod.gov.rs/vsp 
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UPUTSTVO AUTORIMA 
Vojnosanitetski pregled (VSP) je dostupan u režimu otvorenog pris-
tupa. Članci objavljeni u časopisu mogu se besplatno preuzeti sa sajta časopisa http://www.vma.mod.gov.rs/sr/ uz primenu licence Creative 
Commons Autorstvo-Deliti pod istim uslovima (CC BY-SA)  
(http://creativecommons.org/licenses/by-sa/4.0).  
 
VSP objavljuje radove koji nisu ranije nigde objavljivani, niti preda-
ti za objavljivanje redosledom koji određuje uređivački odbor. Svaki 
pokušaj plagijarizma ili autoplagijarizma kažnjava se. Prilikom prijave 
rada u sistem elektronskog uređivanja „Vojnosanitetskog pregle-
da“(http://aseestant.ceon.rs/index.php) neophodno je priložiti izjavu da su 
ispunjeni svi postavljeni tehnički zahtevi uključujući i izjavu koju potpisuju 
svi autori da rad nije ranije ni u celini, niti delimično objavljen niti prihvaćen 
za štampanje u drugom časopisu. Izjavu o pojedinačnom doprinosu svakog 
od autora rada potpisanu od svih autora, treba skenirati i poslati uz rad kao 
dopunsku datoteku. Takođe, autori su obavezni da dostave i potpisanu izjavu 
o nepostojanju sukoba interesa čime postaju odgovorni za ispunjavanje svih 
postavljenih uslova. Ovome sledi odluka o prihvatanju za dalji uređivački po-
stupak. Rukopisi pristigli u Redakciju časopisa podležu internoj i eksternoj 
recenziji. Svi autori dužni su da plate “Article Processing Charge” za pokriće 
troškova jezičke, stručne i tehničke obrade rukopisa, kao i njegovog objavlji-
vanja. Domaći autori plaćaju iznos od 5 000 dinara, a  inostrani 150 eura. 
Dodatna plaćanja nisu predviđena čak i u slučaju da autor koji je već pretho-
dno platio traženi iznos, ima više prihvaćenih radova za objavljivanje u godi-
ni u kojoj je izvršio uplatu. Svi autori koji su platili “Article Processing 
Charge” mogu, ukoliko žele, dobijati štampanu verziju časopisa tokom godi-
ne u kojoj je izvršena uplata. Plaćanje ovog iznosa ne garantuje prihvatanje 
rukopisa za objavljivanje i ne utiče na ishod recenzije. 
Od obaveze plaćanja pokrića navedenih troškova oslobođeni su recenzenti, članovi Uređivačkog odbora i Izdavačkog saveta VSP, studenti i mladi istra-
živači, kao i pretplatnici časopisa.  
 
U VSP-u se objavljuju uvodnici, originalni članci, prethodna ili 
kratka saopštenja, revijski radovi tipa opšteg pregleda (uz uslov da 
autori navođenjem najmanje 5 autocitata potvrde da su eksperti u oblasti 
o kojoj pišu), aktuelne teme, metaanalize, kazuistika, seminar prak-
tičnog lekara, članci iz istorije medicine, lični stavovi, naručeni ko-
mentari, pisma uredništvu, izveštaji sa naučnih i stručnih skupova, pri-
kazi knjiga i drugi prilozi. Radovi tipa originalnih članaka, prethodnih ili 
kratkih saopštenja, metaanalize i kazuistike objavljuju se uz apstrakte 
na srpskom i engleskom jeziku. 
Rukopis se piše sa proredom 1,5 sa levom marginom od 4 cm. Koristi-
ti font veličine 12, a načelno izbegavati upotrebu bold i italic slova, koja 
su rezervisana za podnaslove. Originalni članci, opšti pregledi i metaanali-
ze i članci iz istorije medicine ne smeju prelaziti 16 stranica (bez priloga); 
aktuelne teme – deset, seminar praktičnog lekara – osam, kazuistika – šest, 
prethodna saopštenja – pet, a komentari i pisma uredniku – tri, izveštaji sa 
skupova i prikazi knjiga – dve stranice. 
U celom radu obavezno je korišćenje međunarodnog sistema mera 
(SI) i standardnih međunarodno prihvaćenih termina (sem mm Hg i °C).  
Za obradu teksta koristiti program Word for Windows verzije 97, 
2000, XP ili 2003. Za izradu grafičkih priloga koristiti standardne gra-
fičke programe za Windows, poželjno iz programskog paketa Micro-
soft Office (Excel, Word Graph). Kod kompjuterske izrade grafika 
izbegavati upotrebu boja i senčenja pozadine. 
Radovi se pripremaju u skladu sa Vankuverskim dogovorom.  
Prispeli radovi kao anonimni podležu uređivačkoj obradi i recenziji 
najmanje dva urednika/recenzenta. Primedbe i sugestije uredni-
ka/recenzenata dostavljaju se autoru radi konačnog oblikovanja. Pre ob-
jave, rad se upućuje autoru određenom za korespodenciju na konačnu 
saglasnost.  
Priprema rada 
Delovi rada su: naslovna strana, apstrakt sa ključnim rečima, 
tekst rada, zahvalnost (po želji), literatura, prilozi. 
1. Naslovna strana 
a) Poželjno je da naslov bude kratak, jasan i informativan i da odgovara 
sadržaju, podnaslove izbegavati. 
b) Ispisuju se puna imena i prezimena autora sa oznakama redom: *, †, 
‡, §, ||, ¶, **, ††, ... . 
c) Navode se puni nazivi ustanove i organizacijske jedinice u kojima je 
rad obavljen mesta i države za svakog autora, koristeći standardne znake 
za fusnote. 
d) Zaključak može da bude posebno poglavlje ili se iznosi u poslednjem 
pasusu diskusije. 
e) Podaci o autoru za korespodenciju. 
2. Apstrakt i ključne reči 
Na drugoj stranici nalazi se strukturisani apstrakt (250-300 reči za 
originalne članke i meta-analize) sa naslovom rada. Kratkim rečeni-
cama na srpskom i engleskom jeziku iznosi se Uvod/Cilj rada, osnov-
ne procedure – Metode (izbor ispitanika ili laboratorijskih životinja; 
metode posmatranja i analize), glavni nalazi – Rezultati (konkretni 
podaci i njihova statistička značajnost) i glavni Zaključak. Naglasiti 
nove i značajne aspekte studije ili zapažanja. Strukturisani apstrakt za 
kazuistiku (do 250 reči), sadrži podnaslove Uvod, Prikaz bolesnika i 
Zaključak). Ispod apstrakta, „Ključne reči“ sadrže 3–10 ključnih reči 
ili kratkih izraza koje ukazuju na sadržinu članka.   
3. Tekst članka 
Tekst sadrži sledeća poglavlja: uvod, metode, rezultate i diskusiju. 
Uvod. Posle uvodnih napomena, navesti cilj rada. Ukratko izneti razloge 
za studiju ili posmatranje. Navesti samo važne podatke iz literature a ne 
opširna razmatranja o predmetu rada, kao ni podatke ili zaključke iz rada 
o kome se izveštava. 
Metode. Jasno opisati izbor metoda posmatranja ili eksperimentnih 
metoda (ispitanici ili eksperimentne životinje, uključujući kontrolne). 
Identifikovati metode, aparaturu (ime i adresa proizvođača u zagradi) i 
proceduru, dovoljno detaljno da se drugim autorima omogući reproduk-
cija rezultata. Navesti podatke iz literature za uhodane metode, uključu-
jući i statističke. Tačno identifikovati sve primenjene lekove i hemika-
lije, uključujući generičko ime, doze i načine davanja. Za ispitivanja na 
ljudima i životinjama navesti saglasnost nadležnog etičkog komiteta. 
Rezultate prikazati logičkim redosledom u tekstu, tabelama i ilustra-
cijama. U tekstu naglasiti ili sumirati samo značajna zapažanja. 
U diskusiji naglasiti nove i značajne aspekte studije i izvedene zak-
ljučke. Posmatranja dovesti u vezu sa drugim relevantnim studijama, u 
načelu iz poslednje tri godine, a samo izuzetno i starijim. Povezati zak-
ljučke sa ciljevima rada, ali izbegavati nesumnjive tvrdnje i one zaključ-
ke koje podaci iz rada ne podržavaju u potpunosti.  
Literatura 
U radu literatura se citira kao superskript, a popisuje rednim broje-
vima pod kojima se citat pojavljuje u tekstu. Navode se svi autori, ali 
ako broj prelazi šest, navodi se prvih šest i et al. Svi podaci o citiranoj 
literaturi moraju biti tačni. Literatura se u celini citira na engleskom 
jeziku, a iza naslova se navodi jezik članka u zagradi. Ne prihvata se 
citiranje apstrakata, sekundarnih publikacija, usmenih saopštenja, ne-
objavljenih radova, službenih i poverljivih dokumenata. Radovi koji 
su prihvaćeni za štampu, ali još nisu objavljeni, navode se uz dodatak 
„u štampi“. Rukopisi koji su predati, ali još nisu prihvaćeni za štampu, 
u tekstu se citiraju kao „neobjavljeni podaci“ (u zagradi). Podaci sa 
Interneta citiraju se uz navođenje datuma pristupa tim podacima. 
Primeri referenci: 
Đurović BM. Endothelial trauma in the surgery of cataract. Vojnosanit 
Pregl 2004; 61(5): 491–7. (Serbian) 
Balint B. From the haemotherapy to the haemomodulation. Beograd: 
Zavod za udžbenike i nastavna sredstva; 2001. (Serbian) 
Mladenović T, Kandolf L, Mijušković ŽP. Lasers in dermatology. In: 
Karadaglić Đ, editor. Dermatology. Beograd: Vojnoizdavački zavod & 
Verzal Press; 2000. p. 1437–49. (Serbian) 
Christensen S, Oppacher F. An analysis of Koza's computational ef-
fort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, 
Ryan C, Tettamanzi AG, editors. Genetic programming. EuroGP 2002: 
Proceedings of the 5th European Conference on Genetic Programming; 
2002 Apr 3-5; Kinsdale, Ireland. Berlin: Springer; 2002. p. 182-91. 
Abood S. Quality improvement initiative in nursing homes: the ANA 
acts in an advisory role. Am J Nurs [serial on the Internet]. 2002 Jun [cited 
2002 Aug 12]; 102(6): [about 3 p.]. Available from: 
http://www.nursingworld.org/AJN/2002/june/Wawatch.htm 
Tabele 
Sve tabele pripremaju se sa proredom 1,5 na posebnom listu. Obeležavaju 
se arapskim brojevima, redosledom pojavljivanja, u desnom uglu (Tabela 1), 
a svakoj se daje kratak naslov. Objašnjenja se daju u fus-noti, ne u zaglavlju. 
Svaka tabela mora da se pomene u tekstu. Ako se koriste tuđi podaci, obave-
zno ih navesti kao i svaki drugi podatak iz literature.  
Ilustracije 
Slikama se zovu svi oblici grafičkih priloga i predaju se kao dopunske dato-
teke u sistemu aseestant. Slova, brojevi i simboli treba da su jasni i ujednačeni, 
a dovoljne veličine da prilikom umanjivanja budu čitljivi. Slike treba da budu 
jasne i obeležene brojevima, onim redom kojim se navode u tekstu (Sl. 1; Sl. 2 
itd.). Ukoliko je slika već negde objavljena, obavezno citirati izvor.  
Legende za ilustracije pisati na posebnom listu, koristeći arapske brojeve. 
Ukoliko se koriste simboli, strelice, brojevi ili slova za objašnjavanje pojedi-
nog dela ilustracije, svaki pojedinačno treba objasniti u legendi. Za fotomi-
krografije navesti metod bojenja i podatak o uvećanju. 
Skraćenice i akronimi 
Skraćenice i akronimi u rukopisu treba da budu korišćeni na sledeći način: 
definisati skraćenice i akronime pri njihovom prvom pojavljivanju u tekstu i 
koristiti ih konzistentno kroz čitav tekst, tabele i slike; koristiti ih samo za 
termine koji se pominju više od tri puta u tekstu; da bi se olakšalo čitaocu, 
skraćenice i aktinome treba štedljivo koristiti. 
Abecedni popis svih skraćenica i akronima sa objašnjenjima treba dosta-
viti pri predaji rukopisa. 
      Detaljno uputstvo može se dobiti u redakciji ili na sajtu:  
      www.vma.mod.gov.rs/vsp
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